Atai Life Sciences (ATAI) 10-Q/A 20 Aug 21 2021 Q2 Quarterly report (amended) Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2021	Aug. 11, 2021
Cover [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	This Amendment No. 1 to the Quarterly Report on Form 10-Q/A (the “Amendment”) of ATAI Life Sciences N.V. (the “Company”) amends the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021 (the “Original Filing”) which was filed with the Securities and Exchange Commission on August 16, 2021. The Company is filing this Amendment to file Exhibits 101 and 104 relating to inline XBRL requirements in accordance with Rule 405 of Regulation S-T, which had been omitted from the Original Filing in accordance with the 30-day grace period provided under Regulation S-T for the first quarterly period in which inline XBRL is required. Additionally, in connection with the filing of this Amendment, the Company is including updated certifications from its chief executive officer and chief financial officer as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. This Amendment does not reflect events occurring after the Original Filing. Except for the items described above, this Amendment continues to speak as of the date of the Original Filing, and does not modify, amend or update any other item or disclosures in the Original Filing.
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	ATAI
Title of 12(b) Security	Common shares, par value €0.10 per share
Security Exchange Name	NASDAQ
Entity Registrant Name	ATAI Life Sciences N.V.
Entity Central Index Key	0001840904
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		154,819,776
Entity Interactive Data Current	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity File Number	001-40493
Entity Incorporation, State or Country Code	P7
Document Quarterly Report	true
Document Transition Report	false
Entity Address, Address Line One	ATAI Life Sciences N.V. c/o Mindspace
Entity Address, Address Line Two	Krausenstraße 9-10
Entity Address, City or Town	Berlin
City Area Code	49 89
Local Phone Number	2153 9035
Entity Address, Country	DE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 453,622	$ 97,246
Prepaid expenses and other current assets	3,964	2,076
Short term notes receivable - related party		226
Total current assets	457,586	99,548
Property and equipment, net	331	71
Deferred offering costs		1,575
Other investments	16,107	8,044
Equity method investments	19,780	53,100
Other investments held at fair value	6,886
Long term notes receivable	1,388	911
Long term notes receivable - related parties	3,194	1,060
Other assets	689	339
Total assets	505,961	111,548
Current liabilities:
Accounts payable	6,202	3,083
Accrued liabilities	7,824	9,215
Deferred revenue	120
Short-term notes payable	39
Total current liabilities	14,185	12,298
Contingent consideration liability - related parties	2,466	1,705
Convertible promissory notes - related parties, net of discounts and deferred issuance costs	1,176	1,199
Convertible promissory notes and derivative liability (including a related party convertible promissory note and derivative liability of $0 million and $0.3 million at June 30, 2021 and December 31, 2020, respectively		978
Other liabilities	3,239
Total liabilities	21,066	16,180
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, €0.10 par value ($0.12 par value at June 30, 2021 and December 31, 2020, respectively); 750,000,000 and 173,116,704 shares authorized at June 30, 2021 and December 31, 2020, respectively; 154,819,776 and 114,735,712 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively	17,299	13,372
Additional paid-in capital	691,382	261,626
Accumulated other comprehensive income (loss)	3,937	5,819
Accumulated deficit	(237,768)	(189,995)
Total stockholders' equity attributable to ATAI Life Sciences N.V. stockholders	474,850	90,822
Noncontrolling interests	10,045	4,546
Total stockholders' equity	484,895	95,368
Total liabilities and stockholders' equity	$ 505,961	$ 111,548

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) $ in Millions	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Convertible promissory notes and derivative liability noncurrent, Related party | $	$ 0	$ 0.3
Common stock, par or stated value per share | (per share)	$ 0.12	$ 0.12
Common stock, shares authorized	750,000,000	173,116,704
Common stock, shares, issued	154,819,776	114,735,712
Common stock, shares, outstanding	154,819,776	114,735,712

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
License revenue			$ 19,880,000
Operating expenses:
Research and development	$ 16,026,000	$ 2,854,000	21,611,000	$ 4,998,000
Acquisition of in-process research and development	7,962,000	120,000	8,934,000	120,000
General and administrative	37,331,000	2,851,000	46,604,000	4,421,000
Total operating expenses	61,319,000	5,825,000	77,149,000	9,539,000
Loss from operations	(61,319,000)	(5,825,000)	(57,269,000)	(9,539,000)
Other income (expense), net:
Interest income	35,000	18,000	72,000	38,000
Change in fair value of contingent consideration liability - related parties	(911,000)	(42,000)	(660,000)	(66,000)
Change in fair value of short term notes receivable - related party				718,000
Change in fair value of convertible promissory notes		(1,260,000)		(133,000)
Change in fair value of derivative liability			41,000	(12,000)
Unrealized loss on other investments held at fair value	(5,460,000)		(5,460,000)	0
Unrealized gain on other investments				19,856,000
Loss on conversion of convertible promissory notes	(513,000)		(513,000)
Gain on consolidation of a variable interest entity	3,543,000		3,543,000
Other income (expense), net	(2,676,000)	(37,000)	(1,302,000)	(119,000)
Total other income (expense), net	(5,982,000)	(1,321,000)	(4,279,000)	20,294,000
Net income (loss) before income taxes	(67,301,000)	(7,146,000)	(61,548,000)	10,755,000
Provision for income taxes	(58,000)	0	(64,000)	0
Gain on dilution of equity method investment	16,923,000		16,923,000
Losses from investments in equity method investees, net of tax	(2,937,000)	(9,811,000)	(4,640,000)	(11,831,000)
Net loss	(53,373,000)	(16,957,000)	(49,329,000)	(1,076,000)
Net loss attributable to redeemable noncontrolling interests and noncontrolling interests	(4,912,000)	(600,000)	(1,556,000)	(1,022,000)
Net loss attributable to ATAI Life Sciences N.V. stockholders	$ (48,461,000)	$ (16,357,000)	$ (47,773,000)	$ (54,000)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders — basic and diluted	$ (0.37)	$ (0.18)	$ (0.38)	$ 0
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders — basic and diluted	132,265,075	90,709,312	125,797,732	90,709,312

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (53,373)	$ (16,957)	$ (49,329)	$ (1,076)
Other comprehensive loss:
Foreign currency translation adjustments, net of tax	2,110	784	(1,916)	(106)
Comprehensive income (loss)	(51,263)	(16,173)	(51,245)	(1,182)
Comprehensive income (loss) attributable to redeemable noncontrolling interests and noncontrolling interests	(4,912)	(600)	(1,556)	(1,022)
Foreign currency translation adjustments, net of tax attributable to noncontrolling interests	150	(20)	(34)	(7)
Comprehensive loss attributable to redeemable noncontrolling interests and noncontrolling interests	(4,762)	(620)	(1,590)	(1,029)
Comprehensive income (loss) attributable to ATAI Life Sciences N.V. stockholders	$ (46,501)	$ (15,553)	$ (49,655)	$ (153)

Condensed Consolidated Statem_3

Condensed Consolidated Statements Of Redeemable Noncontrolling Interests and Stockholders' Equity - USD ($) $ in Thousands	Total	Stock Purchase Agreement [Member]	Redeemable Noncontrolling Interests [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]Stock Purchase Agreement [Member]	Share Subscriptions Receivable [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member]	Total Stockholders' Equity Attributable to ATAI Life Sciences N.V. Stockholders [Member]Stock Purchase Agreement [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 31, 2019			$ 142
Beginning Balance at Dec. 31, 2019	$ 59,638			$ 10,510	$ 69,819			$ (1,426)	$ (20,152)	$ 58,751		$ 887
Beginning Balance, Shares at Dec. 31, 2019				90,709,312
Stock-based compensation expense	41				41					41
Foreign currency translation adjustment, net of tax	(890)							(903)		(903)		13
Net (Loss) Income			(33)
Net income (loss)									16,302	16,302		(389)
Net income (loss)	15,913
Issuance of noncontrolling interest	0
Ending Balance, Shares at Mar. 31, 2020				90,709,312
Ending Balance at Mar. 31, 2020	74,702			$ 10,510	69,860			(2,329)	(3,850)	74,191		511
Ending Balance at Mar. 31, 2020			109
Beginning Balance at Dec. 31, 2019			142
Beginning Balance at Dec. 31, 2019	59,638			$ 10,510	69,819			(1,426)	(20,152)	58,751		887
Beginning Balance, Shares at Dec. 31, 2019				90,709,312
Net income (loss)	(54)
Ending Balance, Shares at Jun. 30, 2020				90,709,312
Ending Balance at Jun. 30, 2020	58,800			$ 10,510	70,021			(1,525)	(20,207)	58,799
Beginning Balance at Mar. 31, 2020			109
Beginning Balance at Mar. 31, 2020	74,702			$ 10,510	69,860			(2,329)	(3,850)	74,191		511
Beginning Balance, Shares at Mar. 31, 2020				90,709,312
Stock-based compensation expense	41				41					41
Foreign currency translation adjustment, net of tax	777							804		804		(20)
Net (Loss) Income	(16,848)		(109)
Net income (loss)	(16,357)								(16,357)	(16,357)		(491)
Issuance of common shares, net of issuance costs		$ 120				$ 120					$ 120
Issuance of noncontrolling interest	0
Ending Balance, Shares at Jun. 30, 2020				90,709,312
Ending Balance at Jun. 30, 2020	58,800			$ 10,510	70,021			(1,525)	(20,207)	58,799
Beginning Balance at Dec. 31, 2020	95,368			$ 13,372	261,626			5,819	(189,995)	90,822		4,546
Beginning Balance, Shares at Dec. 31, 2020				114,735,712
Stock-based compensation expense	212				212					212
Foreign currency translation adjustment, net of tax	(4,026)							(3,842)		(3,842)		(184)
Net income (loss)	4,044								688	688		3,356
Issuance of common shares, net of issuance costs	23,510			$ 1,881	162,497		$ (140,868)			23,510
Issuance of common shares, net of issuance costs ,Shares				15,552,688
Issuance of common shares under the Hurdle Share Option Plan, Shares				7,281,376
Issuance of noncontrolling interest	885											885
Ending Balance, Shares at Mar. 31, 2021				137,569,776
Ending Balance at Mar. 31, 2021	119,993			$ 15,253	424,335		(140,868)	1,977	(189,307)	111,390		8,603
Beginning Balance at Dec. 31, 2020	95,368			$ 13,372	261,626			5,819	(189,995)	90,822		4,546
Beginning Balance, Shares at Dec. 31, 2020				114,735,712
Net income (loss)	(47,773)
Ending Balance, Shares at Jun. 30, 2021				154,819,776
Ending Balance at Jun. 30, 2021	497,032			$ 17,299	691,382			3,937	(237,768)	474,850		10,045
Beginning Balance at Mar. 31, 2021	119,993			$ 15,253	424,335		(140,868)	1,977	(189,307)	111,390		8,603
Beginning Balance, Shares at Mar. 31, 2021				137,569,776
Stock-based compensation expense	37,512				37,512					37,512
Foreign currency translation adjustment, net of tax	2,110							1,960		1,960		150
Net (Loss) Income			2,555
Net income (loss)	(48,461)		(2,555)						(48,461)	(48,461)		(2,357)
Net income (loss)	(50,818)
Settlement of issuance of common shares value	140,868						$ 140,868			140,868
Issuance of common shares, net of issuance costs	231,581			$ 2,046	229,535					231,581
Issuance of common shares, net of issuance costs ,Shares				17,250,000
Issuance of noncontrolling interest	3,649											3,649
Ending Balance, Shares at Jun. 30, 2021				154,819,776
Ending Balance at Jun. 30, 2021	$ 497,032			$ 17,299	$ 691,382			$ 3,937	$ (237,768)	$ 474,850		$ 10,045

Condensed Consolidated Statem_4

Condensed Consolidated Statements Of Redeemable Noncontrolling Interests and Stockholders' Equity (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Issuance cost	$ 9	$ 4.9
Settlement of issuance cost	$ 4.9

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Net loss	$ (49,329)	$ (1,076)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	25	5
Amortization of debt discount	191	15
Change in fair value of contingent consideration liability- related parties	660	66
Change in fair value of short term notes receivable - related parties		(718)
Change in fair value of convertible promissory notes		133
Change in fair value of derivative liability	(41)	12
Change in fair value of warrant liability	40
Unrealized loss on other investments held at fair value	5,460	0
Unrealized gain on other investments		(19,856)
Gain on dilution of equity method investment	(16,923)
Loss on conversion of convertible notes	513
Gain on consolidation of a variable interest entity	(3,543)
Losses from investments in equity method investees	4,641	11,831
In-process research and development expense	8,934	120
Stock-based compensation expense	37,724	82
Unrealized foreign exchange gains		(155)
Other	41	(57)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,674)	(513)
Accounts payable	2,380	252
Accrued liabilities	(3,846)	752
Deferred revenue	120
Net cash used in operating activities	(14,627)	(9,107)
Cash flows from investing activities
Purchases of property and equipment	(298)	(8)
Capitalized internal-use software development costs	(155)
Cash acquired in asset acquisitions, net	47
Cash paid for investments in equity method investees	(5,359)
Cash paid for other investments	(23,445)	(17,823)
Purchases of long term notes receivable - related party		(1,198)
Loans to related parties	(2,624)
Cash paid for other assets	(195)
Net cash used in investing activities	(32,029)	(19,029)
Cash flows from financing activities
Proceeds from issuance of common stock	409,884
Cash paid for common stock issuance costs	(10,161)
Proceeds from issuance of issuance of share option awards	534
Proceeds from sale of investment	2,417
Proceeds from issuance of convertible promissory notes	1,588	13,011
Net cash provided by financing activities	404,262	13,011
Effect of foreign exchange rate changes on cash	(1,230)	(204)
Net increase (decrease) in cash and cash equivalents	356,376	(15,329)
Cash and cash equivalents – beginning of the period	97,246	30,062
Cash and cash equivalents – end of the period	453,622	14,733
Supplemental disclosures of non-cash investing and financing information:
Fair value of noncontrolling interests issued in connection with asset acquisitions	885
Fair value of noncontrolling interests issued in connection with consolidation of a VIE	392
Fair value redeemable noncontrolling interests issued in connection with consolidation of a VIE	2,555
Issuance of subsidiary shares in connection with the conversion of convertible notes	3,257
Common stock issuance costs in accounts payable	230
Common stock issuance costs in accrued liabilities	1,958
Conversion of short term notes receivable for other investments		9,003
Issuance of subsidiary shares in connection with a stock purchase agreement		120
Issuance of derivative instrument related to convertible promissory notes	$ 646	$ 203

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business ATAI Life Sciences N.V. (“ATAI”) is the parent company of ATAI Life Sciences AG and, along with its subsidiaries, is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. ATAI was founded to address the significant unmet need and lack of innovation in the mental health treatment landscape as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapies. Since inception, ATAI has either created wholly owned subsidiaries or has made investments in certain controlled entities, including variable interest entities (“VIEs”) for which ATAI is the primary beneficiary under the VIE model (collectively, the “Company”). ATAI is headquartered in Berlin, Germany. Corporate Reorganization and Initial Public Offering ATAI was incorporated pursuant to the laws of the Netherlands as a Dutch private company with limited liability on September 10, 2020 for the purposes of becoming a holding company for ATAI Life Sciences AG and for the purposes of consummating the corporate reorganization described below. ATAI has not conducted any operations prior to the corporate reorganization other than activities incidental to its formation. ATAI Life Sciences AG was formed as a separate company on February 7, 2018. In contemplation of the consummation of ATAI’s initial public offering (“IPO”) of common shares, ATAI undertook a corporate reorganization (the “Corporate Reorganization”). The Corporate Reorganization consisted of several steps as described below: • Exchange of ATAI Life Sciences AG Securities for ATAI Life Sciences B.V. Common Shares and Share Split • Conversion of ATAI Life Sciences B.V. into ATAI Life Sciences N.V . The Corporate Reorganization, as described above, is considered a continuation of ATAI Life Sciences AG resulting in no change in the carrying values of assets or liabilities. As a result, the financial statements for periods prior to the Corporate Reorganization are the financial statements of ATAI Life Sciences AG as the predecessor to ATAI for accounting and reporting purposes. All share, per-share On June 22, 2021, ATAI closed the IPO of its common stock on Nasdaq. As part of the IPO, the Company issued and sold 17,250,000 shares of its common stock, which included 2,250,000 shares sold pursuant to the exercise of the underwriters’ over-allotment option, at a public offering price of $15.00 per share. The Co mpany Impact of COVID-19 In December 2019, a novel strain of coronavirus, severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, COVID-19, SARS-CoV-2, COVID-19, shelter-in-place The Company has been actively monitoring the impact of the COVID-19 COVID-19 COVID-19 Liquidity and Going Concern The Company has incurred significant losses and negative cash flows from operations since its inception. As of June 30, 2021, the Company had cash and cash equivalents of $453.6 million and its accumulated deficit was $237.8 million. The Company has historically financed its operations through the sale of equity securities, sale of convertible notes and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates. The Company currently expects that its existing cash as of June 30, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date the unaudited condensed consolidated financial statements are issued.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements, which include the accounts of ATAI, its wholly owned subsidiaries and controlled entities, are presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of SEC regarding interim financial reporting. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with such rules and regulations. All intercompany transactions and accounts have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position, its results of operations and comprehensive loss, and its cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the prospectus dated June 17, 2021 (“Prospectus”) that forms a part of the Company’s Registration Statements on Form S-1 Significant Accounting Policies During the six months ended June 30, 2021, there were no significant changes to the Company’s significant accounting policies as described in the Company’s audited consolidated financial statement as of and for the year ended December 31, 2020 except as described below. Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s short term notes receivable—related party with COMPASS Pathways plc, convertible promissory notes issued in connection with the 2020 convertible note agreement (the “2020 Convertible Notes”), contingent consideration liability—related parties, derivative liability associated with the Perception convertible promissory notes, redeemable noncontrolling interests, and IPR&D assets and noncontrolling interests recognized in acquisitions, the valuations of common shares and share-based awards, and accruals for research and development costs. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of June 30, 2021 and December 31, 2020, cash and cash equivalents consisted of cash on deposit and cash held in high-yield savings accounts and money market funds . Fair Value Measurements Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s contingent consideration liability—related parties, the 2020 Convertible Notes, derivative liability associated with the Perception convertible promissory notes, investment in Intelgenx Technologies Corp. Initial Warrants and Additional Units Warrant and warrant liability with Neuronasal Inc. are carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above (See Note 7). The carrying amount reflected in the accompanying consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature. The carrying amounts of the Company’s convertible promissory notes—related parties issued in 2018 and 2020 (collectively, the “2018 Convertible Notes”) do not approximate fair value because the fair value is driven by the underlying value of the Company’s common stock to which the notes are able to be converted. As of June 30, 2021, the carrying amount and fair value amount of the convertible promissory note s s The carrying amounts of the Perception convertible promissory notes issued during 2020, do not approximate fair value because carrying amounts are net of unamortized debt discounts. The fair value of the Perception convertible promissory notes was determined based on the changes in expectation and increase in probability of occurrence of certain conversion events, including a qualified equity financing and a licensing transaction, that would have beneficial conversion terms for the note holders. In June 2021, Perception convertible promissory notes converted into shares of Series A preferred stock of Perception pursuant to their original terms. As of June 30, 2021, there were no Perception convertible promissory notes outstanding. As of December 31, 2020, the carrying amount and fair value amount for Perception convertible promissory notes was $0.8 million and $4.6 million, respectively. See Note 10 for additional discussion. Fair Value Option As permitted under Accounting Standards Codification 825, Financial Instruments, or ASC 825, the Company has elected the fair value option to account for its investment in IntelGenx Technologies Corp. (“IntelGenx”) common stock which otherwise would be subject to ASC 323. In accordance with ASC 825, the Company records these common stock investments at fair value with changes in fair value recorded as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. Convertible Promissory Notes and Derivative Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including convertible promissory notes, to determine if such instruments contain features that meet the definition of embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statements of operations at each reporting period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheets. On March 16, 2020, Perception entered into a convertible promissory note agreement with the Company and other investors, including related parties, which provided for the issuance of convertible notes of $3.3 million to the Company and $0.6 million to other investors. On December 1, 2020, Perception entered into an additional convertible promissory note agreement with the Company and other investors, including related parties, which provided for the issuance of convertible notes of up to $12.0 million to the Company in aggregate of which (i) $6.2 million and $0.8 million were issued in December 2020 and January 2021, respectively, under the First Tranche Funding and (ii) $5.0 million was issued under the Second Tranche Funding (See Note 10). The Perception convertible promissory notes issued to the Company represent intercompany debt and are eliminated upon consolidation. In addition, the Perception convertible promissory notes contain certain embedded features, which are redemption features and meet the definition of derivative instruments. The Company classifies these instruments as a liability on its consolidated balance sheets as the redemption features involve substantial discounts, provide for the accelerated repayment of the notes upon the occurrence of specified events, and are not clearly and closely related to its host instrument. The derivative liability was initially recorded at fair value upon issuance of the convertible promissory notes and is subsequently remeasured to fair value at each reporting date. Both the Perception convertible promissory notes and the derivative liability have been classified as long-term and presented as convertible promissory notes and derivative liability in the Company’s consolidated balance sheets. Changes in the fair value of the derivative asset and liability are recognized as a component of other income (expense), net in the consolidated statements of operations. Changes in the fair value of the derivative asset and liability will continue to be recognized until the warrants and convertible promissory notes are longer outstanding . Warrant Liability The Company accounts for the warrants in accordance with the guidance contained in ASC 815-40 re-measurement Licenses of Intellectual Property The Company may enter into collaboration and licensing arrangements for research and development, manufacturing, and commercialization activities with counterparties for the development and commercialization of its product candidates. The agreements may have units of account within the scope of ASC 606 where the counterparties meet the definition of a customer as well as units of account within the scope of ASC 808 where both parties are determined to be active participants. The arrangements may contain multiple components, which may include (i) licenses, or options to obtain licenses to the Company’s intellectual property or sale of the Company’s license, (ii) research and development activities, (iii) participation on joint steering committees, and (iv) the manufacturing of commercial, clinical or preclinical material. Payments pursuant to these arrangements may include non-refundable, In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its collaboration and license agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract within the scope of ASC 606; (ii) determination of whether the promised goods or services are performance obligations including whether they are capable of being distinct and distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and d) the measure of progress in step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based milestones and royalties on license arrangements, should be included in the transaction price as described further below. If a license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other elements, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the counterparties and the availability of its associated expertise in the general marketplace. In addition, the Company considers whether the counterparties can benefit from a promise for its intended purpose without the receipt of the remaining elements, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress as of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, is subject to estimates by management and may change over the course of the arrangement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Customer Options: If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services such as research and development services or manufacturing services, the goods and services underlying the customer options are not considered to be performance obligations at the inception of the arrangement unless a material right is provided to the customer. If the customer option does not represent a material right, the obligation to provide such goods and services is contingent on exercise of the option, and the associated consideration is not included in the transaction price. If a customer option is determined to include a significant and incremental discount and, therefore, represents a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price. Milestone Payments: At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most-likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the respective milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up Royalties: For license arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. Stock-Based Compensation The Company accounts for all stock-based payment awards granted to employees, directors and non-employees as stock-based compensation expense based on their grant date fair value. The Company grants equity awards under its stock-based compensation programs, which may include stock options and restricted common stock. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. Since the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant, and stock-based compensation costs are recognized in the same period and in the same manner as if the entity had paid cash for the goods or services. Stock-based compensation expense is classified in the accompanying condensed consolidated statements of operations based on the function to which the related services are provided. The Company has elected to recognize forfeitures of stock-based compensation awards as they occur. The Company recognizes the compensation cost of awards subject to service-based and performance-based vesting conditions using the accelerated attribution method over the requisite service period if the performance- based vesting conditions are probable of being met. Recognition of compensation cost relating to awards that vest on a “Liquidity Event” (as defined in the award or Partnership agreements) will be deferred until the consummation of such transaction. The Company calculates the fair value of stock options granted using the Black-Scholes option-pricing model with the following assumptions: Expected Volatility Expected Term Risk-Free Interest Rate Dividend Yield As part of the valuation of stock-based compensation under the Black-Scholes option pricing model, it is necessary for the Company to estimate the fair value of its common stock. Prior to the closing of the IPO, the fair value of the Company’s common stock was estimated on each grant date. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants’ Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercised reasonable judgment and considered numerous objective and subjective factors to determine its best estimate of the fair value of its common stock. The estimation of the fair value of the common stock considered factors including the following: the estimated present value of the Company’s future cash flows; the Company’s business, financial condition and results of operations; the Company’s forecasted operating performance; the illiquid nature of the Company’s common stock; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. After the closing of the IPO, the Company’s board of directors determined the fair value of each share of common stock underlying stock-based awards based on the closing price of the Company’s common stock as reported by Nasdaq on the date of grant. Net Income (Loss) per Share Attributable to Common Stockholders The Company computed basic net income (loss) per share attributable to common stockholders by dividing net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net income (loss) per common share after giving consideration to all potentially dilutive common stock, including convertible notes and stock options, outstanding during the period determined using the if-converted Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815—40) ” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU’s amendments are effective for the Company for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years, with early adoption permitted. The Company early adopted this standard on January 1, 2021 applying the modified retrospective transition approach. Upon adoption of ASU 2020-06, the embedded conversion option related to the 2018 Convertible Notes is no longer separated from the host contract and recognized within additional paid-in-capital and is instead accounted for as a single liability measured at amortized cost $ 8,000

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2021
Business Combinations [Abstract]
Acquisitions	3. Acquisitions 2021 Acquisitions PsyProtix, Inc. In February 2021, the Company jointly formed PsyProtix with Chymia, LLC (“Chymia”). PsyProtix was created for the purpose of exploring and developing a metabolomics-based precision psychiatry approach, initially targeting the stratification and treatment of Treatment Resistant Depression (“TRD”) patients. In February 2021, pursuant to a Series A Preferred Stock Purchase Agreement (the “PsyProtix Purchase Agreement”), the Company acquired shares of PsyProtix’s Series A preferred stock in exchange for an initial payment of $0.1 million in cash. In addition, pursuant to the PsyProtix Purchase Agreement, the Company agreed to make aggregate payments to PsyProtix of up to $4.9 million upon the achievement of specified clinical milestones to complete the purchase of the shares and provide additional funding to PsyProtix. The PsyProtix Purchase Agreement resulted in the Company holding a 75.0% voting interest and Chymia holding a 25.0% voting interest in PsyProtix. In connection with the Company’s agreement for additional funding, PsyProtix issued the corresponding Series A preferred shares to the Company provided that the shares are held in an escrow account (the “PsyProtix Escrow Shares”). The PsyProtix Escrow Shares will be released, from time to time, to the Company upon PsyProtix achieving certain milestones as defined in the PsyProtix Purchase Agreement with cash payments to be made by the Company. In addition, the Company has the right, but not the obligation, to make payment for the certain PsyProtix Escrow Shares at any time, regardless of the achievement of any milestones. The PsyProtix Escrow Shares have voting and all other rights until an event of default occurs where the Company fails to make a payment within 10 days following the written notice of the achievement of the relevant milestone. In the event of default, a pro rata portion of the PsyProtix Escrow Shares will automatically be surrendered and be deemed forfeited and canceled, and could result in the Company losing control of PsyProtix’s board of directors and its controlling financial interest in PsyProtix. In addition, prior to the occurrence of the earlier of a certain milestone event or reaching of the Company’s capital contribution threshold of $5.0 million, PsyProtix will issue additional shares of common stock to Chymia to maintain Chymia’s current ownership percentage. This anti-dilution right was concluded to be embedded in the common shares held by Chymia. Immediately following the closing of the PsyProtix Purchase Agreement, PsyProtix loaned $0.1 million to Chymia in exchange for a duly executed promissory note (the “Chymia Note”). The Chymia Note shall accrue interest at a 5% rate per annum until payment in full. The aggregate principal amount of $0.1 million, together with all accrued and unpaid interest and all other amounts payable are due to be paid on the date that is the earlier of (i) five years from the promissory note agreement date or (ii) the occurrence of a liquidation event or a deemed liquidation event (as defined in the PsyProtix’s certificate of incorporation). As of June 30, 2021, the Chymia Note was $0.1 million and included as a component of long-term notes receivable—related parties on the condensed consolidated balance sheets. The PsyProtix Purchase Agreement provided the Company unilateral rights to control all decisions related to the significant activities of PsyProtix. The Company concluded that PsyProtix was not considered a business based on its assessment under ASC 805 and accounted for the Company’s acquisition in PsyProtix as an initial consolidation of a VIE that is not a business under ASC 810 (See Note 4). The assets acquired, liabilities assumed, and noncontrolling interest in the transaction were measured based on their fair values. The Company did not recognize a gain or a loss in connection with the consolidation of PsyProtix as the fair value of the consideration paid of $0.1 million was equivalent to the fair value of the identifiable assets acquired of $0.1 million. Psyber, Inc. Psyber is a globally based startup focused on the development of brain-computer interface-enabled digital therapeutics for treating mental health issues. Psyber was created as a joint venture between the Company and the founders of Psyber. In February 2021, pursuant to a Series A Preferred Stock Purchase Agreement (the “Psyber Purchase Agreement”), the Company acquired shares of Psyber’s Series A preferred stock in exchange for an initial payment of $0.2 million in cash. In addition, pursuant to the Psyber Purchase Agreement, the Company agreed to make aggregate payments to Psyber of up to $1.8 million upon the achievement of specified clinical milestones to complete the purchase of the shares and provide additional funding to Psyber. The Psyber Purchase Agreement resulted in the Company holding a 75.0% voting interest and the founders of Psyber jointly holding a 25.0% voting interest in Psyber. In connection with the Company’s agreement for additional funding, Psyber issued the corresponding Series A preferred shares to the Company provided that the shares are held in an escrow account (the “Psyber Escrow Shares”). The Psyber Escrow Shares will be released, from time to time, to the Company upon Psyber achieving certain milestones as defined in the Psyber Purchase Agreement with cash payments to be made by the Company. In addition, the Company has the right, but not the obligation, to make payment for the certain Psyber Escrow Shares at any time, regardless of the achievement of any milestones. The Psyber Escrow Shares have voting and all other rights until an event of default occurs where the Company fails to make a payment within 10 days following the written notice of the achievement of the relevant milestone. In the event of default, a pro rata portion of the Psyber Escrow Shares will automatically be surrendered and be deemed forfeited and canceled, and could result in the Company losing control of Psyber’s board of directors and its controlling financial interest in Psyber. In addition, prior to the occurrence of the earlier of a certain milestone event or reaching of the Company’s capital contribution threshold of $2.0 million, Psyber will issue additional shares of common stock to the founders of Psyber to maintain the founders’ current ownership percentage. This anti-dilution right was concluded to be embedded in the common shares held by the founders of Psyber. The Psyber Purchase Agreement provided the Company unilateral rights to control all decisions related to the significant activities of Psyber. The Company concluded that Psyber was not considered a business based on its assessment under ASC 805 and accounted for the Company’s acquisition in Psyber as an initial consolidation of a VIE that is not a business under ASC 810 (See Note 4). The assets acquired, liabilities assumed, and noncontrolling interest in the transaction were measured based on their fair values. The Company recognized a gain on consolidation of $2,000. The gain was calculated as the sum of the consideration paid of $0.2 million, less the fair value of identifiable net assets acquired of $0.2 million. InnarisBio, Inc. In February 2021, the Company jointly formed InnarisBio with UniQuest Pty Ltd (“UniQuest”) for the purpose of adding a solgel-based direct-to-brain The InnarisBio Purchase Agreement provided the Company unilateral rights to control all decisions related to the significant activities of InnarisBio. The Company concluded that InnarisBio was not considered a business based on its assessment under ASC 805 and accounted for the Company’s acquisition in InnarisBio as an initial consolidation of a VIE that is not a business under ASC 810 (See Note 4). The assets acquired, liabilities assumed, and noncontrolling interest in the transaction were measured based on their fair values. The Company recognized a loss on consolidation of $7,000 for the six months ended June 30, 2021. The loss was calculated as the sum of the consideration paid of $1.1 million, the fair value of the noncontrolling interest issued of $0.9 million, less the fair value of identifiable net assets acquired of $2.0 million. The fair value of the contingent milestone payments of $0.1 million was included in the total purchase consideration for the noncontrolling interest and recognized as a liability by InnarisBio at the date of acquisition. The fair value of the IPR&D acquired of $1.0 million was reflected as acquired in-process Neuronasal, Inc. Neuronasal, Inc. (“Neuronasal”) is developing a novel intranasal formulation of N-acetylcysteine for acute mild traumatic brain injury. The Company first acquired investments in Neuronasal in December 2019 pursuant to a Preferred Stock Purchase Agreement (the “Neuronasal PSPA”). In December 2019, in connection with the original purchase of the preferred shares, Neuronasal and the Company entered into the Secondary Sale and Put Right Agreement (the “Neuronasal Secondary Sale Agreement”), whereby upon the achievement of certain contingent development milestones, existing common shareholders have the right to sell and the Company has the option but not the obligation to purchase additional shares of common stock at a price determined based on the fair market value per share on the date of exercise. These options are contingent upon the exercise of the options by Neuronasal’s common shareholders to sell shares to the Company. On March 10, 2021, pursuant to the Neuronasal PSPA, the Company purchased additional Series A preferred shares for approximately $0.8 million based on the achievement of certain development milestones. Also, pursuant to the Neuronasal Secondary Sale Agreement, the Company purchased additional common shares for approximately $0.3 million. On May 17, 2021, pursuant to the Neuronasal PSPA the Company exercised its option to purchase additional shares of Series A preferred stock of Neuronasal for an aggregate cost of $1.0 million. The additional purchase on May 17, 2021 resulted in the Company obtaining an aggregate 55.99% ownership interest in Neuronasal, including the Company’s previously acquired investments in Neuronasal’s common and preferred stock, and provided the Company with control of Neuronasal’s board of directors and the unilateral rights to control all decisions related to the significant activities of Neuronasal. Prior to May 17, 2021, the Company accounted for its investments in Neuronasal’s common stock under the equity method and Neuronasal’s preferred stock under the measurement alternative (See Note 5). Following the closing of this acquisition on May 17, 2021, the results of Neuronasal have been consolidated in the Company’s consolidated financial statements. The Company concluded that Neuronasal was not considered a business based on its assessment under ASC 805 and accounted for the Company’s acquisition in Neuronasal as an initial consolidation of a variable interest entity (“VIE”) that is not a business under ASC 810 (See Note 4). The assets acquired, liabilities assumed , and noncontrolling interest in the transaction were measured based on their fair values. The Company recognized a gain of $3.5 million. The gain was calculated as the sum of the consideration paid of $1.0 million, the fair value of the noncontrolling interest issued of $3.0 million, the carrying value of the Company’s investments in Neuronasal’s common stock and preferred stock prior to May 17, 2021 of $0.8 million, less the fair value of identifiable net assets acq u All acquisitions discussed above were considered as asset acquisitions and no goodwill was recognized upon consolidation.

Variable Interest Entities and

Variable Interest Entities and a Voting Interest Entity	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities and a Voting Interest Entity	4. Variable Interest Entities and a Voting Interest Entity Consolidated VIEs At each reporting period, the Company reassesses whether it remains the primary beneficiary for Variable Interest Entities (“VIEs”) consolidated under the VIE model. For the acquisitions further described in Note 3, the Company determined that PsyProtix, Inc., Psyber, Inc., InnarisBio, Inc., and Neuronasal, Inc. are VIEs as each entity does not have sufficient equity at risk to carry out its principal activities without additional subordinated financial support. As of June 30, 2021 and December 31, 2020, the Company has accounted for the following investments as VIEs, excluding the wholly owned subsidiaries: Consolidated Entities Relationship as of June 30, 2021 Relationship as of December 31, 2020 Date Control Obtained Ownership % June 30, 2021 Ownership % December 31, 2020 Perception Neuroscience Holdings, Inc. Controlled VIE Controlled VIE November 2018 58.9 % 50.1 % Kures, Inc. Controlled VIE Controlled VIE August 2019 54.1 % 54.1 % EntheogeniX Biosciences, Inc. Controlled VIE Controlled VIE November 2019 80.0 % 80.0 % DemeRx IB, Inc. Controlled VIE Controlled VIE December 2019 59.5 % 59.5 % Recognify Life Sciences, Inc. Controlled VIE Controlled VIE November 2020 51.9 % 51.9 % PsyProtix, Inc. Controlled VIE — February 2021 75.0 % — Psyber, Inc. Controlled VIE — February 2021 75.0 % — InnarisBio, Inc. Controlled VIE — March 2021 82.0 % — Neuronasal, Inc. Controlled VIE Investment May 2021 56.0 % 37.2 % The entities consolidated by the Company are comprised of wholly and partially owned entities for which the Company is the primary beneficiary under the VIE model as the Company has (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses that could potentially be significant to the VIE, or the right to receive benefits from the VIE that could potentially be significant to the VIE. The results of operations of the consolidated entities are included within the Company’s condensed consolidated financial statements from the date of acquisition to June 30, 2021. As of June 30, 2021 and December 31, 2020, the assets of the consolidated VIEs can only be used to settle the obligations of the respective VIEs. The liabilities of the consolidated VIEs are obligations of the respective VIEs and their creditors have no recourse to the general credit or assets of ATAI. The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all VIEs as of June 30, 2021 (in thousands): Perception Kures EntheogeniX DemeRx IB Recognify PsyProtix Psyber InnarisBio Neuronasal Assets: Current assets: Cash $ 26,741 $ 762 $ 401 $ 5,351 $ 1,493 $ 91 $ 174 $ 816 $ 691 Unbilled receivable — — — — — — — — — Prepaid expenses and other current assets 1,638 84 — 431 15 — — — 560 Total current assets 28,379 846 401 5,782 1,508 91 174 816 1,251 Property and equipment, net 2 — — — — — — — — Goodwill — — — — — — — — — Long term notes receivable — — — 1,075 — 102 — — — Total assets $ 28,381 $ 846 $ 401 $ 6,857 $ 1,508 $ 193 $ 174 $ 816 $ 1,251 Liabilities: Current liabilities: Accounts payabl e $ 743 $ 210 $ 26 $ 495 $ 19 $ — $ 1 $ — $ 253 Accrued liabilities 947 356 31 154 264 9 69 — 384 Deferred revenue 120 — — — — — — — — Convertible — — — — — — — — 38 Total current liabilities 1,810 566 57 649 283 9 70 — 675 Convertible promissory notes and derivative liability — — — — — — — — — Contingent consideration liability 2,363 — — — — — — 103 — Other non-current — — — — — — — — 289 Total liabilities $ 4,173 $ 566 $ 57 $ 649 $ 283 $ 9 $ 70 $ 103 $ 964 The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all consolidated VIEs as of December 31, 2020 (in thousands): Perception Kures EntheogeniX DemeRx IB Recognify Assets: Current assets: Cash $ 6,527 $ 1,264 $ 652 $ 7,252 $ 1,895 Prepaid expenses and other current assets 768 124 — 193 44 Total current assets 7,295 1,388 652 7,445 1,939 Property and equipment, net 4 — — — — Long term notes receivable — — — 1,060 — Total assets $ 7,299 $ 1,388 $ 652 $ 8,505 $ 1,939 Liabilities: Current liabilities: Accounts payable $ 564 $ 220 $ 35 $ 230 $ 64 Accrued liabilities 297 229 11 92 66 Total current liabilities 861 449 46 322 130 Convertible promissory notes and derivative liability 978 — — — — Contingent consideration liability 1,705 — — — — Total liabilities $ 3,544 $ 449 $ 46 $ 322 $ 130 Noncontrolling Interests The Company recognizes noncontrolling interests related to its consolidated VIEs and provides a rollforward of the noncontrolling interests balance, as follows (in thousands): Perception Recognify Psyber InnarisBio Neuronasal Total Balance as of December 31, 2020 $ — $ 4,546 $ — $ — $ — $ 4,546 Issuance of noncontrolling interests — — 8 877 — 885 Net income (loss) attributable to noncontrolling interests - common 1,755 — (8 ) (877 ) — 870 Net income (loss) attributable to noncontrolling interests - preferred 2,608 (122 ) — — — 2,486 Comprehensive loss attributable to noncontrolling interests (184 ) — — — — (184 ) Balance as of March 31, 2021 $ 4,179 $ 4,424 $ — $ — $ — $ 8,603 Issuance of noncontrolling interests 3,257 — — — 392 3,649 Net income (loss) attributable to noncontrolling interests - common (1,755 ) (217 ) — — (392 ) (2,364 ) Net income (loss) attributable to noncontrolling interests - preferred 7 — — — — 7 Comprehensive loss attributable to noncontrolling interests 150 — — — — 150 Balance as of June 30, 2021 $ 5,838 $ 4,207 $ — $ — $ — $ 10,045 Perception Kures Total Balance as of December 31, 2019 $ 487 $ 400 $ 887 Issuance of noncontrolling interests — — — Repurchase of noncontrolling interest — — — Net loss attributable to noncontrolling interests - common — — — Net loss attributable to noncontrolling interests - preferred (297 ) (92 ) (389 ) Comprehensive loss attributable to noncontrolling interests 13 — 13 Balance as of March 31, 2020 $ 203 $ 308 $ 511 Issuance of noncontrolling interests — — — Repurchase of noncontrolling interest — — — Net loss attributable to noncontrolling interests - common — — — Net loss attributable to noncontrolling interests - preferred (183 ) (308 ) (491 ) Comprehensive loss attributable to noncontrolling interests (20 ) — (20 ) Balance as of June 30, 2020 $ — $ — $ — Redeemable Noncontrolling Interests In connection with the consolidation of Kures, the Company recognized the shares of Kures common stock and Series A-1 In connection with the consolidation of DemeRx IB, the Company recognized common stock held by DemeRx as redeemable noncontrolling interests as they are redeemable upon the occurrence of events that are not solely within the control of the Company. The redeemable noncontrolling interests were initially measured at fair value upon issuance and are redeemable at fair value at the holder’s option upon the successful completion of future events. As of June 30, 2021 and December 31, 2020, the Company did not adjust the carrying value of the redeemable noncontrolling interests based on their estimated redemption values since it was not probable that the events that would allow the shares to become redeemable would occur. Subsequent adjustments to increase or decrease the carrying values of the redeemable noncontrolling interests to their estimated redemption values will be made if and when it becomes probable that such events will occur. In connection with the consolidation of Neuronasal, the Company recognized the shares of Neuronasal common stock held by the founders of Neuronasal as redeemable noncontrolling interests as they contain embedded put options that are exercisable by the founders following a successful completion of a future event, which is not solely within the control of the Company. The redeemable noncontrolling interests were initially measured at fair value upon issuance and are redeemable at fair value at the holder’s option upon the successful completion or occurrence of future events. As of June 30, 2021, the Company did not adjust the carrying value of the redeemable noncontrolling interests based on their estimated redemption values since it was not probable that the events that would allow the shares to become redeemable would occur. Subsequent adjustments to increase or decrease the carrying values of the redeemable noncontrolling interests to their estimated redemption values will be made if and when it becomes probable that such events will occur. Redeemable noncontrolling interests are classified in temporary equity as they are redeemable based on events that are not solely within the control of the Company. As of June 30, 2021 and December 31, 2020, the balance of redeemable noncontrolling interests in temporary equity on the condensed consolidated balance sheets was zero. The amount of net loss attributable to redeemable noncontrolling interests of $2.6 The following table provides a rollforward of the redeemable noncontrolling interests balance (in thousands): Kures Neuronasal Total Balance as of December 31, 2020 $ — $ — $ — Issuance of redeemable noncontrolling interests — — — Net loss attributable to redeemable noncontrolling interests - common — — — Balance as of March 31, 2021 $ — $ — $ — Issuance of redeemable noncontrolling interests — 2,555 2,555 Net loss attributable to redeemable noncontrolling interests - common — (2,555 ) (2,555 ) Balance as of June 30, 2021 $ — $ — $ — Kures Total Balance as of December 31, 2019 $ 142 $ 142 Net loss attributable to redeemable noncontrolling interests - preferred (33 ) (33 ) Balance as of March 31, 2020 $ 109 $ 109 Net loss attributable to redeemable noncontrolling interests - preferred (109 ) (109 ) Balance as of June 30, 2020 $ — $ — Non-consolidated The Company evaluated the nature of its investments in Innoplexus AG (“Innoplexus”), DemeRx NB, Inc. (“DemeRx NB”) and IntelGenx and determined that the investments are VIEs as of the date of the Company’s initial investment through June 30, 2021. The Company is not the primary beneficiary as it did not have the power to direct the activities that most significantly impact the investments’ economic performance and therefore concluded that it did not have a controlling financial interest that would require consolidation as of June 30, 2021 and December 31, 2020. The Company will reevaluate if the investments meet the definition of a VIE upon the occurrence of specific reconsideration events. The Company accounted for these investments under either the equity method or the measurement alternative included within ASC 321 (See Note 5). As of June 30, 2021, the Company’s maximum exposure for its non-consolidated million relating to the carrying values in other investments and other investments held at fair value and $3.2 million relating to the carrying value in long term notes receivable – related party. non-consolidated The Company evaluated the nature of its investment in Gaba Therapeutics, Inc. (“Gaba”) and determined that Gaba was a VIE through May 21, 2021 when the Company exercised its option to purchase additional shares or Series A Preferred stock for an aggregate purchase price of $5.0 million (see Note 5). Prior to the option exercise, the Company was not the primary beneficiary as it did not have the power to direct the activities that most significantly impact the investment’s economic performance and therefore concluded that it did not have a controlling financial interest that would require consolidation through May 21, 2021. The completion of the Series A Preferred stock purchase in May 2021 was deemed to be a reconsideration event at which point Gaba was no longer deemed a VIE as Gaba now had sufficient equity at risk to finance its activities through the initial development period without additional subordinated financial support. Entities that do not qualify as a VIE are assessed for consolidation under the voting interest model (“VOE model”). Under the VOE model, the Company consolidates the entity if it determines that it, directly or indirectly, has greater than 50% of the voting shares and that other equity holders do not have substantive voting, participating or liquidation rights. While the Company holds greater than 50% of the outstanding equity interest of Gaba, the Company does not have the power to control the entity. Concurrent with the exercise of the option, the Company executed a side letter with the other equity holders of Gaba agreeing to forego the rights to additional seats on the Board of Directors, resulting in the Company lacking the ability to control the investee. The Company concluded that it does not have a controlling financial interest that would require consolidation under the VOE model and accounted for the investments in Gaba preferred stock under the measurement alternative per ASC 323 (See Note 5). As disclosed in Note 5, as of June 30, 2021, the Company is obligated to purchase additional shares of Series A preferred stock of GABA for up to $1.5 million upon the achievement of certain specified contingent clinical development milestones. This amount has not been included in the Company’s determination of the maximum exposure of loss presented for its non-consolidated The Company had an investment in COMPASS Pathways plc (formerly known as Compass Pathfinder Holding Limited) (“COMPASS”) which was determined to be an investment in a VIE as of December 31, 2019 and through the date prior to its initial public offering in September 2020 (“COMPASS IPO”); however, the Company was not the primary beneficiary as it did not have the power to direct the activities that most significantly impact the investment’s economic performance and therefore concluded that it did not have a controlling financial interest that would require consolidation during this period as of December 31, 2019 and through September 2020. The completion of the COMPASS IPO in September 2020 was deemed to be a reconsideration event. Upon the completion of the COMPASS IPO, the Company’s investment in COMPASS was no longer deemed an investment in a VIE as COMPASS now had sufficient equity at risk to finance its activities without additional subordinated financial support. Entities that do not qualify as a VIE are assessed for consolidation under the voting interest model (“VOE model”). Under the VOE model, the Company consolidates the entity if it determines that it, directly or indirectly, has greater than 50% of the voting shares and that other equity holders do not have substantive voting, participating or liquidation rights. From the date of the COMPASS IPO through December 31, 2020, the Company’s voting interest was 26.3% which included the voting rights provided under the voting agreements as further described in Note 5 below. In April 2021, the voting agreements were terminated. On May 4, 2021, the Company purchased additional equity investments in COMPASS common stock. From the date of the additional investment through June 30, 2021, the Company’s voting interest was 19.4%. The Company concluded that it did not have a controlling financial interest that would require consolidation under the VOE model and accounted for the investments in COMPASS common stock under the equity method (See Note 5) .

Equity Method Investments and O

Equity Method Investments and Other Investments	6 Months Ended
	Jun. 30, 2021
Cash and Cash Equivalents [Abstract]
Equity Method Investments and Other Investments	5. Equity Method Investments and Other Investments Equity Method Investments As of June 30, 2021 and December 31, 2020, the Company accounted for the following investments in the investee’s common stock under the equity method (amounts in thousands): As of June 30, 2021 As of December 31, 2020 Date First Common Stock Carrying Common Stock Carrying Investee Acquired Ownership % Value Ownership % Value Innoplexus A.G. August 2018 35.0 % $ — 35.0 % $ — COMPASS Pathways plc (2) December 2018 19.4 % 19,780 22.1 % — GABA Therapeutics, Inc November 2020 7.5 % (1) — 7.5 % (1) — Neuronasal, Inc October 2020 n/a (3) — 9.8 % (1) — Total $ 19,780 $ — (1) The Company is deemed to have significant influence over this entity through its total ownership interest in the entity’s equity, including the Company’s investment in the respective entity’s preferred stock, described below in Other Investments. (2) Prior to the consummation of the COMPASS IPO in September 2020, COMPASS undertook a corporate reorganization. As part of the corporate reorganization, COMPASS became a wholly owned subsidiary of COMPASS Rx Limited. COMPASS Rx Limited was re-registered as (3) Neuronasal common stock was accounted for under the equity method until the entity was Other Investments The Company has accounted for its other investments that do not have a readily determinable fair value under the measurement alternative. As of June 30, 2021 and December 31, 2020, the carrying values of other investments, which consisted of investments in the investee’s preferred stock and common stock not in the scope of ASC 323 were as follows (in thousands): June 30, December 31, 2021 2020 GABA Therapeutics, Inc. $ 14,682 $ 5,519 DemeRx NB, Inc. 1,067 1,096 Juvenescence Limite d 358 368 Neuronasal, Inc. — 1,061 Total $ 16,107 $ 8,044 The Company’s investments in the preferred stock of COMPASS (through September 2020), Neuronasal (through May 2021), Innoplexus, GABA, and DemeRx NB are not considered as in-substance During the three and six months ended June 30, 2021 and 2020 there were no observable changes in price recorded related to the Company’s Other Investments. During the three and six months ended June 30, 2021 and 2020, the Company evaluated all of its other investments to determine if certain events or changes in circumstance during these time periods in 2021 and 2020 had a significant adverse effect on the fair value of any of its investments in non-consolidated Innoplexus AG Innoplexus AG is a technology company that provides “Data as a Service” and “Continuous Analytics as a Service” solutions that aims to help healthcare organizations leverage their technologies and expedite the drug development process across all stages—preclinical, clinical, regulatory and commercial. The Company first acquired investments in Innoplexus in August 2018. As of December 31, 2020, the Company owned 35.0% of the common stock issued by Innoplexus. The Company has significant influence over Innoplexus through its noncontrolling representation on the investee’s supervisory board. Accordingly, the Company’s investment in Innoplexus’ common stock was accounted for in accordance with the equity method. The Company’s investment in Innoplexus’ preferred stock did not meet the criteria for in-substance In February 2021, the Company entered into a Share Purchase and Assignment Agreement (the “Innoplexus SPA”) to sell its shares of common and preferred stock held in Innoplexus to a current investor of Innoplexus (the “Purchaser”) in exchange for an initial purchase price of approximately $2.4 million. In addition, the Company is entitled to receive contingent payments based on the occurrence of subsequent equity transactions or liquidity events at Innoplexus as determined under the Innoplexus SPA. Pursuant to the Innoplexus SPA, the Purchaser is required to hold a minimum number of shares equivalent to the number of shares purchased from the Company through December 31, 2026. In the event that the Purchaser is in breach of this requirement, the purchaser is required to pay the Company an additional purchase price of approximately $9.6 million. The transaction was accounted for as a secured financing as it did not qualify for sale accounting under ASC Topic 860, Transfers and Servicing In addition, the Innoplexus SPA also provides the rights for the Company to receive additional consideration with a maximum payment outcome of $22.3 million should the equity value of Innoplexus exceed certain thresholds upon the occurrence of certain events. The Company concluded that this feature met the definition of a derivative which required bifurcation. As the probability of the occurrence of certain events defined in the Innoplexus SPA was less than remote, the Company concluded that the fair value of the embedded derivative ascribed to this feature was de minimis as of June 30, 2021. The carrying value of the Company’s investment in Innoplexus was zero as of June 30, 2021 and December 31, 2020. COMPASS Pathways plc COMPASS Pathways plc is a mental health care company dedicated to pioneering the development of a new model of psilocybin therapy with its product COMP360. The Company first acquired investments in COMPASS in December 2018. Common Stock Investment During the first quarter of 2020, the Company’s investment in COMPASS common stock, which was accounted for under the equity method, was reduced to zero after the Company recognized its proportionate share of COMPASS’ net loss from investments in equity method investees. Upon the consummation of the COMPASS IPO, all of the Company’s outstanding shares of COMPASS, including 7,052,003 shares of COMPASS preferred stock were converted into 7,935,663 new ordinary shares of COMPASS Pathways plc. Upon the COMPASS Preferred Stock Conversion, the Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in COMPASS’ preferred shares of $53.1 million in equity method investments in the condensed consolidated balance sheets. The carrying value of the investment in COMPASS common stock was reduced to zero as of December 31,2020 due to IPR&D charge with no alternative future use. Since the Company has no obligation to provide financing support to COMPASS On May 4, 2021, COMPASS From the original acquisition of COMPASS common shares in December 2018 through the COMPASS IPO, the Company is deemed to have significant influence over COMPASS through its ownership interest in COMPASS’ equity, including the Company’s investment in COMPASS preferred stock, described below in Other Investments, and the Company’s noncontrolling representation on the COMPASS’ board of directors. Accordingly, the Company’s investment in COMPASS’ common stock was accounted for in accordance with the equity method. The Company’s investment in COMPASS’ preferred stock did not meet the criteria for in-substance In December 2020, the Company entered into two voting agreements with COMPASS registered shareholders. The voting agreements provided the Company the voting rights attached to the COMPASS ordinary shares held by such COMPASS shareholders. As of December 31, 2020, the Company held 26.3% voting interest in COMPASS, which included the voting rights provided under the voting agreements. The voting agreements did not provide the Company control over COMPASS nor additional board seats and therefore had no impact on the Company’s investment in COMPASS under the equity method. In April 2021, both voting agreements were terminated. During the three months ended June 30, 2021 and 2020, the Company recognized its proportionate share of COMPASS’ net loss of $2.1 million and $ 9.8 million, respectively, as losses from investments in equity method investees, net of tax on the condensed consolidated statements of operations. During the six months ended June 30, 2021 and 2020, the Company recognized its proportionate share of COMPASS’ net loss of $2.1 million and $11.8 million, respectively, as losses from investments in equity method investees, net of tax on the condensed consolidated statements of operations. During the three and six months ended June 30, 2020, the Company’s proportionate share of COMPASS’ net loss was more than the Company’s proportionate share using the common stock ownership percentage described above because the aggregate net losses attributable to the Company’s investment in COMPASS common stock reduced the carrying amount to zero in the first quarter of 2020. Accordingly, the remaining COMPASS’ net losses attributable to the Company was determined based on the Company’s ownership percentage of each class of preferred stock in COMPASS and recorded to the Company’s investments in COMPASS Preferred Stock Investment The Company’s preferred stock ownership in COMPASS is included in Other Investments and obtained through a series of related party transactions since 2018. In connection with COMPASS’ secondary Series A preferred stock offering in March 2020, the Company’s investment in COMPASS’ Series A preferred shares were remeasured to fair value due to the observable price change, resulting an aggregate gain of $19.9 million in unrealized gains on other investments in the condensed consolidated statements of operations during the six months ended June 30, 2020. In March 2020, the Company purchased additional shares of COMPASS Series A preferred stock for £16.1 million or approximately $17.8 million under the secondary Series A preferred stock purchase. In April 2020, COMPASS entered into the Series B preferred stock subscription agreement with other investors for issuance of its Series B preferred stock, which resulted in an automatic conversion of the Company’s COMPASS convertible notes receivable, totaling £6.2 million or $7.6 million on the date of conversion, into shares of COMPASS Series B preferred stock at a conversion price per share representing a 15% discount to the price per share paid by the investors in the COMPASS Series B preferred stock issuance (the “COMPASS Notes Conversion”) (See Note 6). In addition, in April 2020, the Company purchased additional shares of COMPASS Series B preferred stock for $5.3 million and the purchase was completed in August 2020. In September 2020, in connection with the COMPASS IPO, all of the Company’s outstanding shares of 7,052,003 COMPASS preferred stock were converted into new ordinary shares of COMPASS Pathways plc as discussed above (the “COMPASS Preferred Stock Conversion”). Upon the COMPASS Preferred Stock Conversion, the Company accounted for the transaction under the equity method and recorded the carrying value of the Company’s investment in COMPASS’ preferred shares of $53.1 million in equity method investments in the condensed consolidated balance sheets. As of December 31, 2020, the COMPASS Other Investment balance was zero as the Company had no outstanding shares of preferred stock in COMPASS. GABA Therapeutics, Inc. GABA is a California based biotechnology company focused on developing its GRX-917 Common Stock Investment The Company’s investment in GABA’s common stock was accounted for in accordance with the equity method. The Company’s investment in GABA’s preferred stock did not meet the criteria for in-substance The carrying value of the investment in GABA common stock was reduced to zero as of December 31, 2020 due to IPR&D charge with no alternative future use and remained zero as of June 30, 2021. Accordingly, GABA’s net losses attributable to the Company were determined based on the Company’s ownership percentage of preferred stock in GABA and recorded to the Company’s investments in GABA preferred stock discussed below. During the three and six months ended June 30, 2021, the Company recognized its proportionate share of GABA’s net loss of $0.4 million and $1.1 million, respectively as losses from investments in equity method investees, net of tax on the condensed consolidated statements of operations. Preferred Stock Investment In August 2019, GABA and the Company entered into the Preferred Stock Purchase Agreement (the “GABA PSPA”), whereby GABA issued shares of its Series A preferred stock to the Company at a price of approximately $5.5 million. At closing, the Company had over 20% of overall ownership interest in GABA and a noncontrolling representation on the board. On May 15, 2021, GABA and the Company entered into an Amendment to Preferred Stock Purchase Agreement (the Amended GABA PSPA”) under which the GABA PSPA was amended. Pursuant to the Amended PSPA, GABA issued additional shares of its Series A preferred stock to the Company at a price of approximately $0.6 million. As of June 30, 2021 and December 31, 2020, the investment in GABA’s preferred stock was recorded in Other Investments on the condensed consolidated balance sheets under the measurement alternative under ASC 321. Pursuant to the GABA PSPA, the Company is obligated to purchase additional shares of Series A preferred stock for up to $10.0 million with the same price per share as its initial investment, upon the achievement of specified contingent clinical development milestones. On April 13, 2021, pursuant to the GABA PSPA, the Company purchased additional shares of Series A preferred stock of GABA, for an aggregate cost of $5.0 million based on the achievement of certain development milestones. On May 21, 2021, the Company exercised its option to purchase additional shares of Series A preferred stock prior to the achievement of certain development milestone for an aggregate cost of $5.0 million. As of June 30, 2021, the Company completed the purchase of the additional shares of Series A preferred stock for $10.0 million pursuant to the GABA PSPA . Pursuant to the Amended GABA PSPA, the Company is obligated to purchase additional shares of Series A preferred stock from GABA for up to $1.5 million with the same price per share as its initial investment upon the achievement of specified contingent clinical development milestones. In accordance with the amend e Co-Sale The Company has evaluated the contingent obligation (forward) and option and concluded that they both: (i) represent freestanding financial instruments as they are legally detachable and separately exercisable from the underlying shares; and (ii) are equity securities under ASC Topic 321, Investments—Equity Securities (ASC 321). The Company accounted for the contingent obligation based on the measurement alternative under ASC 321 which is included in Other Investments as of June 30, 2021 and December 31, 2020. In November 2020 the Company exercised its option to purchase additional shares of common stock of GABA at a price of approximately $1.8 million pursuant to an Omnibus Amendment Agreement under which the Right of First Refusal and Co-Sale Neuronasal, Inc. Neuronasal is developing a novel intranasal formulation of N-acetylcysteine (“NAC”) for acute mild traumatic brain injury. Common Stock Investment In October 2020, upon the achievement of certain development milestones, the Company made a cash contribution of $0.3 million in exchange for 9.8% of the outstanding common stock of Neuronasal. On March 10, 2021, upon the achievement of certain development milestones, the Company made another cash contribution of $0.5 million in exchange for 10.8% of the outstanding common stock of Neuronasal. The Company recorded its investment in Neuronasal common stock at the carrying cost basis of $0.5 million. At the date of the investment, a basis difference was identified as the cost basis of the Company’s investment in Neuronasal exceeded the Company’s proportionate share of the underlying net assets in Neuronasal. The Company concluded that the basis differences were primarily attributable to Neuronasal’s IPR&D associated with Neuronasal’s novel intranasal formulation of NAC. As the Company’s investments in Neuronasal did not meet the definition of a business due to substantially all of the estimated fair value of the gross assets was concentrated in NAC, the basis differences were attributable to the IPR&D with no alternative future use, were immediately expensed on the dates of investments. The Company’s proportionate share of the basis difference exceeded its carrying value of the equity method investment in Neuronasal and as a result, the March 2021 equity investment balance of $0.5 million was reduced to zero. For the six months ended June 30, 2021, the Company recognized losses from investments in equity method investees, net of tax of $0.5 million in association with the basis difference charge in the Company’s condensed consolidated statements of operations. The Company is deemed to have significant influence over Neuronasal through its total ownership interest in Neuronasal’s equity through the acquisition date of May 17, 2021 (see Note 3), including the Company’s investment in Neuronasal’s preferred stock, and the Company’s noncontrolling representation on Neuronasal’s board of directors. Accordingly, the Company’s investment in Neuronasal’s common stock was accounted for in accordance with the equity method. The Company’s investment in Neuronasal’s preferred stock did not meet the criteria for in-substance The carrying value of the investment in Neuronasal common stock was reduced to zero as of December 31,2020 due to IPR&D charges with no alternative future use. Accordingly, Neuronasal’s net losses attributable to the Company was determined based on the Company’s ownership percentage of preferred stock in Neuronasal and recorded to the Company’s investments in Neuronasal preferred stock discussed below. During the three and six months ended June 30, 2021, immediately prior to the acquisition, the Company recognized its proportionate share of Neuronasal’s net loss of $0.4 million and $1.0 million, respectively as losses from investments in equity method investees, net of tax on the condensed consolidated statements of operations. Preferred Stock Investment In December 2019, Neuronasal and the Company entered into the Neuronasal PSPA and the Neuronasal Secondary Sale Agreement, whereby Neuronasal issued shares of its Series A preferred stock to the Company at a price of approximately $0.5 million. At closing, the Company has a less than 20% of ownership interest in Neuronasal and a noncontrolling representation on the board. In October 2020, pursuant to the Neuronasal PSPA, the Company purchased additional Series A preferred shares at a price of approximately $0.8 million. The investment in Neuronasal preferred shares was recorded in Other Investments on the condensed consolidated balance sheets under the measurement alternative under ASC 321as of June 30, 2021 and December 31, 2020. In October 2020, pursuant to the Neuronasal PSPA, the Company purchased additional Series A preferred shares at a price of approximately $0.8 million upon the achievement of a specified contingent clinical development milestone. On March 10, 2021, pursuant to the Neuronasal PSPA, the Company purchased additional Series A preferred shares for approximately $0.8 million based on the achievement of certain development milestones. Also, pursuant to the Neuronasal Secondary Sale Agreement, the Company purchased additional common shares for approximately $0.3 million. The obligation to purchase additional shares of Series A preferred stock from Neuronasal, and shares of common stock from the existing common shareholders was $1.5 million as of June 30, 2021. On May 17, 2021, pursuant to the Neuronasal PSPA and the Neuronasal Secondary Sale Agreement, the Company, at its sole option, purchased additional shares of Series A preferred stock of Neuronasal for an aggregate cost of $1.0 million. Upon the closing of the purchase occurred on May 17, 2021, the Company obtained a controlling financial interest in Neuronasal. The Company derecognized its other investments in Neuronasal and began to consolidate the operations of Neuronasal into its financial statements. Please see Note 3, “Acquisitions” for further discussion. DemeRx NB In December 2019, the Company jointly formed DemeRx NB with DemeRx. DemeRx and DemeRx NB entered into a Contribution Agreement whereby DemeRx assigned all of its rights, title, and interests in and to all of its assets relating to DMX-1002, In connection with the Contribution Agreement, the parties entered into a Series A Preferred Stock Purchase Agreement (the “DemeRx NB PSPA”) pursuant to which the Company purchased shares of Series A preferred stock of DemeRx NB at a purchase price of $1.0 million. At closing, the Company has less than 20% of ownership interest in DemeRx NB and a noncontrolling representation on the board. The investment in DemeRx NB was recorded in Other Investments on the condensed consolidated balance sheets under the measurement alternative under ASC 321. In accordance with the DemeRx NB PSPA, the Company also has the option but not the obligation to purchase additional shares of Series A preferred stock at a purchase price of up to $19.0 million with the same price per share as its initial investment. As of June 30, 2021, the Company has not exercised its option to purchase any shares of Series A preferred stock of DemeRx NB. The Company has evaluated the option and concluded that it: (i) represents a freestanding financial instrument as it is legally detachable and separately exercisable from the underlying shares; and (ii) is an equity security under ASC 321. The Company accounted for the option based on the measurement alternative under ASC 321 , Investments as of June 30, 2021 and December 31, 2020. Other Investments Held at Fair Value IntelGenx Technologies Corp. IntelGenx is a novel drug delivery company focused on the development and manufacturing of novel oral thin film products for the pharmaceutical market. In March 2021, IntelGenx and the Company entered into the Strategic Development Agreement and Purchaser x x x x s x Unit Un it x until x thirty or premium to the price of the corresponding additional share, or (ii) the price per share under which shares of IntelGen x x x x x Pursuant to the Strategic Development Agreement, the Company engages IntelGenx to conduct research and development projects (“Development Project”) using IntelGenx’s proprietary oral thin film technology. Under the terms of the Strategic Development Agreement, the Company can select four (4) program products. As of the effective date of the Strategic Development Agreement, the Company nominated two (2) program products - DMT and Salvinorin A. % of any funds that IntelGenx received or will receive through the Company’s equity investment under the IntelGenx SPA will be available to be credited towards research and development services that IntelGenx conducts for the Company under the Development Projects. No material research and development services have been performed as of June 30, 2021. The Company has significant influence over IntelGenx through ownership interest in IntelGenx’s equity and the Company’s noncontrolling representation on IntelGenx’s board of directors. The Company qualified for and elected to account for its investment in the IntelGenx common stock under the fair value option. The Company believes that the fair value option better reflects the underlying economics of the IntelGenx common stock investment. The Initial Warrants and Additional Units Warrant are accounted for at fair value under ASC 321. The Company determined that the initial aggregate fair value equals to the transaction price and recorded the common shares $3.0 million, the Initial Warrants at $1.2 million and the Additional Unit Warrants at $8.2 million on a relative fair value basis resulting in no initial gain or loss recognized in the consolidated statements of operations. Subsequently, changes in fair value of the common shares and the Warrants are recorded as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss. As of June 30, 2021, the common shares and the Warrants are recorded at $6.9 million within other investments held at fair value in the condensed consolidated balance sheets. During the three and six months ended June 30, 2021, the Company recognized the change in fair value of the investment in IntelGenx’s common stock and Warrants of $ million loss in the condensed consolidated statements of operations. Summarized Financial Information The following is a summary of financial data for investments accounted for under the equity method of accounting (in thousands): Balance Sheets June 30, 2021 Compass Neuronasal (1) GABA Current assets $ 334,035 $ — $ 10,954 Non-current assets 1,126 — — Total assets $ 335,161 $ — $ 10,954 Current liabilities $ 7,801 $ — $ 162 Non-current liabilities — — — Total liabilities $ 7,801 $ — $ 162 December 31, 2020 Compass Neuronasal (1) GABA Current assets $ 202,404 $ 351 $ 3,302 Non-current 1,052 10 — Total assets $ 203,456 $ 361 $ 3,302 Current liabilities $ 6,895 $ 686 $ 430 Non-current — 48 — Total liabilities $ 6,895 $ 734 $ 430 Statements of operations Three Months Ended June 30, 2021 Compass Neuronasal (1) GABA Revenue $ — $ — $ — Loss from continuing operations $ (19,528 ) $ (409 ) $ (387 ) Net loss $ (19,528 ) $ (409 ) $ (387 ) Three Months Ended June 30, 2020 Compass Neuronasal (1) GABA Revenue $ — $ — $ — Loss from continuing operations $ (17,687 ) $ (382 ) $ (929 ) Net loss $ (17,687 ) $ (382 ) $ (929 ) Six Months Ended June 30, 2021 Compass Neuronasal (1) GABA Revenue $ — $ — $ — Loss from continuing operations $ (33,130 ) $ (985 ) $ (1,046 ) Net loss $ (33,130 ) $ (985 ) $ (1,046 ) Six Months Ended June 30, 2020 Compass Neuronasal (1) GABA Revenue $ — $ — $ — Loss from continuing operations $ (26,392 ) $ (514 ) $ (1,956 ) Net loss $ (26,392 ) $ (514 ) $ (1,956 ) (1) Results from operations for Neuronasal are through May 17, 2021 at which point the entity is consolidated.

Notes Receivable

Notes Receivable	6 Months Ended
	Jun. 30, 2021
Receivables [Abstract]
Notes Receivable	6. Notes Receivable Long Loan to IntelGenx Corp. On March 8, 2021, the Company and IntelGen x x x x Pursuant to the terms of the Term Loans, upon the occurrence of an event of default, the Company may accelerate the Term Loans and declare the principal and any accrued and unpaid interests of the Term Loans to be immediately due and payable. In addition, IntelGen x The Company recorded the Term Loans at cost which included the principal balance of the note and accrued interest, net of any payments received, in Long term notes receivables – related parties on its condensed consolidated balance sheets. As of June 30, 2021, the Term Loans have an outstanding balance of $ million. During the three and six months ended June , , the recognized interest income associated with the Term Loans was immaterial.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurement	7. Fair Value Measurement The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation (in thousands): Fair Value Measurements as of June 30, 2021 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 398,528 $ — $ — $ 398,528 Other investment held at fair value — 2,248 4,638 6,886 $ 398,528 $ 2,248 $ 4,638 $ 405,416 Liabilities: Contingent consideration liability - related parties $ — $ — $ 2,466 $ 2,466 Warrant Liability $ — $ — $ 289 $ 289 $ — $ — $ 2,755 $ 2,755 Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets: $ — Liabilities: Contingent consideration liability - related parties $ — $ — $ 1,705 $ 1,705 Derivative liability — — 214 214 $ — $ — $ 1,919 $ 1,919 During the three and six months ended June 30, 2021 and 2020, there were no transfers between Level 1, Level 2 or Level 3. Valuation of COMPASS Note Receivable-Related Party The fair value of the COMPASS Notes at issuance and financial reporting dates was estimated based on significant inputs not observable in the market, which represent Level 3 measurements within the fair value hierarchy. The Company estimated the fair value of the COMPASS Notes during the first quarter of 2020 and immediately prior to the conversion of the notes in April 2020 using the fair value of the Series B preferred stock of COMPASS. The fair value of the Notes was estimated to be $9.0 million immediately prior to the conversion of the notes. Once the notes were converted, the acquired shares were recorded at a price per share equal to the fair value of the Series B shares of £1,350 or $1,654. The change in fair value in the COMPASS Notes from December 31, 2019 to its conversion to Series B preferred stock in April 2020, were $0.7 million and included in change in fair value of short term notes receivable—related party in the condensed consolidated statements of operations. Contingent Consideration Liability—Related Parties—Perception and Innaris Bio The contingent consideration liability—related parties in the table above relates to milestone and royalty payments in connection with the acquisition of Perception and InnarisBio. The fair value of the contingent consideration liability—related parties was determined based on significant inputs not observable in the market, which represent Level 3 measurements within the fair value hierarchy. The fair value of the contingent milestone and royalty liabilities was estimated based on the discounted cash flow valuation technique. The technique considered the following unobservable inputs: • the probability and timing of achieving the specified milestones and royalties as of each valuation date, • the probability of executing the license agreement, • the expected first year of revenue, and • market-based discount rates The fair value of the contingent milestone and royalty liabilities for InnarisBio was estimated to be $0.1 million as of June 30, 2021. The fair value of the Percept io n R-Ketamine R-Ketamine As of June 30, 2021, the license transaction had closed and the scenario-based method was no longer used (See Note 16). The valuation used inputs that were unobservable with the most significant being the discount rates for royalties on projected clinical milestones and commercial revenue and the probability of success estimates over the following ten years. The fair value of the contingent milestone and royalty liabilities for Perception was estimated to be $2.4 million and $1.7 million as of June 30, 2021 and December 31, 2020, respectively. The fair value of the contingent milestone and royalty liabilities could change in future periods depending on the prospects for the first patient dosing and the outcome of obtaining approval from FDA or regulatory authorities for potential drug product using the solgel-based direct-to-brain intranasal drug delivery technology, and whether the Company realizes a significant increase or decrease in sales upon commercialization. The most significant assumptions in the income approach valuation technique used to estimate the contingent liabilities are the probability of each milestone being met, the probability of number of drug products being developed, projected milestone timing and discount rate. The following table summarizes significant unobservable inputs that are included in the valuation of contingent consideration lability – related for Perception parties as of June 30, 2021 and December 31, 2020: June 30, 2021 December 31, 2020 Weighted Weighted Valuation Technique Significant Unobservable Inputs Input Range Average Input Range Average Discounted cash flow Milestone contingent consideration: Discount rate 5.9% 5.9% 8.4% to 14.1% 9.4% Projected milestone timing 3.5 years 3.5 years 4.0 to 4.3 years 4.1 years Probability of the milestone 51.9% 51.9% 10.5% to 48.7% 34.8% Discounted cash flow with SBM Royalty contingent consideration: Discount rate for royalties 13.0% 13.0% 12.0% to 13.0% 12.5% Discount rate for royalties on milestones 5.9% 5.9% 8.4% 8.4% Projected commercial revenue $270.3 to $2,031 N/A $77.5 to $3,542 N/A Projected clinical milestone revenue $6.0 to $30.0 N/A $6.0 to $30.0 N/A Timing of royalties on commercial revenue 7.8 years 7.8 years 7.8 to 8.5 years 8.1 years Timing of royalties on clinical milestone revenue 0.8 year 0.8 year 1.3 years 1.3 years Probability of success rate 26.5% to 100.0% 29.9% 3.95% to 100.0% 12.6% Probability of the close of the license transaction (1) N/A N/A 80.0% 80.0% (1) This input was used in fourth quarter of 2020 in relation to a potential license transaction that Perception has with a third-party pharmaceutical company. Valuation of 2020 Convertible Notes Payable The fair value of the 2020 Convertible Notes at issuance and at each reporting period was estimated based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The Company used a SBM to incorporate estimates and assumptions concerning company prospects and market indications into a model to estimate the value of the notes. The most significant estimates and assumptions used as inputs in the SBM valuation technique impacting the fair value of the 2020 Convertible Notes are those concerning type, timing and probability of specific scenario outcomes. At the issuance dates of the 2020 Convertible Notes, a qualified financing was assumed to occur within the year following issuance. Specifically, the Company discounted the cash flows for fixed payments by using annualized discount rates that were applied across valuation dates from issuance dates of the 2020 Convertible Notes until conversion in November 2020. The discount rates were based on certain considerations including: time to payment, an assessment of the credit position of ATAI, market yields of companies with similar credit risk at the date of valuation estimation, and calibrated rates based on the fair value relative to the original issue price from the 2020 Convertible Notes. Payments that are sensitive to the total equity value of the Company at the date of payment were valued at each valuation date using an option pricing model (“OPM”). Key assumptions used in the OPM included risk free rate, volatility across the period of the valuation dates, dividend yield, and a period of estimation commensurate with time until payment. The inputs to the option pricing model were determined based on assessment of the Company’s most recent financing transaction, assessed and adjusted for the market value of a group of publicly traded peer guideline companies and relevant equity indices as of each valuation date from issuance to conversion. The following table summarizes significant unobservable inputs by valuation technique that are included in the valuation of the 2020 Convertible Notes from the issuance date of the notes in January 2020 to June 30, 2020: June 30, 2020 Weighted Valuation Technique Significant Unobservable Inputs Input Range Average SBM Discount rate 0.6% to 7.2% 1.6% Expected term 0.5 to 1.0 years 0.8 years Probability scenarios: Conversion upon a financing event 50.0 % to 60.0% 52.0% OPM Risk free rate -0.6% to -0.7% -0.6% Volatility 70.0% to 80.0% 75.0% Dividend yield 0% 0% Valuation of Derivative Liability—Perception Convertible Notes The derivative liability in the table above relates to the embedded conversion features in connection with the Perception Convertible Notes issued in 2020 and 2021 discussed in Note 10. The Perception March 2020 Notes contained a derivative, which is related to embedded conversion feature upon a qualified financing transaction. The Perception December 2020 Notes contained a derivative, which is related to embedded conversion features upon a qualified financing transaction and a licensing transaction. The fair value of the embedded conversion features at issuance of the Perception Convertible Notes and subsequent financial reporting dates was estimated based on significant inputs not observable in the market, which represent Level 3 measurements within the fair value hierarchy. The Company used a SBM to incorporate estimates and assumptions concerning company prospects and market indications into a model to estimate the value of the derivative liability. An SBM considers a range of various potential scenario outcomes assumed to occur with associated probabilities. Cash flow outcomes are then discounted to present value to estimate fair value. The SBM procedure is as follows: (i) estimate future cash flows that arise from scenario outcomes, (ii) discount the cash flows to present value using a market-based discount rate and (iii) probability weight the present values to form a probability weighted, expected return analysis that estimates fair value at the subject valuation date. The most significant estimates and assumptions used as inputs in the SBM valuation technique impacting the fair value of the embedded conversion features are those concerning the scenario outcomes’ type, timing and probability. At the issuance dates of the Perception Convertible Notes and at December 31, 2020, a qualified financing and a licensing transaction were assumed to occur within the year following issuance which the Company estimated 20 percent and 80 percent probability of occurrence of a qualified financing and a licensing transaction, respectively. As the derivative liability associated with the Perception March 2020 Notes was related to the embedded conversion feature upon a qualified financing transaction the fair value of the derivative liability associated with the Perception March 2020 Notes was reduced to zero because of a zero percent probability of the occurrence of a qualified financing transaction as of June 30, 2021. The Company calculated the payment due to the holders of Perception Convertible Notes with and without the embedded conversion feature and discounted to present value. The Company discounted the cash flows using a discount rate of 17.0 percent annualized at the issuance dates, and at December 31, 2020 based on an assessment of the credit position of Perception and market yields of companies with similar credit risk at the date of valuation estimation. On May 31, 2021, the Company issued convertible notes under the Second Tranche Funding (see Note 10). In connection with the issuance of these notes, the Company determined the fair value of the derivative liability related to the embedded conversion option by calculating the payment due to the holders of these notes with and without the conversion feature. The Company discounted the cash flows using a discount rate of 18.0 percent annualized at the issuance date, based on an assessment of the credit position of Perception and market yields of companies with similar credit risk at the date of valuation estimation. On June 10, 2021, the Perception Convertible Notes converted into shares of Series A preferred stock of Perception pursuant to their original terms. The Company remeasured the embedded derivatives related to the Perception Convertible Notes at fair value immediately prior to conversion on June 10, 2021. The Company calculated the payments due to the holders of Perception Convertible Notes with and without the conversion feature. The Company discounted the cash flows using a discount rate of 18.0 percent at June 10, 2021, based on an assessment of the credit position of Perception and market yields of companies with similar credit risk at the date of valuation estimation. The fair value of the embedded conversion features, including the embedded conversion features associated with the notes issued under the Second Tranche Funding was determined to be $0.8 million immediately before the conversion of the Perception Convertible Notes on June 10, 2021 and reduced to zero upon conversion of the notes. The fair value of the embedded conversion features was determined to be $0.2 million as of December 31, 2020. The significant unobservable inputs that are included in the valuation of the derivative liability as of December 31, 2020 include: December 31, 2020 Weighted Significant Unobservable Inputs Input Range Average Discount rate 17.0% 17.0% Expected term 1 year 1 year Probability scenarios: Qualified financing transaction 20% 20% Licensing transaction 80% 80% Warrant Liability The warrant liability in the table above relates to issued and outstanding warrants to purchase shares of Neuronasal’s common stock acquired in connection with the acquisition of Neuronasal. The warrants was classified as other liability in the accompanying condensed consolidated balance sheet as the underlying common stock was determined to be contingently, but not currently, redeemable. The warrant liability was recorded at fair value utilizing the Black-Scholes option pricing model which represent Level 3 measurements within the fair value hierarchy. The Black Scholes option pricing model is based on the estimated market value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock. The Company adjusted the carrying value of the warrant to its estimated fair value at each reporting date, with any related increase or decrease in the fair value recorded as an increase or decrease to other income (expense) in the statements of operations. The fair value of the warrant liability was estimated to be $0.2 million as of June 30, 2021. The following table summarizes significant unobservable inputs that are included in the valuation of the warrant lability as of June 30, 2021: June 30, 2021 Exercise Price $ 0.01 Stock Price $ 36.12 Dividend Yield 0.00 % Expected Term (in Years) 3.25 Risk-Free Interest Rate 0.51 % Expected Volatility 98 % IntelGenx Common Stock, Initial Warrants and Additional Units Warrant The Company’s investment in IntelGenx consist of Common Stock Initial Warrants and Additional Units Warrant (collectively the “Warrants”). The Company determined Warrants do not meet the definition of derivative instrument per ASC 815. The Company determined that the initial aggregate fair value equals to the transaction price and recorded the common shares $3.0 million, the Initial Warrants at $1.2 million and the Additional Units Warrant at $8.2 million on a relative fair value basis resulting in no initial gain or loss recognized in the consolidated statements of operations. The fair value of Common Shares is estimated by applying discount for lack of marketability (DLOM) of 13.7% as of May 14, 2021 and 10.7% as of June 30, 2021. The Initial Warrant asset was recorded at fair value utilizing the Black-Scholes option pricing model. The Black Scholes option pricing model is based on the estimated market value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends, and expected volatility of the price of the underlying common stock. The expected volatility is based on a peer group volatility which is a Level 3 input within the fair value hierarchy. The following table summarizes significant inputs that are included in the valuation of the Initial Warrants as of June 30, 2021: June 30, Value of Underlying $ 0.46 Exercise Price $ 0.35 Risk Free Rate 0.43 % Expected Term (in Years) 2.9 Expected Volatility 100 % Dividend Yield 0.00 % The fair value of the Additional Units is estimated using a Binomial Lattice in a risk-neutral framework (a special case of the Income Approach). Specifically, the future stock price of the IntelGenX is modeled assuming a Geometric Brownian Motion (GBM) in a risk-neutral framework. For each modeled future price, the Additional Unit is calculated based on the contractual terms (incorporating any optimal early exercise), and then discounted at the term-matched risk-free rate. Finally, the value of the Additional Units is calculated as the probability-weighted present value over all future modeled payoffs. The following table summarizes significant unobservable inputs that are included in the valuation of the Additional Units Warrant as of June 30, 2021: June 30, 2021 Tranche 1 Number Units 14,920,000 Tranche 2 Number Units 115,080,000 Additional Warrants Term (in years) 3.00 Additional Units Term (in Years) 2.87 Maximum Term (in Years) 5.87 Stock Price $ 0.460 Expected Volatility 100 % Warrant Strike $ 0.556 Unit Purchase Price 1st Year $ 0.331 Unit Purchase Price 2nd Year $ 0.500 Unit Purchase Price 3rd Year $ 0.750 Wfraction 0.68 Risk-Free Rate 1.02 % Dividend Yield 0.00 % Number of time-steps 500 The following table provides a roll forward of the aggregate fair values of the Company’s financial instruments described above, for which fair value is determined using Level 3 inputs Other Contingent liability - related Derivative Warrant Balance as of December 31, 2020 $ — $ 1,705 $ 214 $ — Initial fair value of instrument — 101 304 — Change in fair value — (251 ) (41 ) — Balance as of March 31, 2021 $ — $ 1,555 $ 477 $ — Initial fair value of instrument 9,358 — 343 249 Change in fair value (4,720 ) 911 — 40 Extinguishment of l — — (820 ) — Balance as of June 30, 2021 $ 4,638 $ 2,466 $ — $ 289 Compass Notes Receivable - related party Contingent Consideration liability - related parties 2020 Convertible Notes Payable Derivative Liability Balance as of December $ 8,244 $ 572 $ — $ — Initial fair value of instrument — — — 31 Issuance of notes payable — — 9,707 — Change in fair value 718 24 (1,127 ) — Foreign currency transaction adjustments 41 — (38 ) — Balance as of March 31, 2020 $ 9,003 $ 596 $ 8,542 $ 31 Initial fair value of instrument — — — 184 Issuance of notes payable — — 2,668 — Conversion of notes receivable (9,003 ) — — — Change in fair value — 42 1,260 — Foreign currency transaction adjustments — — 212 — Balance as of June 30, 2020 $ — $ 638 $ 12,682 $ 215

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid expenses and other current assets	8. Prepaid Expenses and Other Current Assets Prepaid expenses consist of the following (in thousands): June December Prepaid research and development related expenses $ 2,408 $ 313 Research and development tax credit 1,029 556 Sales tax receivables 315 509 Prepaid insurance 101 144 Other 111 554 Total $ 3,964 $ 2,076

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2021
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	9. Accrued Liabilities Accrued liabilities consist of the following (in thousands): June 0 1 December 0 Accrued accounting, legal, and other professional fees $ 3,324 $ 2,858 Taxes payable 1,323 997 Accrued external research and development expenses 1,138 347 Accrued payroll 1,103 1,098 Accrued advisory fees — 3,819 Other liabilities 936 96 Total $ 7,824 $ 9,215

Convertible Promissory Notes

Convertible Promissory Notes	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Convertible Promissory Notes	10. Convertible Promissory Notes 2018 Convertible Promissory Notes—Related Parties Convertible promissory notes—related parties, net of discounts and deferred issuance costs, consisted of the following (in thousands): June 30, December 31, Convertible notes issued in November 2018 $ 190 $ 195 Convertible notes issued in October 2020 995 1,022 Unamortized discount and deferred issuance costs (9 ) (18 ) Total $ 1,176 $ 1,199 During November 2018, the Company executed a terms and conditions agreement (the “Convertible Note Agreement”) under which it would issue up to €1.0 million or $1.2 million in convertible promissory notes to investors. An investor would become a party to the Convertible Note Agreement and would be issued a convertible promissory note by executing and delivering a subscription form. In November 2018, certain investors subscribed to the Convertible Note Agreement and the Company issued convertible promissory notes in the aggregate principal amount of €0.2 million or $0.2 million. In October 2020, certain investors subscribed to the Convertible Note Agreement and the Company issued the remainder of the 2018 Convertible Notes in the aggregate principal amount of €0.8 million or $1.0 million (collectively, the “2018 Convertible Notes”). The total aggregate principal amount of the 2018 Convertible Notes is $1.2 million as of December 31, 2020. The 2018 Convertible Notes are non-interest-bearing, one In connection with the Convertible Note Agreement, the Company issued convertible notes in the principal amounts of €0.1 million or $0.1 million to the founders of Perception, who are also related parties of the Company in November 2018 (See Note 18). Perception is a biotech firm acquired by the Company on November 5, 2018. Upon the purchase of certain assets of Perception in November 2018, Perception was deemed to have been a VIE, of which the Company is the primary beneficiary (See Note 4). In addition, in connection with the Convertible Note Agreement, the Company issued convertible notes in the principal amounts of €0.5 million or $0.6 million to Apeiron, the family office of the Company’s founder, and €0.3 million or $0.4 million to one other shareholder of the Company and the founder of COMPASS in October 2020 (See Note 18). The Company concluded that both the embedded conversion feature, which is exercisable by the investor at any time during the maturity, and the contingent put option, which would trigger upon the occurrence of an event of default of the 2018 Convertible Notes, do not meet the criteria to be bifurcated and separately accounted for as derivatives and were recorded net of discount and issuance costs, or a reduction to the carrying value of the notes issued in November 2018, with a corresponding adjustment to additional paid in capital. The discount is being amortized using the effective interest method over the period from the respective date of issuance to the Maturity Date. The Company determined that the October 2020 notes were issued in exchange for services previously provided by the Company’s founders and other shareholders and were fully vested and non-forfeitable non-employees, The fair value of the October 2020 notes exceeded the principal amount that will be due at maturity. Therefore, at initial recognition, the October 2020 notes were accounted for as convertible debt issued at a substantial premium, such that the face value of the note is recorded as a liability premium was recorded as paid-in capital. 2020 Convertible Promissory Note s In January 2020, the Company executed a terms and conditions agreement (the “2020 Convertible Note Agreement”) under which it would issue up to €30.0 million, or $33.5 million, in convertible promissory notes to various investors. The total aggregate principal amount of the 2020 Convertible Notes was $12.4 million as of June 30, 2020. For the three and six months ended June 30, 2020, the interest expense and change in fair value in the 2020 Convertible Notes from its various issuance dates to the conversion date totaled $1.2 million and $0.1 million, respectively and is included in change in fair value of convertible promissory notes in the condensed consolidated statements of operations. Perception Convertible Promissory Notes On March 16, 2020, Perception entered into a convertible promissory note agreement with the Company and other investors, including related parties, which provided for the issuance of convertible notes of $3.9 million (the “Perception Note Purchase Agreement”). The notes bear interest at an annual rate of 5% and are due and payable on June 30, 2022, unless earlier converted (the “Perception March 2020 Notes”). On December 1, 2020, Perception entered into an additional convertible promissory note agreement (the “Perception December 2020 Convertible Note Agreement”) with the Company and other investors, including related parties, which provided for the issuance of convertible notes of up to $12.0 million. Pursuant to the Perception December 2020 Convertible Note Agreement, the convertible notes are issued in two tranches: (i) up to $7.0 million under the first tranche funding (the “First Tranche Funding”), with $6.2 million and $0.8 million issued in December 2020 and January 2021, respectively, and (ii) up to an additional $5.0 million under the second tranche funding (the “Second Tranche Funding”), was Under the Second Tranche Funding, Perception issued The notes bear interest at an annual rate of 5% and are due and payable on February 28, 2022, unless earlier converted (the “Perception December 2020 Notes” and together with the Perception March 2020 Notes, the “Perception Convertible Notes”). In the event of a qualified sale of preferred stock resulting in gross proceeds to Perception of at least $5.0 million, all the principal and accrued and unpaid interest under the Perception Convertible Notes will automatically convert, into the same equity securities issued by Perception at a 25% discount from the lowest price of the security issued. In the event that Perception receives upfront proceeds of $5.0 million or more in a licensing transaction, all the principal and accrued and unpaid interest under the Perception convertible notes will automatically convert, into shares of Series A Preferred Stock of Perception at a price per share of $0.75 for the Perception March 2020 Notes and 75% of the fair market value of the Series A Preferred Stock of Perception for the Perception December 2020 Notes. Upon a change in control of Perception, all the principal and accrued and unpaid interest under the Perception Convertible Notes will automatically convert i The Perception March 2020 Notes contained an embedded conversion features in the event of a qualified financing whereas the Perception December 2020 Notes contained both embedded conversion features in the event of a qualified financing and upon the occurrence of a licensing transaction. The Company concluded that both the embedded conversion features met the definition of embedded derivatives that were required to be bifurcated and accounted for as a separate unit of accounting. As of December 31, 2020, the Company recorded the fair value of the derivative liabilities of $0.4 million as a liability with the offset being recorded as a debt discount on the issuance dates of the Perception Convertible Notes. Both the liability and the offsetting debt discount are presented together in convertible promissory notes and derivative liability on the consolidated balance sheets. The resulting debt discount is being amortized to interest expense using the effective interest method over the terms of the Perception Convertible Notes. This interest expense is recorded in other income (expense), net in the consolidated statements of operations. The derivative liabilities are subsequently remeasured to fair value at each reporting date with changes in fair value recognized as a component of other income (expense), net in the consolidated statements of operations. Upon issuance of the notes under the Second Tranche Funding, the Company recorded the fair value of the derivative liabilities of $0.3 million as a liability with an offset being recorded as a debt discount. On June 10, 2021, Perception received proceeds of $20.0 million pursuant to the licensing and collaboration arrangement between Perception and Otsuka Pharmaceutical Co., LTD (“Otsuka”) (See Note 16). Upon receipt of the proceeds, the Perception Convertible Notes automatically converted into 6,456,595 shares of Series A preferred stock of Perception pursuant to their original terms. The Company, Sonia Weiss Pick and Family, Apeiron, and other investors received 5,403,791 shares, 440,415 shares, 27,809 shares and 584,580 shares of Perception Series A preferred stock, respectively, upon conversion of the Perception Convertible Notes. The amounts associated with the shares of Perception Series A preferred stock issued to the Company represent intercompany transactions and are eliminated upon consolidation. The Company remeasured the derivative liability immediately prior to the conversion of the Perception Notes and recorded an immaterial net gain million with an offset to Series A preferred stock, and no gain or loss was recognized. The shares issued upon conversion of the Perception March 2020 and December 2020 Notes issued to the Company represent an intercompany transaction and, therefore, eliminate in consolidation. As of December 31, 2020, the fair value of the derivative liability was $0.2 million, including an immaterial amount of derivative liability relating to Sonia Weiss Pick and Family. As of June 30, 2020, the fair value of the derivative liability was $0.2 million, including $0.1 million of derivative liability relating to Sonia Weiss Pick and Family and Apeiron. The Company recorded a net loss of $12,000 resulting from the change in the fair value of derivative for the three months ended June 30, 2020. The Company recorded a net gain $44,000 resulting from the change in fair value of the derivative liability for the six months ended June 30, 2020. The Company recognized interest expense of $0.1 million, including amortization of debt discount of $93,000 during the three months ended June 30, 2021. The Company recognized interest expense of $0.2 million, including amortization of debt discount of $0.2 million during the six months ended June 30, 2021. As of December 31, 2020, the unamortized debt discount on the Perception Convertible Notes was $0.3 million. As of June 30, 2021, there was no unamortized debt discount due to the conversion of the Perception Convertible Notes into Series A convertible preferred stock of Perception on June 10, 2021. The debt issuance costs associated with the Perception Convertible Notes were not material.

Common Stock

Common Stock	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Common Stock	11. Common Stock In January 2021, pursuant to an additional closing from the common stock issuance in November and December 2020, the Company issued and sold 2,133,328 shares of common stock to Apeiron at the same issuance price, for cash proceeds of $12.2 million. In March 2021, the Company issued and sold 13,419,360 shares of common stock to new and existing investors, including related parties, at a price of €9.69 or $11.71 per share, for cash proceeds of $152.2 million, net of issuance costs of $4.9 million. On June 22, 2021, ATAI closed the IPO of its common stock on Nasdaq All common shareholders have identical rights. Each share of common stock entitles the holder to one vote on all matters submitted to the stockholders for a vote. All holders of common stock are entitled to receive dividends, as may be declared by the Company’s board of directors. Upon liquidation, common stockholders will receive distribution on a pro rata basis. As of June 30, 2021 and December 31, 2020, no cash dividends have been declared or paid.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	12. Stock-Based Compensation Atai Life Sciences 2020 Equity Incentive Plan Effective August 21, 2020, the Company adopted an equity-based compensation plan, the 2020 Equity Incentive Plan (as amended from time to time, “2020 Incentive Plan”). The 2020 Incentive Plan is administered by the Company’s Board. The pl a , individuals enables The Company has reserved up to 22,658,192 shares of common stock, excluding any shares issued under its Hurdle Share Option Program described below, for issuance to executive officers, directors , other Plan and all subsequent grants are subject to the Atai Life Sciences 2021 Incentive Award Plan discussed below. Atai Life Sciences 2021 Incentive Award Plan Effective April 23, 2021 ) , , individuals enables other The Company has reserved up to 16,000,000 shares of common stock, for issuance to executive officers, directors and employees and consultants of the Company pursuant to the 2021 Incentive Plan. Shares that are expired, terminated, surrendered, or canceled without having been fully exercised will be available for future awards. As of June 30, 2021, 14,573,575 shares were available for future grants under the 2021 Incentive Plan. Stock Options The stock options outstanding noted below consist primarily The December 31, 2020 stock options outstanding balance noted below includes 3,176,976 stock options that will vest over a four-year service period, only if and when a “Liquidity Event” (as defined in the 2020 Incentive Plan) occurs within five years of the date of grant. During the six months ended June 30, 2021 of these options held by e mployees such that, if the Company achieves an Initial Public Offering (“IPO”) (as defined in the awards) by June 30, 2021 or December 31, 2021, an additional % or %, respectively, will accelerate and vest upon the occurrence of the transaction. In each case provided, however, no option shall become vested before the first anniversary of the respective vesting start date. The Company applied modification accounting under ASC , which resulted in a new measurement of compensation cost, and the original grant-date fair value of the award is no longer used to measure compensation cost for the award. The weighted average fair value on the new measurement date amounted to $ . In June of 2021, the Company achieved a Liquidity Event and therefore began In addition, during the six The following is a summary of stock option activity for from December 31, 2020 to June 30, 2021: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2020 11,331,232 $ 1.54 4.64 $ 47,735 Granted 14,051,289 (1) 8.69 — — Exercised — — — — Cancelled or forfeited (1,584,528 ) (2) 2.37 — — Outstanding as of June 30, 2021 23,797,993 ( 3 $ 5.71 4.49 $ 304,470 Options exercisable as of June 30, 2021 5,512,278 $ 0.85 4.14 $ 97,291 (1) Includes (a) 5,391,184 stock options that will vest over a two to four-year service period, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant. If the Company achieves an IPO (as defined in the awards) by June 30, 2021 or December 31, 2021, an additional 25% or 12.5%, respectively, the stock options will accelerate and vest upon the occurrence of the transaction, (b) 5,241,785 stock options that will vest over a one to four-year service period, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant (c) 1,460,784 stock options that will vest at the end of a four-year service period and upon the satisfaction of specified performance-based vesting conditions, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant, (d) 624,000 stock options that will vest over a three-year service period, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant, (e) 400,688 stock options that will vest over a four-year service period and upon the satisfaction of specified performance-based vesting conditions including liquidity-based conditions, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant. If the Company achieves an IPO (as defined in the awards) by June 30, 2021 or December 31, 2021, an additional 25% or 12.5%, respectively, will accelerate and satisfy the service-based vesting condition upon the occurrence of the transaction, (f) 400,000 stock options that will vest over a two-year (2) Includes 1,152,192 Exchange Shares (3) With the satisfaction of the Liquidity Event (as defined in the awards) during the three months ended June 30, 2021, the outstanding options include The weighted-average grant-date fair value of options granted during the six months ended June 30, 2021, was $6.39 . The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. During the six months ended June 30, 2021, the assumptions used in the Black-Scholes option pricing model were as follows: June 30, Weighted average expected term in years 3.64 Weighted average expected stock price volatility 81.2% Risk-free interest rate (0.76)%-1.27% Expected dividend yield 0% For the three months ended June 30, 2021 and 2020, the Company recorded stock-based compensation expense of $20.6 million and $0.0 million, respectively. For the six months ended June 30, 2021 and 2020, the Company recorded stock-based compensation expense of $20.6 million and $0.0 million, respectively. As of June 30, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $85.4 million, which is expected to be recognized over a weighted average period of 2.41 years. Atai Life Sciences Hurdle Share Option Plan In August 21, 2020, the Partnership (as defined below) approved and implemented an employee stock option plan for selected executives, employees, and consultants of the Partnership (so-called The Partnership has reserved up to 8,000,000 shares (“HSOP Shares”) pursuant to the HSOP Plan. The Partnership is authorized to subscribe for the additional shares under HSOP Plan. Each HSOP Option contains both service and performance-based vesting conditions, including a liquidity-based condition, and gives the holder the option to purchase HSOP Shares. As of June 30, 2021, 718,624 shares were available for future grants under the HSOP Plan. The HSOP Plan mimics the economics of a typical stock option plan, however, HSOP Options result in HSOP Shares being issued to the Partnership at the grant date. The grantee is required to pay a nominal value (€0.06 per share) for the shares upon grant (“Nominal Upfront Payment”). The nominal amount paid at the grant date is refundable if the HSOP Options do not vest or are forfeited. Otherwise, the nominal amount is refundable until the later of the occurrence of a Liquidity Event (as defined in the “HSOP Plan”) or the exercise date. The HSOP Shares issued under the HSOP plan to the Partnership are indirectly owned by HSOP Options holders via their interest in the Partnership. However, each HSOP Option holder signed a nonrevocable power of attorney ceding virtually all rights and decisions, including their rights as shareholders to the Managing Partner (as defined in the Partnership agreement) of the Partnership. HSOP Option holders have a forfeitable right to distributions until the HSOP Options vest, at which time the right becomes nonforfeitable. Accordingly, the HSOP Shares issued to the Partnership and allocated to the HSOP Options holders are not considered outstanding for accounting purposes. Therefore, the Company accounted for the Nominal Upfront Payment as an in-substance (“Non-recourse corporate reorganization The 2% per annum interest rate is fixed and not linked to something other than a service, performance, or market condition, therefore, the Company accounted for the fixed rate interest charge as an in-substance non-recourse correlating o HSOP Options The HSOP Options outstanding noted below consist of service and performance-based options to purchase HSOP Shares. These HSOP Options have a fifteen-year contractual term. These HSOP Options vest over a three to four-year service period, only if and when a “Liquidity Event” (as defined in the Partnership agreement) occurs within fifteen years of the date of grant. If a Change in Control (as defined in the Partnership agreement) or in the event the holder’s service with the Partnership is terminated due to his death or disability by June 30, 2021 or December 31, 2021, an additional 25% or 12.5%, respectively, HSOP options will accelerate and vest upon the occurrence of the transaction. These awards are subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company. In June of 2021, the Company achieved a Liquidity Event and therefore began The following is a summary of stock option activity for from December 31, 2020 to June 30, 2021: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2020 — — — — Granted 7,281,376 (1) 6.64 — — Exercised — — — — Cancelled or forfeited — — — — Outstanding as of June 30, 2021 7,281,376 $ 6.64 14.51 $ 86,346 Options exercisable as of June 30, 2021 2,736,372 $ 6.63 14.51 $ 32,483 (1) Includes 4,543,936 Exchange Shares The weighted-average grant-date fair value of options granted during the six months ended June 30, 2021, was $4.37. The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. During the six months ended June 30, 2021, the assumptions used in the Black-Scholes option pricing model were as follows: June 30, Weighted average expected term in years 8.00 Weighted average expected stock price volatility 70.0% Risk-free interest rate (0.70)%-(0.65)% Expected dividend yield 0% For the three months ended June 30, 2021 and 2020, the Company recorded stock-based compensation expense of $16.7 million and $0.0 million, respectively. For the six months ended June 30, 2021 and 2020, the Company recorded stock-based compensation expense of $16.7 million and $0.0 million, respectively. As of June 30, 2021, total unrecognized compensation cost related to the unvested stock-based awards was $14.3 million which is expected to be recognized over a weighted average period of 1.53 years. Kures 2019 Stock Option and Grant Plan Effective August 27, 2019, Kures adopted an equity-based compensation plan. The Kures 2019 Stock Option and Grant Plan provides for Kures to grant incentive stock options or nonqualified stock options, restricted stock awards and other stock-based awards to employees, directors, consultants of Kures. Kures has reserved up to 954,315 shares of common stock for issuance to directors of Kures pursuant to the Kures 2019 Stock Option and Grant Plan. A t The Kures 2019 Stock Option and Grant Plan is administered by Kures’ board of directors. Shares that are expired, terminated, surrendered , Stock Options The stock options outstanding noted below consist primarily of service-based options to purchase Common Stock, the majority of which vest over a four-year period and have a ten-year Number Weighted- Weighted- Aggregate Value Outstanding as of December 31, 2020 600,000 $ 0.10 9.58 $ — Granted — — — — Exercised — — — — Cancelled or forfeited — — — — Outstanding as of June 30, 2021 600,000 $ 0.10 9.08 $ — Options exercisable as of June 30, 2021 237,500 $ 0.10 9.08 $ — For the three months ended June 30, 2021 and 2020, the Company recorded stock-based compensation expense of $2,618 and $0.0, respectively. For the six months ended June 30, 2021 and 2020, the Company recorded stock-based compensation expense of $5,207 and $0.0, respectively . Kures Restricted Common Stock Awards Immediately following the acquisition detailed in Note 3, the Board of Directors of Kures issued 4,937,530 unvested restricted common shares to directors of Kures. The restricted common stock vest over a two to three-year period, subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company. The Company measures all non-cash The Company reflects restricted stock awards as issued and outstanding shares of common stock when vested and the shares have been delivered to the individual. The following table summarizes Kures’ restricted common stock aw a RSA Weighted Unvested balance as of December 31, 2020 2,743,066 $ 0.10 Granted — — Vested (822,924 ) 0.10 Forfeited — — Unvested balance as of June 30, 2021 1,920,142 $ 0.10 For the three months ended June 30, 2021 and 2020, the Company recorded stock-based compensation expense associated with restricted stock awards of $42,761 and $41,033, respectively. For the six months ended June 30, 2021 and 2020, the Company recorded stock-based compensation expense associated with restricted stock awards of $83,343 and $82,067, respectively. The fair value of restricted stock that vested during the si x Recognify Restricted Common Stock Awards Immediately following the acquisition detailed in Note 3, the Board of Directors of Recognify issued 1,017,917 unvested restricted common shares to directors and consultants of Recognify. The restricted common stock typically vest over a two to four-year period, subject to the risk of forfeiture until vested by virtue of continued employment or service to the Company. The Company reflects restricted stock awards as issued and outstanding shares of common stock when vested and the shares have been delivered to the individual. The following table summarizes Recognify’ restricted common stock awards activity from December 31, 2020 to June 30, 2021: RSA Weighted Unvested balance as of December 31, 2020 952,387 $ 1.71 Granted Vested (198,684 ) 1.71 Forfeited — — Unvested balance as of June 30, 2021 753,703 $ 1.71 The Company acquired Recognify in November 2020. The Company det e For the three months ended June 30, 2021, the Company recorded stock-based compensation expense of $ 0.2 0.3 The total fair value of shares vested during the six Stock-Based Compensation Stock-based compensation expense is allocated to either research and development or general and administrative expense on the consolidated statements of operations based on the cost center to which the option holder belongs. For the three months ended June, 2020, the Company recorded total stock-based compensation expense associated with Kures’ restricted stock awards of $41,033 within research and development expense on the condensed consolidated statements of operations. For the six months ended June, 2020, the Company recorded total stock-based compensation expense associated with Kures’ restricted stock awards of $ 82,067 The following table summarizes the total stock-based compensation expense by function for the three months ended June 30, 2021, which includes expense related to stock options and restricted stock awards (in thousands): Three Months Ended June 30, 2021 Atai Atai Kures Kures Recognify Total Research and development $ 8,698 $ — $ 3 $ 43 $ 115 $ 8,859 General and administrative 11,940 16,650 — — 63 $ 28,653 Total share based compensation expense $ 20,638 $ 16,650 $ 3 $ 43 $ 178 $ 37,512 The following table summarizes the total stock-based compensation expense by function for the six months ended June 30, 2021, which includes expense related to stock options and restricted stock awards (in thousands): Six Months Ended June 30, 2021 Atai Atai Kures Kures Recognify Total Research and development $ 8,698 $ — $ 5 $ 83 $ 222 $ 9,008 General and administrative 11,940 16,650 — — 125 $ 28,715 Total share based compensation expense $ 20,638 $ 16,650 $ 5 $ 83 $ 347 $ 37,723

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The Company records its quarterly income tax expense by utilizing an estimated annual effective tax rate applied to its period to date earnings as adjusted for any discrete items arising during the quarter. The tax effect for discrete items are recorded in the period in which they occur. The Company recorded $58,000 0 0

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share	14. Net Loss Per Share Basic and diluted net loss per share attributable to ATAI stockholders were calculated as follows (in thousands, except share and per share data): Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Numerator: Net income $ (53,373 ) $ (16,957 ) $ (49,329 ) $ (1,076 ) Net income (loss) attributable to redeemable noncontrolling interests and noncontrolling interests (4,912 ) (600 ) (1,556 ) (1,022 ) Net income attributable to ATAI Life Sciences N.V. shareholders - and diluted $ (48,461 ) $ (16,357 ) $ (47,773 ) $ (54 ) Denominator: 132,265,075 90,709,312 125,797,732 90,709,312 Net income per share attributable to ATAI Life Sciences N.V. and diluted $ (0.37 ) $ (0.18 ) $ (0.38 ) $ (0.00 ) HSOP Shares issued to the Partnership and allocated to the HSOP Options holders are not considered outstanding for accounting purposes and not included in the calculation of basic weighted average common shares outstanding in the table above because the HSOP Option holders have a forfeitable right to distributions until the HSOP Options vest, at which time the right becomes nonforfeitable. The following also represents maximum amount of outstanding shares of potentially dilutive securities were excluded from the computation of diluted net income (loss) per share attributable to common shareholders for the periods presented because including them would have been antidilutive: Potentially dilutive securities to the Company’s common shares: As of June 30, 2021 2020 Options to purchase common stock 23,797,993 — HSOP options to purchase common stock 7,281,376 — 2020 Convertible Promissory Notes (Note 11 ) — 3,679,485 2018 Convertible Promissory Notes - Related Parties (Note 11) 16,000,000 2,560,000 47,079,369 6,239,485 The 2018 Convertible Promissory Notes – related party that would be issuable upon the exercise of conversion rights of convertible note holders for 1,000,000 and 160,000 shares of common stock of ATAI Life Sciences AG, respectively. The 2018 Convertible Promissory Notes – related party remained outstanding following completion of the share exchange and ATAI Life Sciences AG became the wholly owned subsidiary of ATAI Life Sciences N.V after the Corporate Reorganization described in Note 1 through June 30, 2021. Upon conversion, it is expected the shares would be exchanged on a one-for-sixteen basis for shares of ATAI Life Sciences N.V. which is reflected in the table above. The 2020 Convertible Notes converted into 8,773,056 of shares of the Company’s common stock in November 2020 in connection with e as of

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Research and Development Agreements The Company may also enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies and with other vendors for preclinical studies, supplies and other services and products for operating purposes. Indemnification In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to vendors, lessors, business partners, board members, officers and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by the Company, negligence or willful misconduct of the Company, violations of law by the Company, or intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with directors and certain officers and employees that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers or employees. No demands have been made upon the Company to provide indemnification under such agreements, and thus, there are no claims that the Company is aware of that could have a material effect on the Company’s consolidated financial statements. The Company also maintains director and officer insurance, which may cover certain liabilities arising from its obligation to indemnify the Company’s directors. To date, the Company has not incurred any material costs and has not accrued any liabilities in the consolidated financial statements as a result of these provisions. Contingencies From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is unable to predict the outcome of these matters or the ultimate legal and financial liability, and at this time cannot reasonably estimate the possible loss or range of loss and accordingly has not accrued a related liability. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company accrues a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company does not record a liability, but instead discloses the nature and the amount of the claim, and an estimate of the loss or range of loss, if such an estimate can be made. Legal fees are expensed as incurred. The Company currently believes that the outcome of these legal proceedings, either individually or in the aggregate, will not have a material effect on its consolidated financial position, results of operations or cash flows.

License Agreements

License Agreements	6 Months Ended
	Jun. 30, 2021
License Agreements [Abstract]
License Agreements	16. License Agreements Otsuka License and Collaboration Agreement On March 11, 2021, the Company entered into a license and collaboration agreement (the “Otsuka Agreement”) with Otsuka Pharmaceutical Co., LTD (“Otsuka”) under which the Company granted exclusive rights to Otsuka to develop and commercialize products containing arketamine, known as PCN-101, PCN-101 PCN-101 Otsuka owed the Company an upfront, non-refundable PCN-101 The Otsuka Agreement will expire upon the fulfillment of Otsuka’s royalty obligations on a product-by-product The Company first assessed the Otsuka Agreement under ASC 808 to determine whether the Otsuka Agreement or units of accounts within the Otsuka Agreement represent a collaborative arrangement based on the risks and rewards and activities of the parties. The Company concluded that Otsuka is a customer in the context of the Otsuka Agreement and the units of account are within the scope of ASC 606. The Company determined that the combined promise of the exclusive license to PCN-101 non-exclusive Based on this assessment, the Company concluded three performance obligations exists at the outset of the Otsuka Agreement: (i) the exclusive license to PCN-101 For the three and six Accelerate License Agreement On April 27, 2021, Psyber entered into a license arrangement with Accelerate Technologies Pte. Ltd. (“Accelerate”), whereby Accelerate grants Psyber non-exclusive BCI-enabled Member Countries of the European Union, Canada, Australia and New Zealand as a potential treatment for mental health and behavior change, such as substance use disorders including opioid use disorder, mood and anxiety disorders including post-traumatic stress disorder, and treatment-resistant depression. Psyber will pay Accelerate an upfront payment of $0.1 million, up to $0.3 million upon the achievement of certain clinical and sale milestones, and low to mid single digit royalty payments based on net sales. Columbia Stock Purchase and License Agreement In June 2020, Kures entered into a license agreement with Columbia, pursuant to which, Kures obtained an exclusive license under certain patents and technical information to discover, develop, manufacture, use and commercialize such patents or other products in all uses and applications (“Columbia IP”). In addition, in consideration for the rights to the Columbia IP, Kures entered into a Stock Purchase Agreement (the “SPA”) with Columbia in contemplation of the license agreement. Pursuant to the SPA, Kures issued to Columbia certain shares of the Kures’ capital stock, representing 5% of Kures common stock on a fully diluted basis, in accordance with the terms and conditions of the SPA. Kures can, from time to time, issue to Columbia additional shares of Kures’ common stock, at a per share price equal to the then fair market value of each such share. The antidilution protection provision shall be maintained up to and through the achievement of certain milestone events. At the acquisition date, the Company recorded the fair value of the shares of Kures common stock issued to Columbia of $0.1 million to Company’s additional-paid-in-capital and a debit to research and development expense for the corresponding acquired in-process research and development as it had no alternative future use at the time of the acquisition. In addition, Kures is obligated to pay tiered royalties ranging in the low to mid-single-digit percentage based on net sales of products licensed under the agreement. If Kures receives revenue from sublicensing any of its rights under the agreement, Kures is also obligated to pay a portion of that revenue to Columbia. Starting from the fourth anniversary of the effective date of the Kures License Agreement, Kures is obligated to pay Columbia annual license fees ranging from $10,000 to $0.1 million, creditable against royalties. Kures is also obligated to make milestone payments aggregating up to $15.5 million upon the achievement of certain clinical or regulatory and sales-based milestones for the first indication for each of the licensed product and up to $7.3 million for each subsequent indication for each of such products. In addition, Kures is obligated to pay Columbia a portion of the non-royalty sublicense payments it receives from a third party receiving a sublicense to practice the rights licensed to Kures under the license agreement, ranging from a low teen to low double-digit percentage. Kures has the right to terminate the Columbia agreement for any reason upon a 90-day notice and if Columbia materially breaches the agreement and fails to remedy any such default. Columbia has the right to terminate the Columbia agreement if Kures declares bankruptcy, becomes insolvent or otherwise materially breaches the agreement and fails to remedy any such default within specified cure periods. Such termination does not preclude Columbia’s rights to any milestone payments, royalties, and other payments described above. The Columbia agreement will remain in effect until terminated by the parties according to their rights. During the three and six months ended June 30, 2020, the Company made no material payments in connection with the Columbia agreement.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	17. Related Party Transactions ATAI Formation In connection with the formation of ATAI in 2018, the Company entered into a series of transactions with its shareholders, Apeiron, Galaxy Group Investments LLC. (“Galaxy”) and HCS Beteiligungsgesellschaft mbH (“HCS”) whereby these shareholders contributed their investments in COMPASS, Innoplexus and Juvenescence to the Company in exchange for ATAI’s common stock of equivalent value. Apeiron is the family office of the Company’s founder who owns 21.0% and 21.7% of the outstanding common stock in the Company as of June 30, 2021 and December 31, 2020, respectively. Galaxy is a NYC-based Convertible Note Agreements with Perception In March 2020, Perception entered into the Perception Note Purchase Agreement with the Company and other investors, including related parties, which provided for the issuance of convertible notes of up to $ million, among which Perception issued convertible notes in the aggregate principal amount of $ million to the Company and $ million to Sonia Weiss Pick and Family, and $ million to other investors. In addition, in December 2020, Perception entered into the Perception December 2020 Convertible Note Agreement with the Company and other investors, including related parties, which provided for the issuance of convertible notes of up to $ million in two tranches. Under the First Tranche Funding of $ million, Perception issued an aggregate principal amount of $ million to the Company and $ million to other investors as of December 31, 2020 and $ million to Apeiron, $ million to Sonia Weiss Pick and Family, and $ million to other investors in January 2021. Under the Second Tranche Funding of $ million, Perception issued an aggregate of $ million to the Company, $ million to Apeiron, $ million to Sonia Weiss Pick and Family, and $ million to other investors . On June 10, 2021, the Company received $20.0 million pursuant to the licensing and collaboration arrangement with Otsuka. Upon receipt of the proceeds, the Perception Convertible Notes automatically converted into Series A preferred stock pursuant to their original terms. Sonia Weiss Pick and Family and Aperion received 440,415 shares and 27,809 shares of Perception Series A preferred stock, respectively, upon conversion of the Perception Convertible Notes. The conversion of the Perception December 2020 Notes was accounted for an extinguishment. The March 2020 Notes were accounted for as a conversion. These transactions are further described in Note 10. Common Stock In January 2021, pursuant to an additional closing from the common stock issuance in November and December 2020, the Company issued and sold 2,133,328 shares of common stock to Apeiron at the same issuance price, for cash proceeds of $12.2 million. In March 2021, in connection with the Company’s issuance of 13,419,360 shares of common stock, at a price of €9.69 or $11.71 per share, the Company issued common shares to Apeiron for a total purchase price of $14.5 million, and issued common shares to Presight II, L.P. for a total purchase price of $13.9 million (See Note 11). Apeiron is the co-managing Directed Share Program In connection with ATAI’s initial public offering, the underwriters reserved 27% of the common shares for sale at the initial offering price to the Company’s managing directors, supervisory directors and certain other parties. Apeiron participated in the program and purchased $10.5 million Consulting Agreement with Mr. Angermayer In January 2021, the Company entered into a consulting agreement, (the “Consulting Agreement”), with Mr. Angermayer, one of the Company’s co-founders Related Party Receivable In February 2021, the Company advanced $0.8 million to a member of the management team to cover the personal payroll and income taxes on their taxable income from the exercise of stock options. This receivable was repaid in May 2021.

Defined Contribution Plan

Defined Contribution Plan	6 Months Ended
	Jun. 30, 2021
Retirement Benefits [Abstract]
Defined Contribution Plan	18. Defined Contribution Plan The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation The Company made an immaterial amount of 401(k) contributions for the three months and six months ended June 30, 2021 and 2020, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	19. Subsequent Events Purchase of Psyber Preferred Stock In July 2021, pursuant to the Psyber Purchase Agreement, the Company purchased additional Series A preferred shares for an aggregate cost of approximately $0.7 million based on the achievement of certain development milestones. Termination of Attersee Credit Line In July 2021, the Company terminated its credit line with Attersee, which remained unused as of the date of cancellation.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements, which include the accounts of ATAI, its wholly owned subsidiaries and controlled entities, are presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and applicable rules and regulations of SEC regarding interim financial reporting. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with such rules and regulations. All intercompany transactions and accounts have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position, its results of operations and comprehensive loss, and its cash flows for the periods presented. The results of operations for the three and six months ended June 30, 2021 are not necessarily indicative of the results to be expected for the year ending December 31, 2021 or for any other future annual or interim period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the prospectus dated June 17, 2021 (“Prospectus”) that forms a part of the Company’s Registration Statements on Form S-1
Use of Estimates	Use of Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but are not limited to the fair value of the Company’s short term notes receivable—related party with COMPASS Pathways plc, convertible promissory notes issued in connection with the 2020 convertible note agreement (the “2020 Convertible Notes”), contingent consideration liability—related parties, derivative liability associated with the Perception convertible promissory notes, redeemable noncontrolling interests, and IPR&D assets and noncontrolling interests recognized in acquisitions, the valuations of common shares and share-based awards, and accruals for research and development costs. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of three months or less from the purchase date to be cash equivalents. As of June 30, 2021 and December 31, 2020, cash and cash equivalents consisted of cash on deposit and cash held in high-yield savings accounts and money market funds .
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value on a recurring basis in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: Level 1—Observable inputs such as unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active; and Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company’s contingent consideration liability—related parties, the 2020 Convertible Notes, derivative liability associated with the Perception convertible promissory notes, investment in Intelgenx Technologies Corp. Initial Warrants and Additional Units Warrant and warrant liability with Neuronasal Inc. are carried at fair value, determined according to Level 3 inputs in the fair value hierarchy described above (See Note 7). The carrying amount reflected in the accompanying consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values, due to their short-term nature. The carrying amounts of the Company’s convertible promissory notes—related parties issued in 2018 and 2020 (collectively, the “2018 Convertible Notes”) do not approximate fair value because the fair value is driven by the underlying value of the Company’s common stock to which the notes are able to be converted. As of June 30, 2021, the carrying amount and fair value amount of the convertible promissory note s s The carrying amounts of the Perception convertible promissory notes issued during 2020, do not approximate fair value because carrying amounts are net of unamortized debt discounts. The fair value of the Perception convertible promissory notes was determined based on the changes in expectation and increase in probability of occurrence of certain conversion events, including a qualified equity financing and a licensing transaction, that would have beneficial conversion terms for the note holders. In June 2021, Perception convertible promissory notes converted into shares of Series A preferred stock of Perception pursuant to their original terms. As of June 30, 2021, there were no Perception convertible promissory notes outstanding. As of December 31, 2020, the carrying amount and fair value amount for Perception convertible promissory notes was $0.8 million and $4.6 million, respectively. See Note 10 for additional discussion.
Fair Value Option	Fair Value Option As permitted under Accounting Standards Codification 825, Financial Instruments, or ASC 825, the Company has elected the fair value option to account for its investment in IntelGenx Technologies Corp. (“IntelGenx”) common stock which otherwise would be subject to ASC 323. In accordance with ASC 825, the Company records these common stock investments at fair value with changes in fair value recorded as a component of other income (expense), net in the consolidated statement of operations and comprehensive loss.
Convertible Promissory Notes and Derivative Instruments	Convertible Promissory Notes and Derivative Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including convertible promissory notes, to determine if such instruments contain features that meet the definition of embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statements of operations at each reporting period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheets. On March 16, 2020, Perception entered into a convertible promissory note agreement with the Company and other investors, including related parties, which provided for the issuance of convertible notes of $3.3 million to the Company and $0.6 million to other investors. On December 1, 2020, Perception entered into an additional convertible promissory note agreement with the Company and other investors, including related parties, which provided for the issuance of convertible notes of up to $12.0 million to the Company in aggregate of which (i) $6.2 million and $0.8 million were issued in December 2020 and January 2021, respectively, under the First Tranche Funding and (ii) $5.0 million was issued under the Second Tranche Funding (See Note 10). The Perception convertible promissory notes issued to the Company represent intercompany debt and are eliminated upon consolidation. In addition, the Perception convertible promissory notes contain certain embedded features, which are redemption features and meet the definition of derivative instruments. The Company classifies these instruments as a liability on its consolidated balance sheets as the redemption features involve substantial discounts, provide for the accelerated repayment of the notes upon the occurrence of specified events, and are not clearly and closely related to its host instrument. The derivative liability was initially recorded at fair value upon issuance of the convertible promissory notes and is subsequently remeasured to fair value at each reporting date. Both the Perception convertible promissory notes and the derivative liability have been classified as long-term and presented as convertible promissory notes and derivative liability in the Company’s consolidated balance sheets. Changes in the fair value of the derivative asset and liability are recognized as a component of other income (expense), net in the consolidated statements of operations. Changes in the fair value of the derivative asset and liability will continue to be recognized until the warrants and convertible promissory notes are longer outstanding .
Warrant Liability	Warrant Liability The Company accounts for the warrants in accordance with the guidance contained in ASC 815-40 re-measurement
Licenses of Intellectual Property	Licenses of Intellectual Property The Company may enter into collaboration and licensing arrangements for research and development, manufacturing, and commercialization activities with counterparties for the development and commercialization of its product candidates. The agreements may have units of account within the scope of ASC 606 where the counterparties meet the definition of a customer as well as units of account within the scope of ASC 808 where both parties are determined to be active participants. The arrangements may contain multiple components, which may include (i) licenses, or options to obtain licenses to the Company’s intellectual property or sale of the Company’s license, (ii) research and development activities, (iii) participation on joint steering committees, and (iv) the manufacturing of commercial, clinical or preclinical material. Payments pursuant to these arrangements may include non-refundable, In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its collaboration and license agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract within the scope of ASC 606; (ii) determination of whether the promised goods or services are performance obligations including whether they are capable of being distinct and distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and d) the measure of progress in step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for sales-based milestones and royalties on license arrangements, should be included in the transaction price as described further below. If a license to the Company’s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from consideration allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a promise or performance obligation is distinct from the other elements, the Company considers factors such as the research, development, manufacturing and commercialization capabilities of the counterparties and the availability of its associated expertise in the general marketplace. In addition, the Company considers whether the counterparties can benefit from a promise for its intended purpose without the receipt of the remaining elements, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress as of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods over which revenue should be recognized, is subject to estimates by management and may change over the course of the arrangement. Such a change could have a material impact on the amount of revenue the Company records in future periods. Customer Options: If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services such as research and development services or manufacturing services, the goods and services underlying the customer options are not considered to be performance obligations at the inception of the arrangement unless a material right is provided to the customer. If the customer option does not represent a material right, the obligation to provide such goods and services is contingent on exercise of the option, and the associated consideration is not included in the transaction price. If a customer option is determined to include a significant and incremental discount and, therefore, represents a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company allocates the transaction price to material rights based on the relative standalone selling price. Milestone Payments: At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most-likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the respective milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up Royalties: For license arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for all stock-based payment awards granted to employees, directors and non-employees as stock-based compensation expense based on their grant date fair value. The Company grants equity awards under its stock-based compensation programs, which may include stock options and restricted common stock. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the requisite service period, which is the vesting period, on a straight-line basis. Since the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant, and stock-based compensation costs are recognized in the same period and in the same manner as if the entity had paid cash for the goods or services. Stock-based compensation expense is classified in the accompanying condensed consolidated statements of operations based on the function to which the related services are provided. The Company has elected to recognize forfeitures of stock-based compensation awards as they occur. The Company recognizes the compensation cost of awards subject to service-based and performance-based vesting conditions using the accelerated attribution method over the requisite service period if the performance- based vesting conditions are probable of being met. Recognition of compensation cost relating to awards that vest on a “Liquidity Event” (as defined in the award or Partnership agreements) will be deferred until the consummation of such transaction. The Company calculates the fair value of stock options granted using the Black-Scholes option-pricing model with the following assumptions: Expected Volatility Expected Term Risk-Free Interest Rate Dividend Yield As part of the valuation of stock-based compensation under the Black-Scholes option pricing model, it is necessary for the Company to estimate the fair value of its common stock. Prior to the closing of the IPO, the fair value of the Company’s common stock was estimated on each grant date. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants’ Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercised reasonable judgment and considered numerous objective and subjective factors to determine its best estimate of the fair value of its common stock. The estimation of the fair value of the common stock considered factors including the following: the estimated present value of the Company’s future cash flows; the Company’s business, financial condition and results of operations; the Company’s forecasted operating performance; the illiquid nature of the Company’s common stock; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. After the closing of the IPO, the Company’s board of directors determined the fair value of each share of common stock underlying stock-based awards based on the closing price of the Company’s common stock as reported by Nasdaq on the date of grant.
Net Income (Loss) per Share Attributable to Common Stockholders	Net Income (Loss) per Share Attributable to Common Stockholders The Company computed basic net income (loss) per share attributable to common stockholders by dividing net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net income (loss) per common share after giving consideration to all potentially dilutive common stock, including convertible notes and stock options, outstanding during the period determined using the if-converted
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815—40) ” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU’s amendments are effective for the Company for fiscal years beginning after December 15, 2023 and interim periods within those fiscal years, with early adoption permitted. The Company early adopted this standard on January 1, 2021 applying the modified retrospective transition approach. Upon adoption of ASU 2020-06, the embedded conversion option related to the 2018 Convertible Notes is no longer separated from the host contract and recognized within additional paid-in-capital and is instead accounted for as a single liability measured at amortized cost $ 8,000

Variable Interest Entities an_2

Variable Interest Entities and a Voting Interest Entity (Tables)	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Primary Beneficiary for VIEs Consolidated Under the VIE Model	As of June 30, 2021 and December 31, 2020, the Company has accounted for the following investments as VIEs, excluding the wholly owned subsidiaries: Consolidated Entities Relationship as of June 30, 2021 Relationship as of December 31, 2020 Date Control Obtained Ownership % June 30, 2021 Ownership % December 31, 2020 Perception Neuroscience Holdings, Inc. Controlled VIE Controlled VIE November 2018 58.9 % 50.1 % Kures, Inc. Controlled VIE Controlled VIE August 2019 54.1 % 54.1 % EntheogeniX Biosciences, Inc. Controlled VIE Controlled VIE November 2019 80.0 % 80.0 % DemeRx IB, Inc. Controlled VIE Controlled VIE December 2019 59.5 % 59.5 % Recognify Life Sciences, Inc. Controlled VIE Controlled VIE November 2020 51.9 % 51.9 % PsyProtix, Inc. Controlled VIE — February 2021 75.0 % — Psyber, Inc. Controlled VIE — February 2021 75.0 % — InnarisBio, Inc. Controlled VIE — March 2021 82.0 % — Neuronasal, Inc. Controlled VIE Investment May 2021 56.0 % 37.2 %
Summary of the Assets and Liabilities for all Consolidated VIEs	The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all VIEs as of June 30, 2021 (in thousands): Perception Kures EntheogeniX DemeRx IB Recognify PsyProtix Psyber InnarisBio Neuronasal Assets: Current assets: Cash $ 26,741 $ 762 $ 401 $ 5,351 $ 1,493 $ 91 $ 174 $ 816 $ 691 Unbilled receivable — — — — — — — — — Prepaid expenses and other current assets 1,638 84 — 431 15 — — — 560 Total current assets 28,379 846 401 5,782 1,508 91 174 816 1,251 Property and equipment, net 2 — — — — — — — — Goodwill — — — — — — — — — Long term notes receivable — — — 1,075 — 102 — — — Total assets $ 28,381 $ 846 $ 401 $ 6,857 $ 1,508 $ 193 $ 174 $ 816 $ 1,251 Liabilities: Current liabilities: Accounts payabl e $ 743 $ 210 $ 26 $ 495 $ 19 $ — $ 1 $ — $ 253 Accrued liabilities 947 356 31 154 264 9 69 — 384 Deferred revenue 120 — — — — — — — — Convertible — — — — — — — — 38 Total current liabilities 1,810 566 57 649 283 9 70 — 675 Convertible promissory notes and derivative liability — — — — — — — — — Contingent consideration liability 2,363 — — — — — — 103 — Other non-current — — — — — — — — 289 Total liabilities $ 4,173 $ 566 $ 57 $ 649 $ 283 $ 9 $ 70 $ 103 $ 964 The following table presents the assets and liabilities (excluding intercompany balances that were eliminated in consolidation) for all consolidated VIEs as of December 31, 2020 (in thousands): Perception Kures EntheogeniX DemeRx IB Recognify Assets: Current assets: Cash $ 6,527 $ 1,264 $ 652 $ 7,252 $ 1,895 Prepaid expenses and other current assets 768 124 — 193 44 Total current assets 7,295 1,388 652 7,445 1,939 Property and equipment, net 4 — — — — Long term notes receivable — — — 1,060 — Total assets $ 7,299 $ 1,388 $ 652 $ 8,505 $ 1,939 Liabilities: Current liabilities: Accounts payable $ 564 $ 220 $ 35 $ 230 $ 64 Accrued liabilities 297 229 11 92 66 Total current liabilities 861 449 46 322 130 Convertible promissory notes and derivative liability 978 — — — — Contingent consideration liability 1,705 — — — — Total liabilities $ 3,544 $ 449 $ 46 $ 322 $ 130
Schedule of Non Controlling Interest Recognized to Its Consolidated VIEs Roll Forward	The Company recognizes noncontrolling interests related to its consolidated VIEs and provides a rollforward of the noncontrolling interests balance, as follows (in thousands): Perception Recognify Psyber InnarisBio Neuronasal Total Balance as of December 31, 2020 $ — $ 4,546 $ — $ — $ — $ 4,546 Issuance of noncontrolling interests — — 8 877 — 885 Net income (loss) attributable to noncontrolling interests - common 1,755 — (8 ) (877 ) — 870 Net income (loss) attributable to noncontrolling interests - preferred 2,608 (122 ) — — — 2,486 Comprehensive loss attributable to noncontrolling interests (184 ) — — — — (184 ) Balance as of March 31, 2021 $ 4,179 $ 4,424 $ — $ — $ — $ 8,603 Issuance of noncontrolling interests 3,257 — — — 392 3,649 Net income (loss) attributable to noncontrolling interests - common (1,755 ) (217 ) — — (392 ) (2,364 ) Net income (loss) attributable to noncontrolling interests - preferred 7 — — — — 7 Comprehensive loss attributable to noncontrolling interests 150 — — — — 150 Balance as of June 30, 2021 $ 5,838 $ 4,207 $ — $ — $ — $ 10,045 Perception Kures Total Balance as of December 31, 2019 $ 487 $ 400 $ 887 Issuance of noncontrolling interests — — — Repurchase of noncontrolling interest — — — Net loss attributable to noncontrolling interests - common — — — Net loss attributable to noncontrolling interests - preferred (297 ) (92 ) (389 ) Comprehensive loss attributable to noncontrolling interests 13 — 13 Balance as of March 31, 2020 $ 203 $ 308 $ 511 Issuance of noncontrolling interests — — — Repurchase of noncontrolling interest — — — Net loss attributable to noncontrolling interests - common — — — Net loss attributable to noncontrolling interests - preferred (183 ) (308 ) (491 ) Comprehensive loss attributable to noncontrolling interests (20 ) — (20 ) Balance as of June 30, 2020 $ — $ — $ —
Schedule of Roll Forward of the Redeemable Noncontrolling Interests Balance	The following table provides a rollforward of the redeemable noncontrolling interests balance (in thousands): Kures Neuronasal Total Balance as of December 31, 2020 $ — $ — $ — Issuance of redeemable noncontrolling interests — — — Net loss attributable to redeemable noncontrolling interests - common — — — Balance as of March 31, 2021 $ — $ — $ — Issuance of redeemable noncontrolling interests — 2,555 2,555 Net loss attributable to redeemable noncontrolling interests - common — (2,555 ) (2,555 ) Balance as of June 30, 2021 $ — $ — $ — Kures Total Balance as of December 31, 2019 $ 142 $ 142 Net loss attributable to redeemable noncontrolling interests - preferred (33 ) (33 ) Balance as of March 31, 2020 $ 109 $ 109 Net loss attributable to redeemable noncontrolling interests - preferred (109 ) (109 ) Balance as of June 30, 2020 $ — $ —

Equity Method Investments and_2

Equity Method Investments and Other Investments (Tables)	6 Months Ended
	Jun. 30, 2021
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments	As of June 30, 2021 and December 31, 2020, the Company accounted for the following investments in the investee’s common stock under the equity method (amounts in thousands): As of June 30, 2021 As of December 31, 2020 Date First Common Stock Carrying Common Stock Carrying Investee Acquired Ownership % Value Ownership % Value Innoplexus A.G. August 2018 35.0 % $ — 35.0 % $ — COMPASS Pathways plc (2) December 2018 19.4 % 19,780 22.1 % — GABA Therapeutics, Inc November 2020 7.5 % (1) — 7.5 % (1) — Neuronasal, Inc October 2020 n/a (3) — 9.8 % (1) — Total $ 19,780 $ — (1) The Company is deemed to have significant influence over this entity through its total ownership interest in the entity’s equity, including the Company’s investment in the respective entity’s preferred stock, described below in Other Investments. (2) Prior to the consummation of the COMPASS IPO in September 2020, COMPASS undertook a corporate reorganization. As part of the corporate reorganization, COMPASS became a wholly owned subsidiary of COMPASS Rx Limited. COMPASS Rx Limited was re-registered as (3) Neuronasal common stock was accounted for under the equity method until the entity was
Schedule Of Equity Method Investment Summarized Balance Sheet	The following is a summary of financial data for investments accounted for under the equity method of accounting (in thousands): Balance Sheets June 30, 2021 Compass Neuronasal (1) GABA Current assets $ 334,035 $ — $ 10,954 Non-current assets 1,126 — — Total assets $ 335,161 $ — $ 10,954 Current liabilities $ 7,801 $ — $ 162 Non-current liabilities — — — Total liabilities $ 7,801 $ — $ 162 December 31, 2020 Compass Neuronasal (1) GABA Current assets $ 202,404 $ 351 $ 3,302 Non-current 1,052 10 — Total assets $ 203,456 $ 361 $ 3,302 Current liabilities $ 6,895 $ 686 $ 430 Non-current — 48 — Total liabilities $ 6,895 $ 734 $ 430
Shedule Of Equity Method Investment Summarized Statement Of Operations	Statements of operations Three Months Ended June 30, 2021 Compass Neuronasal (1) GABA Revenue $ — $ — $ — Loss from continuing operations $ (19,528 ) $ (409 ) $ (387 ) Net loss $ (19,528 ) $ (409 ) $ (387 ) Three Months Ended June 30, 2020 Compass Neuronasal (1) GABA Revenue $ — $ — $ — Loss from continuing operations $ (17,687 ) $ (382 ) $ (929 ) Net loss $ (17,687 ) $ (382 ) $ (929 ) Six Months Ended June 30, 2021 Compass Neuronasal (1) GABA Revenue $ — $ — $ — Loss from continuing operations $ (33,130 ) $ (985 ) $ (1,046 ) Net loss $ (33,130 ) $ (985 ) $ (1,046 ) Six Months Ended June 30, 2020 Compass Neuronasal (1) GABA Revenue $ — $ — $ — Loss from continuing operations $ (26,392 ) $ (514 ) $ (1,956 ) Net loss $ (26,392 ) $ (514 ) $ (1,956 ) (1) Results from operations for Neuronasal are through May 17, 2021 at which point the entity is consolidated.
Investment	June 30, December 31, 2021 2020 GABA Therapeutics, Inc. $ 14,682 $ 5,519 DemeRx NB, Inc. 1,067 1,096 Juvenescence Limite d 358 368 Neuronasal, Inc. — 1,061 Total $ 16,107 $ 8,044

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Basis and Diluted Net Loss Per Share Attributable to ATAI Stockholders	Basic and diluted net loss per share attributable to ATAI stockholders were calculated as follows (in thousands, except share and per share data): Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Numerator: Net income $ (53,373 ) $ (16,957 ) $ (49,329 ) $ (1,076 ) Net income (loss) attributable to redeemable noncontrolling interests and noncontrolling interests (4,912 ) (600 ) (1,556 ) (1,022 ) Net income attributable to ATAI Life Sciences N.V. shareholders - and diluted $ (48,461 ) $ (16,357 ) $ (47,773 ) $ (54 ) Denominator: 132,265,075 90,709,312 125,797,732 90,709,312 Net income per share attributable to ATAI Life Sciences N.V. and diluted $ (0.37 ) $ (0.18 ) $ (0.38 ) $ (0.00 )
Schedule of Computation of Diluted net Income (Loss) Per Share Attributable to Common Shareholders	Potentially dilutive securities to the Company’s common shares: As of June 30, 2021 2020 Options to purchase common stock 23,797,993 — HSOP options to purchase common stock 7,281,376 — 2020 Convertible Promissory Notes (Note 11 ) — 3,679,485 2018 Convertible Promissory Notes - Related Parties (Note 11) 16,000,000 2,560,000 47,079,369 6,239,485

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of Share-based Payment Arrangement, Option, Activity	The following is a summary of stock option activity for from December 31, 2020 to June 30, 2021: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2020 11,331,232 $ 1.54 4.64 $ 47,735 Granted 14,051,289 (1) 8.69 — — Exercised — — — — Cancelled or forfeited (1,584,528 ) (2) 2.37 — — Outstanding as of June 30, 2021 23,797,993 ( 3 $ 5.71 4.49 $ 304,470 Options exercisable as of June 30, 2021 5,512,278 $ 0.85 4.14 $ 97,291 (1) Includes (a) 5,391,184 stock options that will vest over a two to four-year service period, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant. If the Company achieves an IPO (as defined in the awards) by June 30, 2021 or December 31, 2021, an additional 25% or 12.5%, respectively, the stock options will accelerate and vest upon the occurrence of the transaction, (b) 5,241,785 stock options that will vest over a one to four-year service period, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant (c) 1,460,784 stock options that will vest at the end of a four-year service period and upon the satisfaction of specified performance-based vesting conditions, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant, (d) 624,000 stock options that will vest over a three-year service period, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant, (e) 400,688 stock options that will vest over a four-year service period and upon the satisfaction of specified performance-based vesting conditions including liquidity-based conditions, only if and when a “Liquidity Event” (as defined in the awards) occurs within five years of the date of grant. If the Company achieves an IPO (as defined in the awards) by June 30, 2021 or December 31, 2021, an additional 25% or 12.5%, respectively, will accelerate and satisfy the service-based vesting condition upon the occurrence of the transaction, (f) 400,000 stock options that will vest over a two-year (2) Includes 1,152,192 Exchange Shares (3) With the satisfaction of the Liquidity Event (as defined in the awards) during the three months ended June 30, 2021, the outstanding options include
Summary of Employee Stock Ownership Plan (ESOP) Disclosures	The following is a summary of stock option activity for from December 31, 2020 to June 30, 2021: Number of Weighted- Weighted- Aggregate Outstanding as of December 31, 2020 — — — — Granted 7,281,376 (1) 6.64 — — Exercised — — — — Cancelled or forfeited — — — — Outstanding as of June 30, 2021 7,281,376 $ 6.64 14.51 $ 86,346 Options exercisable as of June 30, 2021 2,736,372 $ 6.63 14.51 $ 32,483 (1) Includes 4,543,936 Exchange Shares
Summary of Share-based Compensation Arrangements by Share-based Payment Award	The following is a summary of stock option from December 31, 2020 to June 30, 2021: Number Weighted- Weighted- Aggregate Value Outstanding as of December 31, 2020 600,000 $ 0.10 9.58 $ — Granted — — — — Exercised — — — — Cancelled or forfeited — — — — Outstanding as of June 30, 2021 600,000 $ 0.10 9.08 $ — Options exercisable as of June 30, 2021 237,500 $ 0.10 9.08 $ —
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table summarizes the total stock-based compensation expense by function for the three months ended June 30, 2021, which includes expense related to stock options and restricted stock awards (in thousands): Three Months Ended June 30, 2021 Atai Atai Kures Kures Recognify Total Research and development $ 8,698 $ — $ 3 $ 43 $ 115 $ 8,859 General and administrative 11,940 16,650 — — 63 $ 28,653 Total share based compensation expense $ 20,638 $ 16,650 $ 3 $ 43 $ 178 $ 37,512 The following table summarizes the total stock-based compensation expense by function for the six months ended June 30, 2021, which includes expense related to stock options and restricted stock awards (in thousands): Six Months Ended June 30, 2021 Atai Atai Kures Kures Recognify Total Research and development $ 8,698 $ — $ 5 $ 83 $ 222 $ 9,008 General and administrative 11,940 16,650 — — 125 $ 28,715 Total share based compensation expense $ 20,638 $ 16,650 $ 5 $ 83 $ 347 $ 37,723
Two Thousand And Twenty Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	During the six months ended June 30, 2021, the assumptions used in the Black-Scholes option pricing model were as follows: June 30, Weighted average expected term in years 3.64 Weighted average expected stock price volatility 81.2% Risk-free interest rate (0.76)%-1.27% Expected dividend yield 0%
HSOP Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The Company estimates the fair values of stock options using the Black-Scholes option-pricing model on the date of grant. During the six months ended June 30, 2021, the assumptions used in the Black-Scholes option pricing model were as follows: June 30, Weighted average expected term in years 8.00 Weighted average expected stock price volatility 70.0% Risk-free interest rate (0.70)%-(0.65)% Expected dividend yield 0%
Kures Restricted Common Stock Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units And Weighted Average grant Date Fair Value	The following table summarizes Kures’ restricted common stock aw a RSA Weighted Unvested balance as of December 31, 2020 2,743,066 $ 0.10 Granted — — Vested (822,924 ) 0.10 Forfeited — — Unvested balance as of June 30, 2021 1,920,142 $ 0.10
Recognify Restricted Common Stock Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units And Weighted Average grant Date Fair Value	The following table summarizes Recognify’ restricted common stock awards activity from December 31, 2020 to June 30, 2021: RSA Weighted Unvested balance as of December 31, 2020 952,387 $ 1.71 Granted Vested (198,684 ) 1.71 Forfeited — — Unvested balance as of June 30, 2021 753,703 $ 1.71

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Fair Value Measurement on Recurring Basis	The following table presents information about the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation (in thousands): Fair Value Measurements as of June 30, 2021 Using: Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market funds $ 398,528 $ — $ — $ 398,528 Other investment held at fair value — 2,248 4,638 6,886 $ 398,528 $ 2,248 $ 4,638 $ 405,416 Liabilities: Contingent consideration liability - related parties $ — $ — $ 2,466 $ 2,466 Warrant Liability $ — $ — $ 289 $ 289 $ — $ — $ 2,755 $ 2,755 Fair Value Measurements as of December 31, 2020 Using: Level 1 Level 2 Level 3 Total Assets: $ — Liabilities: Contingent consideration liability - related parties $ — $ — $ 1,705 $ 1,705 Derivative liability — — 214 214 $ — $ — $ 1,919 $ 1,919
Summary of Fair Value Measurement on Recurring Basis, Unobservable Input Reconciliation	The following table provides a roll forward of the aggregate fair values of the Company’s financial instruments described above, for which fair value is determined using Level 3 inputs Other Contingent liability - related Derivative Warrant Balance as of December 31, 2020 $ — $ 1,705 $ 214 $ — Initial fair value of instrument — 101 304 — Change in fair value — (251 ) (41 ) — Balance as of March 31, 2021 $ — $ 1,555 $ 477 $ — Initial fair value of instrument 9,358 — 343 249 Change in fair value (4,720 ) 911 — 40 Extinguishment of l — — (820 ) — Balance as of June 30, 2021 $ 4,638 $ 2,466 $ — $ 289 Compass Notes Receivable - related party Contingent Consideration liability - related parties 2020 Convertible Notes Payable Derivative Liability Balance as of December $ 8,244 $ 572 $ — $ — Initial fair value of instrument — — — 31 Issuance of notes payable — — 9,707 — Change in fair value 718 24 (1,127 ) — Foreign currency transaction adjustments 41 — (38 ) — Balance as of March 31, 2020 $ 9,003 $ 596 $ 8,542 $ 31 Initial fair value of instrument — — — 184 Issuance of notes payable — — 2,668 — Conversion of notes receivable (9,003 ) — — — Change in fair value — 42 1,260 — Foreign currency transaction adjustments — — 212 — Balance as of June 30, 2020 $ — $ 638 $ 12,682 $ 215
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Fair Value Measurement Inputs and Valuation Techniques	The following table summarizes significant inputs that are included in the valuation of the Initial Warrants as of June 30, 2021: June 30, Value of Underlying $ 0.46 Exercise Price $ 0.35 Risk Free Rate 0.43 % Expected Term (in Years) 2.9 Expected Volatility 100 % Dividend Yield 0.00 %
Additional Warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Fair Value Measurement Inputs and Valuation Techniques	The following table summarizes significant unobservable inputs that are included in the valuation of the Additional Units Warrant as of June 30, 2021: June 30, 2021 Tranche 1 Number Units 14,920,000 Tranche 2 Number Units 115,080,000 Additional Warrants Term (in years) 3.00 Additional Units Term (in Years) 2.87 Maximum Term (in Years) 5.87 Stock Price $ 0.460 Expected Volatility 100 % Warrant Strike $ 0.556 Unit Purchase Price 1st Year $ 0.331 Unit Purchase Price 2nd Year $ 0.500 Unit Purchase Price 3rd Year $ 0.750 Wfraction 0.68 Risk-Free Rate 1.02 % Dividend Yield 0.00 % Number of time-steps 500
Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Fair Value Measurement Inputs and Valuation Techniques	The following table summarizes significant unobservable inputs that are included in the valuation of the warrant lability as of June 30, 2021: June 30, 2021 Exercise Price $ 0.01 Stock Price $ 36.12 Dividend Yield 0.00 % Expected Term (in Years) 3.25 Risk-Free Interest Rate 0.51 % Expected Volatility 98 %
Contingent Consideration Lability Related Parties [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Fair Value Measurement Inputs and Valuation Techniques	The following table summarizes significant unobservable inputs that are included in the valuation of contingent consideration lability – related for Perception parties as of June 30, 2021 and December 31, 2020: June 30, 2021 December 31, 2020 Weighted Weighted Valuation Technique Significant Unobservable Inputs Input Range Average Input Range Average Discounted cash flow Milestone contingent consideration: Discount rate 5.9% 5.9% 8.4% to 14.1% 9.4% Projected milestone timing 3.5 years 3.5 years 4.0 to 4.3 years 4.1 years Probability of the milestone 51.9% 51.9% 10.5% to 48.7% 34.8% Discounted cash flow with SBM Royalty contingent consideration: Discount rate for royalties 13.0% 13.0% 12.0% to 13.0% 12.5% Discount rate for royalties on milestones 5.9% 5.9% 8.4% 8.4% Projected commercial revenue $270.3 to $2,031 N/A $77.5 to $3,542 N/A Projected clinical milestone revenue $6.0 to $30.0 N/A $6.0 to $30.0 N/A Timing of royalties on commercial revenue 7.8 years 7.8 years 7.8 to 8.5 years 8.1 years Timing of royalties on clinical milestone revenue 0.8 year 0.8 year 1.3 years 1.3 years Probability of success rate 26.5% to 100.0% 29.9% 3.95% to 100.0% 12.6% Probability of the close of the license transaction (1) N/A N/A 80.0% 80.0% (1) This input was used in fourth quarter of 2020 in relation to a potential license transaction that Perception has with a third-party pharmaceutical company.
Two Thousand Twenty Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Fair Value Measurement Inputs and Valuation Techniques	The following table summarizes significant unobservable inputs by valuation technique that are included in the valuation of the 2020 Convertible Notes from the issuance date of the notes in January 2020 to June 30, 2020: June 30, 2020 Weighted Valuation Technique Significant Unobservable Inputs Input Range Average SBM Discount rate 0.6% to 7.2% 1.6% Expected term 0.5 to 1.0 years 0.8 years Probability scenarios: Conversion upon a financing event 50.0 % to 60.0% 52.0% OPM Risk free rate -0.6% to -0.7% -0.6% Volatility 70.0% to 80.0% 75.0% Dividend yield 0% 0%
Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of Fair Value Measurement Inputs and Valuation Techniques	The significant unobservable inputs that are included in the valuation of the derivative liability as of December 31, 2020 include: December 31, 2020 Weighted Significant Unobservable Inputs Input Range Average Discount rate 17.0% 17.0% Expected term 1 year 1 year Probability scenarios: Qualified financing transaction 20% 20% Licensing transaction 80% 80%

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Prepaid Expense and Other Assets, Current [Abstract]
Summary of prepaid expenses and other current assets	June December Prepaid research and development related expenses $ 2,408 $ 313 Research and development tax credit 1,029 556 Sales tax receivables 315 509 Prepaid insurance 101 144 Other 111 554 Total $ 3,964 $ 2,076

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Accrued Liabilities, Current [Abstract]
Summary of accrued liabilities	Accrued liabilities consist of the following (in thousands): June 0 1 December 0 Accrued accounting, legal, and other professional fees $ 3,324 $ 2,858 Taxes payable 1,323 997 Accrued external research and development expenses 1,138 347 Accrued payroll 1,103 1,098 Accrued advisory fees — 3,819 Other liabilities 936 96 Total $ 7,824 $ 9,215

Convertible Promissory Notes (T

Convertible Promissory Notes (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Summary of convertible promissory notes	Convertible promissory notes—related parties, net of discounts and deferred issuance costs, consisted of the following (in thousands): June 30, December 31, Convertible notes issued in November 2018 $ 190 $ 195 Convertible notes issued in October 2020 995 1,022 Unamortized discount and deferred issuance costs (9 ) (18 ) Total $ 1,176 $ 1,199

Organization and Description _2

Organization and Description of Business - Additional Information (Detail) $ / shares in Units, $ in Thousands	Jun. 22, 2021USD ($)$ / sharesshares	Jun. 07, 2021€ / shares	Jun. 30, 2021USD ($)$ / shares	Jun. 30, 2021€ / shares	Mar. 31, 2021€ / shares	Mar. 31, 2021$ / shares	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2020€ / shares
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock, Conversion basis		1.6 to one	1 to 10 basis
Common stock, par or stated value per share | (per share)		€ 0.10	$ 0.12	€ 0.10			$ 0.12	€ 0.10
Shares issued, price per share | (per share)					€ 9.69	$ 11.71
Cash and cash equivalents			$ 453,622				$ 97,246
Accumulated deficit			$ (237,768)				$ (189,995)
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Issuance of common shares, net of issuance costs ,Shares | shares	17,250,000
Shares issued, price per share | $ / shares	$ 15
Proceeds from initial public offering	$ 231,600
Underwriting discount	18,100
Other offering costs	$ 9,000
Over-Allotment Option [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Exercise of stock options ,Shares | shares	2,250,000

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	May 31, 2021	Jan. 31, 2021	Dec. 31, 2020	Dec. 01, 2020	Mar. 16, 2020
Accounting Policies [Line Items]
Carrying amount of convertible promissory note	$ 0			$ 800
Fair value amount of convertible promissory note				4,600
Unamortized debt discount			$ 8,000
Perception December 2020 Convertible Note Agreement [Member]
Accounting Policies [Line Items]
Debt Instrument, Face Amount					$ 12,000
First Tranche Funding [Member] | Perception December 2020 Convertible Note Agreement [Member]
Accounting Policies [Line Items]
Debt Instrument, Face Amount			$ 800	6,200	$ 7,000
Second Tranche Funding [Member]
Accounting Policies [Line Items]
Debt Instrument, Face Amount		$ 5,000
Convertible Notes Receivable [Member]
Accounting Policies [Line Items]
Investments						$ 3,300
Investments by other investor						$ 600
2018 Convertible Notes [Member]
Accounting Policies [Line Items]
Carrying amount of convertible promissory note	200			200
Fair value amount of convertible promissory note	44,300			12,300
2020 Convertible Notes [Member]
Accounting Policies [Line Items]
Carrying amount of convertible promissory note	1,000			1,000
Fair value amount of convertible promissory note	$ 232,300			$ 64,400

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($)	May 17, 2021	Mar. 10, 2021	Feb. 28, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Business Combinations [Line Items]
Long-term notes receivable—related parties				$ 3,194,000		$ 1,060,000
Fair value of the IPR&D				8,934,000	$ 120,000
Business Acquisition, Equity Interest Issued or Issuable, Value	$ 800,000
PsyProtix Purchase Agreement [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired			$ 100,000
Estimated fair value of contingent consideration			$ 4,900,000
Number of days of voting and other rights of expiration date			10 days
Company's capital contribution threshold limit			$ 5,000,000
Loan received			$ 100,000
Interest rate			5.00%
Aggregate principal amount			$ 100,000
Long-term notes receivable—related parties			$ 100,000
Gain or loss in connection with Business Combination				0
Business Combination, consideration paid				100,000
Business Combination, identifiable assets acquired				100,000
PsyProtix Purchase Agreement [Member] | PsyProtix, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests			75.00%
PsyProtix Purchase Agreement [Member] | Chymia, LLC [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests			25.00%
Psyber Purchase Agreement [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired			$ 200,000
Estimated fair value of contingent consideration			$ 1,800,000
Number of days of voting and other rights of expiration date			10 days
Company's capital contribution threshold limit			$ 2,000,000
Gain or loss in connection with Business Combination				2,000
Business Combination, consideration paid				200,000
Business Combination, identifiable assets acquired				200,000
Psyber Purchase Agreement [Member] | Psyber, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests			75.00%
Psyber Purchase Agreement [Member] | Psyber, LLC [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests			25.00%
InnarisBio Purchase Agreement [Member]
Business Combinations [Line Items]
Cash consideration, net of cash acquired			$ 1,100,000
Estimated fair value of contingent consideration			$ 3,900,000
Number of days of voting and other rights of expiration date			10 days
Gain or loss in connection with Business Combination				7,000
Business Combination, consideration paid				1,100,000
Business Combination, identifiable assets acquired				2,000,000
Business Combination, fair value of the noncontrolling interest issued				900,000
Purchase consideration for the noncontrolling interest and recognized as a liability				100,000
Fair value of the IPR&D				1,000,000
InnarisBio Purchase Agreement [Member] | InnarisBio, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests			82.00%
InnarisBio Purchase Agreement [Member] | UniQuest, LLC [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests			18.00%
Neuronasal, Inc. [Member]
Business Combinations [Line Items]
Business Acquisition, Percentage of Voting Interests	55.99%
Gain or loss in connection with Business Combination				3,500,000
Business Combination, consideration paid				1,000,000
Business Combination, identifiable assets acquired	$ 8,300,000			$ 3,000,000
Fair value of the IPR&D	8,000,000
Neuronasal, Inc. [Member] | Series A Preferred Stock [Member]
Business Combinations [Line Items]
Business Combination, purchase of shares	$ 1,000,000	$ 800,000
Neuronasal, Inc. [Member] | Common Stock [Member]
Business Combinations [Line Items]
Business Combination, purchase of shares		$ 300,000

Variable Interest Entities an_3

Variable Interest Entities and a Voting Interest Entity - Additional information (Detail) - USD ($) $ in Thousands	May 21, 2021	Apr. 13, 2021	Aug. 01, 2019	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2020
Variable Interest Entity [Line Items]
Net loss attributable to redeemable noncontrolling interests				$ (4,912)	$ (600)	$ (1,556)	$ (1,022)
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount				23,000		23,000			$ 8,000
Variable Interest Entity, Nonconsolidated, Comparison of Carrying Amount of Assets and Liabilities to Maximum Loss Exposure				3,200		$ 3,200			$ 200
Payments to Acquire Investments								$ 1,000
GABA Options [Member]
Variable Interest Entity [Line Items]
Payments to Acquire Investments			$ 5,500
Series A Preferred Stock [Member] | GABA Options [Member] | Amended GABA PSPA [Member]
Variable Interest Entity [Line Items]
Payments to acquire additional investments	$ 5,000	$ 5,000
Minimum [Member] | Condition For Determning Consolidation Under Voting Interest Model [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage	50.00%
Maximum [Member] | GABA Therapeutics Inc [Member]
Variable Interest Entity [Line Items]
Minority interest ownership percentage by the parent	50.00%
PsyProtix, Inc. [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage						75.00%
Net loss attributable to redeemable noncontrolling interests				$ 2,600	$ 100
Compass Pathfinder Holding Limited [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage						26.30%
Compass Pathfinder Holding Limited [Member] | Series A Preferred Stock [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage						19.40%
Compass Pathfinder Holding Limited [Member] | Minimum [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage						50.00%
GABA [member] | Series A Preferred Stock [Member]
Variable Interest Entity [Line Items]
Payments to Acquire Investments						$ 1,500

Variable Interest Entities an_4

Variable Interest Entities and a Voting Interest Entity - Summary of Primary Beneficiary for VIEs Consolidated Under the VIE Model (Detail)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Perception Neuroscience Holdings, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	Controlled VIE	Controlled VIE
Date Control Obtained	November 2018
Ownership %	58.90%	50.10%
Kures, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	Controlled VIE	Controlled VIE
Date Control Obtained	August 2019
Ownership %	54.10%	54.10%
EntheogeniX Biosciences, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	Controlled VIE	Controlled VIE
Date Control Obtained	November 2019
Ownership %	80.00%	80.00%
DemeRx IB, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	Controlled VIE	Controlled VIE
Date Control Obtained	December 2019
Ownership %	59.50%	59.50%
Recognify Life Sciences, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	Controlled VIE	Controlled VIE
Date Control Obtained	November 2020
Ownership %	51.90%	51.90%
PsyProtix, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	Controlled VIE
Date Control Obtained	February 2021
Ownership %	75.00%
Psyber, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	Controlled VIE
Date Control Obtained	February 2021
Ownership %	75.00%
InnarisBio, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	Controlled VIE
Date Control Obtained	March 2021
Ownership %	82.00%
Neuronasal, Inc. [Member]
Variable Interest Entity [Line Items]
Relationship	Controlled VIE	Investment
Date Control Obtained	May 2021
Ownership %	56.00%	37.20%

Variable Interest Entities an_5

Variable Interest Entities and a Voting Interest Entity - Summary of the Assets and Liabilities for all Consolidated VIEs (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Prepaid expenses and other current assets	$ 3,964	$ 2,076
Total current assets	457,586	99,548
Property and equipment, net	331	71
Long term notes receivable	1,388	911
Total assets	505,961	111,548
Current liabilities:
Accounts payable	6,202	3,083
Accrued liabilities	7,824	9,215
Deferred revenue	120
Total current liabilities	14,185	12,298
Convertible promissory notes and derivative liability		978
Contingent consideration liability	2,466	1,705
Other non-current liabilities	3,239
Total liabilities	21,066	16,180
Perception [Member]
Current assets:
Cash	26,741	6,527
Unbilled receivable	0
Prepaid expenses and other current assets	1,638	768
Total current assets	28,379	7,295
Property and equipment, net	2	4
Long term notes receivable		0
Total assets	28,381	7,299
Current liabilities:
Accounts payable	743	564
Accrued liabilities	947	297
Deferred revenue	120
Total current liabilities	1,810	861
Convertible promissory notes and derivative liability		978
Contingent consideration liability	2,363	1,705
Total liabilities	4,173	3,544
Kures [Member]
Current assets:
Cash	762	1,264
Unbilled receivable	0
Prepaid expenses and other current assets	84	124
Total current assets	846	1,388
Property and equipment, net		0
Long term notes receivable	0	0
Total assets	846	1,388
Current liabilities:
Accounts payable	210	220
Accrued liabilities	356	229
Total current liabilities	566	449
Convertible promissory notes and derivative liability		0
Contingent consideration liability		0
Total liabilities	566	449
EntheogeniX [Member]
Current assets:
Cash	401	652
Prepaid expenses and other current assets	0
Total current assets	401	652
Property and equipment, net	0
Long term notes receivable		0
Total assets	401	652
Current liabilities:
Accounts payable	26	35
Accrued liabilities	31	11
Deferred revenue	0
Total current liabilities	57	46
Convertible promissory notes and derivative liability		0
Contingent consideration liability	0	0
Total liabilities	57	46
DemeRx IB [Member]
Current assets:
Cash	5,351	7,252
Prepaid expenses and other current assets	431	193
Total current assets	5,782	7,445
Property and equipment, net		0
Long term notes receivable	1,075	1,060
Total assets	6,857	8,505
Current liabilities:
Accounts payable	495	230
Accrued liabilities	154	92
Total current liabilities	649	322
Convertible promissory notes and derivative liability		0
Contingent consideration liability		0
Total liabilities	649	322
Recognify [Member]
Current assets:
Cash	1,493	1,895
Prepaid expenses and other current assets	15	44
Total current assets	1,508	1,939
Property and equipment, net		0
Long term notes receivable		0
Total assets	1,508	1,939
Current liabilities:
Accounts payable	19	64
Accrued liabilities	264	66
Total current liabilities	283	130
Convertible promissory notes and derivative liability		0
Contingent consideration liability		0
Total liabilities	283	$ 130
PsyProtix [Member]
Current assets:
Cash	91
Total current assets	91
Long term notes receivable	102
Total assets	193
Current liabilities:
Accrued liabilities	9
Total current liabilities	9
Total liabilities	9
Psyber [Member]
Current assets:
Cash	174
Total current assets	174
Property and equipment, net	0
Total assets	174
Current liabilities:
Accounts payable	1
Accrued liabilities	69
Total current liabilities	70
Total liabilities	70
InnarisBio [Member]
Current assets:
Cash	816
Total current assets	816
Total assets	816
Current liabilities:
Contingent consideration liability	103
Total liabilities	103
Neuronasal Inc [Member]
Current assets:
Cash	691
Prepaid expenses and other current assets	560
Total current assets	1,251
Total assets	1,251
Current liabilities:
Accounts payable	253
Accrued liabilities	384
Convertible promissory notes and derivative liability—current portion	38
Total current liabilities	675
Other non-current liabilities	289
Total liabilities	$ 964

Variable Interest Entities an_6

Variable Interest Entities and a Voting Interest Entity - Schedule of Non Controlling Interest Recognized to Its Consolidated VIEs Roll Forward (Detail) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020
Noncontrolling Interest [Line Items]
Opening balance	$ 8,603	$ 4,546	$ 511	$ 887
Issuance of noncontrolling interests	3,649	885	0	0
Repurchase of noncontrolling interest			0	0
Net income (loss) attributable to noncontrolling interests—common	(2,364)	870	0
Net loss attributable to redeemable noncontrolling interests - common				(389)
Net loss attributable to noncontrolling interests - preferred	7	2,486	(491)	0
Comprehensive loss attributable to noncontrolling interests	150	(184)	(20)	13
Closing balance	10,045	8,603	0	511
Perception [Member]
Noncontrolling Interest [Line Items]
Opening balance	4,179	0	203	487
Issuance of noncontrolling interests	3,257	0
Net income (loss) attributable to noncontrolling interests—common	(1,755)	1,755
Net loss attributable to redeemable noncontrolling interests - common				(297)
Net loss attributable to noncontrolling interests - preferred	7	2,608	(183)
Comprehensive loss attributable to noncontrolling interests	150	(184)	(20)	13
Closing balance	5,838	4,179	0	203
Recognify [Member]
Noncontrolling Interest [Line Items]
Opening balance	4,424	4,546
Issuance of noncontrolling interests		0
Net income (loss) attributable to noncontrolling interests—common	(217)	0
Net loss attributable to noncontrolling interests - preferred		(122)
Comprehensive loss attributable to noncontrolling interests		0
Closing balance	4,207	4,424
Psyber [Member]
Noncontrolling Interest [Line Items]
Opening balance		0
Issuance of noncontrolling interests		8
Net income (loss) attributable to noncontrolling interests—common		(8)
Net loss attributable to noncontrolling interests - preferred		0
Comprehensive loss attributable to noncontrolling interests		0
InnarisBio [Member]
Noncontrolling Interest [Line Items]
Opening balance		0
Issuance of noncontrolling interests		877
Net income (loss) attributable to noncontrolling interests—common		(877)
Net loss attributable to noncontrolling interests - preferred		0
Comprehensive loss attributable to noncontrolling interests		$ 0
Kures [Member]
Noncontrolling Interest [Line Items]
Opening balance			308	400
Net loss attributable to redeemable noncontrolling interests - common				(92)
Net loss attributable to noncontrolling interests - preferred			(308)
Closing balance			$ 0	$ 308
Neuronasal Inc [Member]
Noncontrolling Interest [Line Items]
Issuance of noncontrolling interests	392
Net income (loss) attributable to noncontrolling interests—common	$ (392)

Variable Interest Entities an_7

Variable Interest Entities and a Voting Interest Entity - Schedule of Roll Forward of the Redeemable Noncontrolling Interests Balance (Detail) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020
Redeemable Noncontrolling Interest [Line Items]
Opening balance	$ 0	$ 0	$ 109	$ 142
Issuance of redeemable noncontrolling interests	2,555	0
Net loss attributable to redeemable noncontrolling interests—preferred	(2,555)	0	(109)	(33)
Closing balance	0	0	0	109
Kures [Member]
Redeemable Noncontrolling Interest [Line Items]
Opening balance	0	0	109	142
Issuance of redeemable noncontrolling interests	0	0
Net loss attributable to redeemable noncontrolling interests—preferred	0	0	(109)	(33)
Closing balance	0	0	$ 0	$ 109
Neuronasal Inc [Member]
Redeemable Noncontrolling Interest [Line Items]
Opening balance	0	0
Issuance of redeemable noncontrolling interests	2,555	0
Net loss attributable to redeemable noncontrolling interests—preferred	(2,555)	0
Closing balance	$ 0	$ 0

Equity Method Investments and_3

Equity Method Investments and Other Investments - Summary of Equity Method Investments (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Equity Method Investments	$ 19,780	$ 53,100
innoplexus AG [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Description of Principal Activities	August 2018
Equity Method Investments	$ 0	$ 0
Equity Method Investment, Ownership Percentage	35.00%	35.00%
COMPASS Pathways Plc Two [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Description of Principal Activities	December 2018
Equity Method Investments	$ 19,780	$ 0
Equity Method Investment, Ownership Percentage	19.40%	22.10%
GABA Therapeutics Inc [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Description of Principal Activities	November 2020
Equity Method Investments	$ 0	$ 0
Equity Method Investment, Ownership Percentage	7.50%	7.50%
Neuronasal Inc [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Description of Principal Activities	October 2020
Equity Method Investments	$ 0	$ 0
Equity Method Investment, Ownership Percentage		9.80%

Equity Method Investments and_4

Equity Method Investments and Other Investments - Summary of financial data for investments (Detail) - USD ($) $ in Thousands		Jun. 30, 2021	Dec. 31, 2020
Shedule Of Equity Method Investment Summarized Balance Sheet [Line Items]
Current assets		$ 457,586	$ 99,548
Total assets		505,961	111,548
Current liabilities		14,185	12,298
Total liabilities		21,066	16,180
GABA Therapeutics Inc [Member]
Shedule Of Equity Method Investment Summarized Balance Sheet [Line Items]
Current assets		10,954	3,302
Non-current assets		0	0
Total assets		10,954	3,302
Current liabilities		162	430
Non-current liabilities		0	0
Total liabilities		162	430
Neuronasal Inc [Member]
Shedule Of Equity Method Investment Summarized Balance Sheet [Line Items]
Current assets	[1]	0	351
Non-current assets	[1]	0	10
Total assets	[1]	0	361
Current liabilities	[1]	0	686
Non-current liabilities	[1]	0	48
Total liabilities	[1]	0	734
COMPASS Pathways Plc Two [Member]
Shedule Of Equity Method Investment Summarized Balance Sheet [Line Items]
Current assets		334,035	202,404
Non-current assets		1,126	1,052
Total assets		335,161	203,456
Current liabilities		7,801	6,895
Non-current liabilities		0	0
Total liabilities		$ 7,801	$ 6,895
[1]	Results from operations for Neuronasal are through May 17, 2021 at which point the entity is consolidated.

Equity Method Investments and_5

Equity Method Investments and Other Investments - Summary of Statements of operations (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Shedule Of Equity Method Investment Summarized Statement Of Operations [Line Items]
Revenue				$ 19,880
Net loss		$ (53,373)	$ (16,957)	(49,329)	$ (1,076)
COMPASS Pathways Plc Two [Member]
Shedule Of Equity Method Investment Summarized Statement Of Operations [Line Items]
Revenue		0	0	0	0
Loss from continuing operations		(19,528)	(17,687)	(33,130)	(26,392)
Net loss		(19,528)	(17,687)	(33,130)	(26,392)
Neuronasal Inc [Member]
Shedule Of Equity Method Investment Summarized Statement Of Operations [Line Items]
Revenue	[1]	0	0	0	0
Loss from continuing operations	[1]	(409)	(382)	(985)	(514)
Net loss	[1]	(409)	(382)	(985)	(514)
GABA Therapeutics Inc [Member]
Shedule Of Equity Method Investment Summarized Statement Of Operations [Line Items]
Revenue		0	0	0	0
Loss from continuing operations		(387)	(929)	(1,046)	(1,956)
Net loss		$ (387)	$ (929)	$ (1,046)	$ (1,956)
[1]	Results from operations for Neuronasal are through May 17, 2021 at which point the entity is consolidated.

Equity Method Investments and_6

Equity Method Investments and Other Investments - Summary of Equity Method Investments and Other Investments (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Investment [Line Items]
Other Long-term Investments	$ 16,107	$ 8,044
DemeRx NB Inc [Member]
Investment [Line Items]
Other Long-term Investments	1,067	1,096
Juvenescence Limited [Member]
Investment [Line Items]
Other Long-term Investments	358	368
GABA Therapeutics Inc [Member]
Investment [Line Items]
Other Long-term Investments	$ 14,682	5,519
Neuronasal Inc [Member]
Investment [Line Items]
Other Long-term Investments		$ 1,061

Equity Method Investments and_7

Equity Method Investments and Other Investments - Additional information (Detail) $ / shares in Units, £ in Millions	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 07, 2021	May 21, 2021USD ($)	May 17, 2021USD ($)	May 14, 2021USD ($)$ / sharesshares	May 04, 2021USD ($)shares	Apr. 13, 2021USD ($)	Nov. 30, 2020USD ($)	Oct. 31, 2020USD ($)	Aug. 01, 2019USD ($)	Feb. 28, 2021USD ($)	Oct. 31, 2020USD ($)	Sep. 30, 2020shares	Apr. 30, 2020USD ($)	Mar. 31, 2020USD ($)shares	Mar. 31, 2020GBP (£)shares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)shares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)shares	Dec. 31, 2019USD ($)shares	Mar. 31, 2021shares	Mar. 14, 2021	Dec. 31, 2020USD ($)shares	Dec. 01, 2020USD ($)shares	Apr. 30, 2020GBP (£)
Cash and Cash Equivalents [Line Items]
Equity method investment, Investee shares sold																			$ 9,600,000
Equity method investment, Shares transaction date																			Dec. 31, 2026
Secured debt																			$ 2,400,000
Equity Method Investments	$ 19,780,000																$ 19,780,000		19,780,000					$ 53,100,000
Shares, Outstanding | shares													7,052,003
Equity method investment, Quoted market value	308,100,000																308,100,000		308,100,000					378,100,000
Income losses from investments in equity method investees																	(2,937,000)	$ (9,811,000)	(4,640,000)	$ (11,831,000)
Unrealized gain loss on investments																			19,900,000
Payments to acquire investments																					$ 1,000,000
Other long term investment	$ 16,107,000																$ 16,107,000		$ 16,107,000					$ 8,044,000
Business acquisition, Share price | $ / shares	$ 0.50																$ 0.50		$ 0.50
Common stock, Conversion basis		1.6 to one																	1 to 10 basis
Fair value option gain loss																	$ (5,460,000)		$ (5,460,000)	$ 0
Common Stock And Warrants [Member]
Cash and Cash Equivalents [Line Items]
Fair value option gain loss																	$ 5,500,000		$ 5,500,000
IntelGenx [Member]
Cash and Cash Equivalents [Line Items]
Percentage of voting interest acquired	25.00%																25.00%		25.00%
Payments to acquire investments					$ 12,300,000
Number of share purchased during period | shares	1
Common stock, Conversion basis	Each Additional Unit Warrant will be comprised of (i) one share of common stock and (ii) one half of one warrant (the “Additional Warrants”).
Number of months determining unit price	12 months
IntelGenx [Member] | Warrant [Member]
Cash and Cash Equivalents [Line Items]
Class of warrant or right, Number of securities called by warrant | shares	44,000,000																44,000,000		44,000,000
Investment measured at fair value as per fair value option					$ 1,200,000
IntelGenx [Member] | Common Stock And Warrants [Member]
Cash and Cash Equivalents [Line Items]
Investment measured at fair value as per fair value option	$ 6,900,000																$ 6,900,000		$ 6,900,000
IntelGenx SPA [Member]
Cash and Cash Equivalents [Line Items]
Number of share purchased during period | shares					1
Business acquisition, Share price | $ / shares					$ 0.35
Number of years determining units purchase	3 years
IntelGenx SPA [Member] | Maximum [Member] | Condition For The Issue Of Additional Unit Warrants [Member]
Cash and Cash Equivalents [Line Items]
Investment owned number of shares | shares	74,600,000																74,600,000		74,600,000
IntelGenx SPA [Member] | Minimum [Member] | Condition For The Issue Of Additional Unit Warrants [Member]
Cash and Cash Equivalents [Line Items]
Investment owned number of shares | shares	74,600,000																74,600,000		74,600,000
Preferred Stock [Member] | Series A Preferred Stock [Member]
Cash and Cash Equivalents [Line Items]
Payments to acquire investments															$ 17.8	£ 16.1
Common Stock [Member]
Cash and Cash Equivalents [Line Items]
Shares, Outstanding | shares	154,819,776														90,709,312	90,709,312	154,819,776	90,709,312	154,819,776	90,709,312	90,709,312	137,569,776		114,735,712
Common Stock [Member] | IntelGenx [Member]
Cash and Cash Equivalents [Line Items]
Investment measured at fair value as per fair value option					$ 3,000,000
Warrant [Member] | IntelGenx [Member]
Cash and Cash Equivalents [Line Items]
Number of years determining number securities called by warrants	3 years
Investment measured at fair value as per fair value option					1,200,000
Unit [Member]
Cash and Cash Equivalents [Line Items]
Business acquisition, Share price | $ / shares	$ 0.331																$ 0.331		$ 0.331
Unit [Member] | IntelGenx [Member]
Cash and Cash Equivalents [Line Items]
Business acquisition, Share price | $ / shares	$ 0.75																$ 0.75		$ 0.75
Percentage Of Premium To Market Price	20.00%
Additional Shares [Member] | IntelGenx [Member]
Cash and Cash Equivalents [Line Items]
Investment measured at fair value as per fair value option					$ 8,200,000
Securities Purchase Agreement [Member] | IntelGenx SPA [Member] | Strategic Development Agreement [Member]
Cash and Cash Equivalents [Line Items]
Percentage of the funds to be used for research and development purpose																							20.00%
Securities Purchase Agreement [Member] | IntelGenx SPA [Member] | Condition For The Issue Of Additional Unit Warrants [Member]
Cash and Cash Equivalents [Line Items]
Percentage of the volume weighted average price of the common share	20.00%																20.00%		20.00%
Number of consecutive trading days for determining the volume weighted average price of common shares																			30 days
innoplexus AG [Member]
Cash and Cash Equivalents [Line Items]
Equity method investment, Ownership percentage	35.00%																35.00%		35.00%					35.00%
Equity Method Investments	$ 0																$ 0		$ 0					$ 0
innoplexus AG [Member] | Innoplexus SPA [Member]
Cash and Cash Equivalents [Line Items]
Equity method investment, Investee shares sold											$ 2,400,000
Equity method investment, Proceeds																			$ 22.3
COMPASS Pathways Plc Two [Member]
Cash and Cash Equivalents [Line Items]
Equity method investment, Ownership percentage	19.40%																19.40%		19.40%					22.10%
Equity Method Investments	$ 19,780,000																$ 19,780,000		$ 19,780,000					$ 0
Stock holders equity, Reverse stock split																			Immediately prior to the completion of the COMPASS IPO, the different classes of issued share capital of COMPASS Pathways plc were reorganized into a single class of ordinary shares through a reverse share split.
Shares, Outstanding | shares																									0
Percentage of voting interest acquired																								26.30%
Income losses from investments in equity method investees																	$ 2,100,000	$ 9.8	$ 2,100,000	$ 11,800,000
Other long term investment																									$ 0
Business Combination, Consideration Transferred						$ 5,000,000
COMPASS Pathways Plc Two [Member] | Maximum [Member]
Cash and Cash Equivalents [Line Items]
Convertible Notes Receivables														$ 7,600,000
COMPASS Pathways Plc Two [Member] | Minimum [Member]
Cash and Cash Equivalents [Line Items]
Convertible Notes Receivables | £																										£ 6.2
COMPASS Pathways Plc Two [Member] | Series B Preferred Stock [Member]
Cash and Cash Equivalents [Line Items]
Payments to acquire investments														$ 5,300,000
COMPASS Pathways Plc Two [Member] | Series B Preferred Stock [Member] | Convertible Notes Receivable [Member]
Cash and Cash Equivalents [Line Items]
Percentage of discount to price per share paid														15.00%
COMPASS Pathways Plc Two [Member] | Preferred Stock [Member]
Cash and Cash Equivalents [Line Items]
Equity Method Investments																								$ 53,100,000
Shares, Outstanding | shares													7,052,003
COMPASS Pathways Plc Two [Member] | Common Stock [Member]
Cash and Cash Equivalents [Line Items]
Equity Method Investments																								$ 0
Stock issued during period, Conversion of units | shares													7,935,663
COMPASS Pathways Plc Two [Member] | Additional Shares [Member]
Cash and Cash Equivalents [Line Items]
Stock Issued During Period, Shares, Acquisitions | shares						4,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares						140,000
Gain loss on dilution						$ 16,900,000
GABA Therapeutics Inc [Member]
Cash and Cash Equivalents [Line Items]
Equity method investment, Ownership percentage	7.50%																7.50%		7.50%					7.50%
Equity Method Investments	$ 0																$ 0		$ 0					$ 0
Income losses from investments in equity method investees																	400,000		1,100,000
Other long term investment	14,682,000																14,682,000		14,682,000					$ 5,519,000
GABA Therapeutics Inc [Member] | Series A Preferred Stock [Member]
Cash and Cash Equivalents [Line Items]
Option to purchase additional shares value	10,000,000																10,000,000		10,000,000
Neuronasal Inc [Member]
Cash and Cash Equivalents [Line Items]
Equity method investment, Ownership percentage																								9.80%
Equity Method Investments	0																0		0					$ 0
Income losses from investments in equity method investees																	400,000		1,000,000
Other long term investment																								$ 1,061,000
Neuronasal Inc [Member] | Cost Basis [Member]
Cash and Cash Equivalents [Line Items]
Equity Method Investments	500,000																500,000		500,000
GABA Options [Member]
Cash and Cash Equivalents [Line Items]
Equity method investment, Ownership percentage										20.00%
Income losses from investments in equity method investees																	500,000
Payments to acquire investments										$ 5,500,000
GABA Options [Member] | Series A Preferred Stock [Member]
Cash and Cash Equivalents [Line Items]
Option to purchase additional shares value	1,500,000																1,500,000		1,500,000
GABA Options [Member] | Common Stock [Member]
Cash and Cash Equivalents [Line Items]
Option to purchase additional shares value										$ 2,000,000
GABA Options [Member] | Amended GABA PSPA | Series A Preferred Stock [Member]
Cash and Cash Equivalents [Line Items]
Equity securities without readily determinable fair value	10,000,000																10,000,000		10,000,000
Payments to acquire additional investments			$ 5,000,000				$ 5,000,000
Option to purchase additional shares value	1,500,000																1,500,000		1,500,000
GABA Options [Member] | Omnibus Amendment Agreement [Member]
Cash and Cash Equivalents [Line Items]
Stock Issued During Period, Value, Stock Options Exercised								$ 1,800,000
Neuronasal Options [Member]
Cash and Cash Equivalents [Line Items]
Equity method investment, Ownership percentage																					20.00%
Neuronasal Options [Member] | Series A Preferred Stock [Member]
Cash and Cash Equivalents [Line Items]
Payments to acquire investments																					$ 500,000
Obligation to purchase additional shares value	1,500,000																1,500,000		1,500,000
Payments to acquire additional investments				$ 300,000					$ 800,000			$ 800,000
DemeRx NB Options [Member]
Cash and Cash Equivalents [Line Items]
Equity method investment, Ownership percentage																					20.00%
DemeRx NB Options [Member] | Series A Preferred Stock [Member]
Cash and Cash Equivalents [Line Items]
Option to purchase additional shares value	$ 19,000,000																$ 19,000,000		$ 19,000,000

Notes Receivable - Additional I

Notes Receivable - Additional Information (Detail) - USD ($) $ in Millions	May 14, 2021	May 11, 2021	Jun. 30, 2021	Mar. 08, 2021
Unit [Member] | Minimum [Member]
Notes Receivable [Line Items]
Proceeds from issuance of equity	$ 3
Term Loan Receivable [Member]
Notes Receivable [Line Items]
Loans and lease receivable, Outstanding			$ 2.5
Loans Receivable [Member]
Notes Receivable [Line Items]
Receivables, Maturity description			On May 14, 2021, the Company entered into an amendment agreement to the loan agreement under which the Maturity Date will be the first business day following the first closing of a subscription for additional units if the proceeds from such subscription amount to at least $3.0 million.
IntelGenx Corp [Member]
Notes Receivable [Line Items]
Loans receivable, Fixed interest rate			8.00%
IntelGenx Corp [Member] | Additional Term Loan And March Term Loan [Member]
Notes Receivable [Line Items]
Payments to acquire notes receivable		$ 0.5
IntelGenx Corp [Member] | March Term Loan Receivable [Member]
Notes Receivable [Line Items]
Receivable, Face amount				$ 2
IntelGenx Corp [Member] | Additional Term Loan Receivable [Member]
Notes Receivable [Line Items]
Receivable, Face amount				$ 0.5
IntelGenx Corp [Member] | Term Loan Receivable [Member]
Notes Receivable [Line Items]
Receivables, Maturity terms			120 days

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Fair Value Measurement Inputs and Valuation Techniques (Detail) $ in Millions	Jun. 30, 2021USD ($)yr$ / sharesshares	May 31, 2021	Dec. 31, 2020USD ($)yr
Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member] | Tranche One [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of units | shares	14,920,000
Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member] | Tranche Two [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Number of units | shares	115,080,000
Measurement Input, Discount Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input	18	18	17
Measurement Input, Expected Term [Member] | Level 3 [Member] | Warrant [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	2.9
Measurement Input, Expected Term [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	3
Measurement Input, Expected Term [Member] | Neuronasal Inc [Member] | Level 3 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability, Measurement Input	3.25
Probability of Close of License Transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	80
Measurement Input, Risk Free Interest Rate [Member] | Level 3 [Member] | Warrant [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	0.43
Measurement Input, Risk Free Interest Rate [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	1.02
Measurement Input, Risk Free Interest Rate [Member] | Neuronasal Inc [Member] | Level 3 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability, Measurement Input	0.51
Measurement Input, Price Volatility [Member] | Level 3 [Member] | Warrant [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	100
Measurement Input, Price Volatility [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	100
Measurement Input, Price Volatility [Member] | Neuronasal Inc [Member] | Level 3 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability, Measurement Input	98
Measurement Input, Expected Dividend Rate [Member] | Level 3 [Member] | Warrant [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	0
Measurement Input, Expected Dividend Rate [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	0
Measurement Input, Expected Dividend Rate [Member] | Neuronasal Inc [Member] | Level 3 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability, Measurement Input	0
Measurement Input, Expected Dividend Rate [Member] | OPM [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	0
Measurement Input, Expected Dividend Rate [Member] | OPM [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	0
Measurement Input, Exercise Price [Member] | Level 3 [Member] | Warrant [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input | $ / shares	0.35
Measurement Input, Exercise Price [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input | $ / shares	0.556
Measurement Input, Exercise Price [Member] | Neuronasal Inc [Member] | Level 3 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability, Measurement Input | $ / shares	0.01
Measurement Input, Share Price [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input | $ / shares	0.460
Measurement Input, Share Price [Member] | Neuronasal Inc [Member] | Level 3 [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Liability, Measurement Input | $ / shares	36.12
Value Of Underlying [Member] | Level 3 [Member] | Warrant [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input | $ / shares	0.46
Additional Units Term [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	2.87
Maximum Term In Years [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	5.87
Unit Purchase Price Year One [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input | $ / shares	0.331
Unit Purchase Price Year Two [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input | $ / shares	0.500
Unit Purchase Price Year Three [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input | $ / shares	0.750
W Fraction [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	0.68
Number Of Time Steps [Member] | Level 3 [Member] | Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Alternative Investment, Measurement Input	500
Contingent Consideration Lability Related Parties [Member] | Measurement Input, Discount Rate [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	5.9
Contingent Consideration Lability Related Parties [Member] | Measurement Input, Discount Rate [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			8.4
Contingent Consideration Lability Related Parties [Member] | Measurement Input, Discount Rate [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			14.1
Contingent Consideration Lability Related Parties [Member] | Measurement Input, Discount Rate [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	5.9		9.4
Contingent Consideration Lability Related Parties [Member] | Measurement Input, Expected Term [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	3.5
Contingent Consideration Lability Related Parties [Member] | Measurement Input, Expected Term [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			4
Contingent Consideration Lability Related Parties [Member] | Measurement Input, Expected Term [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			4.3
Contingent Consideration Lability Related Parties [Member] | Measurement Input, Expected Term [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	3.5		4.1
Contingent Consideration Lability Related Parties [Member] | Measurement Input Probability of the Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	51.9
Contingent Consideration Lability Related Parties [Member] | Measurement Input Probability of the Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			10.5
Contingent Consideration Lability Related Parties [Member] | Measurement Input Probability of the Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			48.7
Contingent Consideration Lability Related Parties [Member] | Measurement Input Probability of the Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	51.9		34.8
Contingent Consideration Lability Related Parties [Member] | Measurement Input Discount Rate for Royalties [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	13
Contingent Consideration Lability Related Parties [Member] | Measurement Input Discount Rate for Royalties [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			12
Contingent Consideration Lability Related Parties [Member] | Measurement Input Discount Rate for Royalties [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			13
Contingent Consideration Lability Related Parties [Member] | Measurement Input Discount Rate for Royalties [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	13		12.5
Contingent Consideration Lability Related Parties [Member] | Measurement Input Discount Rate for Royalties on Milestones [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	5.9		8.4
Contingent Consideration Lability Related Parties [Member] | Measurement Input Discount Rate for Royalties on Milestones [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	5.9		8.4
Contingent Consideration Lability Related Parties [Member] | Projected Commercial Revenue [Member] | Discounted Cash Flow with SBM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability | $	$ 270.3		$ 77.5
Contingent Consideration Lability Related Parties [Member] | Projected Commercial Revenue [Member] | Discounted Cash Flow with SBM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability | $	2,031		3,542
Contingent Consideration Lability Related Parties [Member] | Projected Clinical Milestone Revenue [Member] | Discounted Cash Flow with SBM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability | $	6		6
Contingent Consideration Lability Related Parties [Member] | Projected Clinical Milestone Revenue [Member] | Discounted Cash Flow with SBM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability | $	$ 30		$ 30
Contingent Consideration Lability Related Parties [Member] | Timing of Royalties on Commercial Revenue [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	7.8
Contingent Consideration Lability Related Parties [Member] | Timing of Royalties on Commercial Revenue [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			7.8
Contingent Consideration Lability Related Parties [Member] | Timing of Royalties on Commercial Revenue [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			8.5
Contingent Consideration Lability Related Parties [Member] | Timing of Royalties on Commercial Revenue [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	7.8		8.1
Contingent Consideration Lability Related Parties [Member] | Timing of Royalties on Clinical Milestone Revenue [Member] | Valuation Technique, Discounted Cash Flow [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.8		1.3
Contingent Consideration Lability Related Parties [Member] | Timing of Royalties on Clinical Milestone Revenue [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	0.8		1.3
Contingent Consideration Lability Related Parties [Member] | Probability of Success Rate [Member] | Discounted Cash Flow with SBM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	26.5		3.95
Contingent Consideration Lability Related Parties [Member] | Probability of Success Rate [Member] | Discounted Cash Flow with SBM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	100		100
Contingent Consideration Lability Related Parties [Member] | Probability of Success Rate [Member] | Discounted Cash Flow with SBM [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input	29.9		12.6
Contingent Consideration Lability Related Parties [Member] | Probability of Close of License Transaction [Member] | Discounted Cash Flow with SBM [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			80
Contingent Consideration Lability Related Parties [Member] | Probability of Close of License Transaction [Member] | Discounted Cash Flow with SBM [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input			80
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Discount Rate [Member] | SBM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	0.6
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Discount Rate [Member] | SBM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	7.2
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Discount Rate [Member] | SBM [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	1.6
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Expected Term [Member] | SBM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	0.5
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Expected Term [Member] | SBM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	1
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Expected Term [Member] | SBM [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	0.8
Two Thousand Twenty Convertible Note [Member] | Conversion Upon Financing Event [Member] | SBM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	50
Two Thousand Twenty Convertible Note [Member] | Conversion Upon Financing Event [Member] | SBM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	60
Two Thousand Twenty Convertible Note [Member] | Conversion Upon Financing Event [Member] | SBM [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	52
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | OPM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	(0.6)
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | OPM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	(0.7)
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | OPM [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	(0.6)
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Price Volatility [Member] | OPM [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	70
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Price Volatility [Member] | OPM [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	80
Two Thousand Twenty Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member] | OPM [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Measurement Input	75
Derivative [Member] | Measurement Input, Discount Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input			17
Derivative [Member] | Measurement Input, Discount Rate [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input			17
Derivative [Member] | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input			1
Derivative [Member] | Measurement Input, Expected Term [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input			1
Derivative [Member] | Qualified Financing Transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input			20
Derivative [Member] | Qualified Financing Transaction [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input			20
Derivative [Member] | Licensing Transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input			80
Derivative [Member] | Licensing Transaction [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, Measurement Input			80

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Fair Value Measurement on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Cash equivalents:
Money market funds	$ 398,528
Other investment held at fair value	6,886
Assets fair value	405,416
Liabilities:
Contingent consideration liability—related parties	2,466	$ 1,705
Derivative liability		214
Warrant Liability	289
Liability fair value	2,755	1,919
Fair Value, Inputs, Level 1 [Member]
Cash equivalents:
Money market funds	398,528
Other investment held at fair value	0
Assets fair value	398,528
Liabilities:
Contingent consideration liability—related parties	0	0
Derivative liability		0
Liability fair value	0	0
Fair Value, Inputs, Level 2 [Member]
Cash equivalents:
Money market funds	0
Other investment held at fair value	2,248
Assets fair value	2,248
Liabilities:
Contingent consideration liability—related parties	0	0
Derivative liability		0
Liability fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Cash equivalents:
Money market funds	0
Other investment held at fair value	4,638
Assets fair value	4,638
Liabilities:
Contingent consideration liability—related parties	2,466	1,705
Derivative liability		214
Warrant Liability	289
Liability fair value	$ 2,755	$ 1,919

Fair Value Measurement - Summ_3

Fair Value Measurement - Summary of Fair Value Measurement on Recurring Basis, Unobservable Input Reconciliation (Detail) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020
Other Investments At Fair Value [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Initial fair value of instrument - Other	$ 9,358
Change in fair value - Other	(4,720)
Ending Balance	4,638
Contingent Consideration Lability Related Parties [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	1,555	$ 1,705
Initial fair value of instrument		101
Change in fair value	911	(251)
Ending Balance	2,466	1,555
Beginning Balance			$ 596	$ 572
Gain on conversion of notes				24
Change in fair value			42
Ending Balance			638	596
Derivative Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	477	214
Initial fair value of instrument		304
Change in fair value		(41)
Extinguishment of liability	(820)
Ending Balance		$ 477
Beginning Balance			31
Initial fair value of instrument	343		184
Conversion of notes receivable				31
Ending Balance			215	31
Compass Notes Receivable Related Party [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance			9,003	8,244
Conversion of notes receivable			(9,003)
Gain on conversion of notes				718
Foreign currency transaction adjustments				41
Ending Balance				9,003
Two Thousand Twenty Convertible Promissory Notes [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of notes payable			2,668	9,707
Beginning Balance			8,542
Gain on conversion of notes				(1,127)
Change in fair value			1,260
Foreign currency transaction adjustments			212	(38)
Ending Balance			$ 12,682	$ 8,542
Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Initial fair value of instrument	249
Change in fair value	40
Ending Balance	$ 289

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) $ / shares in Units, $ in Millions	4 Months Ended
	Apr. 30, 2020USD ($)	Jun. 30, 2021USD ($)$ / shares	Jun. 30, 2021€ / shares	May 31, 2021	May 14, 2021USD ($)	Dec. 31, 2020USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Convertible Notes		$ 9
Fair value of embedded conversion features		$ 0.8				$ 0.2
Debt Instrument, Convertible, Conversion Price | (per share)		$ 1,654	€ 1,350
change in fair value of short term notes receivable	$ 0.7
Fair value of the contingent milestone and royalty liabilities		$ 0.1
Fair value of common stock by applying discount for lack of marketability		10.70%			13.70%
Common Stock [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment measured at fair value as per fair value option					$ 3
Warrant [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment measured at fair value as per fair value option					1.2
Additional Warrants [Member] | IntelGenx [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment measured at fair value as per fair value option					$ 8.2
Level 3 [Member] | Neuronasal Inc [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrant liability		$ 0.2
Contingent Milestone [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of the contingent milestone and royalty liabilities		2.4				1.7
Royalty Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of the contingent milestone and royalty liabilities		$ 2.4				$ 1.7
Probability of Close of License Transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
License transaction, measurement input		80
Probability of Failure of License Transaction [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
License transaction, measurement input		20
Qualified Financing Transactions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Perception Convertible Notes, Measurement Input		20
Licensing Transactions [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Perception Convertible Notes, Measurement Input		80
Measurement Input, Discount Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Perception Convertible Notes, Measurement Input		18		18		17

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Research And Development Related Expenses	$ 2,408	$ 313
Research and development tax credit	1,029	556
Sales tax receivables	315	509
Prepaid insurance	101	144
Other	111	554
Total	$ 3,964	$ 2,076

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Accrued Liabilities, Current [Abstract]
Accrued accounting, legal, and other professional fees	$ 3,324	$ 2,858
Taxes payable	1,323	997
Accrued external research and development expenses	1,138	347
Accrued payroll	1,103	1,098
Accrued advisory fees		3,819
Other liabilities	936	96
Total	$ 7,824	$ 9,215

Convertible Promissory Notes -

Convertible Promissory Notes - Summary of Convertible Promissory Notes (Detail) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Unamortized discount and deferred issuance costs	$ (9)	$ (18)
Total	1,176	1,199
Convertible Notes Issued in November 2018 [Member]
Debt Instrument [Line Items]
Long-term Debt	190	195
Convertible Notes Issued in October 2020 [Member]
Debt Instrument [Line Items]
Long-term Debt	$ 995	$ 1,022

Convertible Promissory Notes _2

Convertible Promissory Notes - Additional Information (Detail) € / shares in Units, $ / shares in Units, € in Millions

Jun. 10, 2021USD ($)shares

Dec. 31, 2020USD ($)

Jun. 30, 2021USD ($)$ / shares

Jun. 30, 2020USD ($)

Jun. 30, 2021USD ($)$ / shares

Jun. 30, 2020USD ($)

Jun. 30, 2021€ / shares

May 31, 2021USD ($)

Jan. 31, 2021USD ($)

Dec. 01, 2020USD ($)

Oct. 31, 2020USD ($)

Oct. 31, 2020EUR (€)

Jun. 30, 2020EUR (€)

Mar. 16, 2020USD ($)

Jan. 31, 2020USD ($)

Jan. 31, 2020EUR (€)

Nov. 30, 2018USD ($)

Nov. 30, 2018EUR (€)

Debt Instrument [Line Items]

Debt conversion price | (per share)

$ 1,654

$ 1,654

€ 1,350

Amortization of debt discount

$ 191,000

$ 15,000

Unamortized debt discount

$ 8,000,000

Second Tranche Funding [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 5,000,000

2020 Convertible Note Agreement [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 33,500,000

€ 30

Convertible promissory notes, outstanding

Interest expense and change in fair value of convertible notes

1,200,000

100,000

Perception March 2020 Notes [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 3,900,000

Convertible promissory notes, interest rate

5.00%

Fair value of derivative liabilities

$ 200,000

200,000

200,000

Gain from change in fair value of the derivative liability

12,000

44,000

Fair value of Perception Series A preferred stock

$ 600,000

Gain (loss) from change in fair value of the derivative liability

12,000

44,000

Perception March 2020 Notes [Member] | Sonia Weiss Pick And Family [Member]

Debt Instrument [Line Items]

Fair value of derivative liabilities

$ 100,000

$ 100,000

Perception December 2020 Convertible Note Agreement [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 12,000,000

Convertible promissory notes, interest rate

5.00%

5.00%

Fair value of derivative liabilities

400,000

Proceeds from licensing and collaboration arrangement

$ 20,000,000

Gain from change in fair value of the derivative liability

$ 41,000

Loss on extinguishment of notes

$ 500,000

Debt carrying value

2,700,000

Fair value of Perception Series A preferred stock

2,200,000

Gain (loss) from change in fair value of the derivative liability

41,000

Perception December 2020 Convertible Note Agreement [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Convertible notes conversion, shares issued | shares

6,456,595

Perception December 2020 Convertible Note Agreement [Member] | First Tranche Funding [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 6,200,000

$ 800,000

$ 7,000,000

Perception December 2020 Convertible Note Agreement [Member] | Second Tranche Funding [Member]

Debt Instrument [Line Items]

Fair value of derivative liabilities

$ 300,000

300,000

Perception December 2020 Convertible Note Agreement [Member] | ATAI LIFE SCIENCES N.V. [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Convertible notes conversion, shares issued | shares

5,403,791

Perception December 2020 Convertible Note Agreement [Member] | ATAI LIFE SCIENCES N.V. [Member] | Second Tranche Funding [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

4,200,000

Perception December 2020 Convertible Note Agreement [Member] | Sonia Weiss Pick And Family [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Convertible notes conversion, shares issued | shares

440,415

Perception December 2020 Convertible Note Agreement [Member] | Sonia Weiss Pick And Family [Member] | Second Tranche Funding [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

300,000

Perception December 2020 Convertible Note Agreement [Member] | Other Investors [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Convertible notes conversion, shares issued | shares

584,580

Perception December 2020 Convertible Note Agreement [Member] | Other Investors [Member] | Second Tranche Funding [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

400,000

Perception December 2020 Convertible Note Agreement [Member] | Apeiron [Member] | Series A Preferred Stock [Member]

Debt Instrument [Line Items]

Convertible notes conversion, shares issued | shares

27,809

Perception December 2020 Convertible Note Agreement [Member] | Apeiron [Member] | Second Tranche Funding [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 200,000

Perception December 2020 Convertible Note Agreement [Member] | Qualified Sale of Preferred Stock [Member]

Debt Instrument [Line Items]

Minimum proceeds expected from sale of preferred stock for debt conversion

$ 5,000,000

Debt conversion price, discount percentage

25.00%

Perception December 2020 Convertible Note Agreement [Member] | Licensing Transaction [Member]

Debt Instrument [Line Items]

Minimum licensing transaction for debt conversion

$ 5,000,000

Debt conversion price | $ / shares

$ 0.75

$ 0.75

Debt conversion price, threshold percentage

75.00%

Perception December 2020 Convertible Note Agreement [Member] | Change In control [Member]

Debt Instrument [Line Items]

Debt conversion price | $ / shares

$ 0.75

$ 0.75

Perception Convertible Notes [Member]

Debt Instrument [Line Items]

Interest expense

$ 100,000

$ 200,000

Amortization of debt discount

93,000,000,000

200,000

Unamortized debt discount

$ 300,000

Two Thousand Eighteen Convertible Note Agreement [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 100,000

$ 100,000

$ 1,000,000

€ 0.8

€ 0.1

$ 200,000

€ 0.2

Aggregate principal amount

$ 1,200,000

Two Thousand Eighteen Convertible Note Agreement [Member] | Maximum [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 1,200,000

€ 1

Two Thousand Eighteen Convertible Note Agreement [Member] | Apeiron [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

600,000

0.5

Two Thousand Eighteen Convertible Note Agreement [Member] | Other Shareholder [Member]

Debt Instrument [Line Items]

Convertible promissory notes issued

$ 400,000

€ 0.3

Common Stock - Additional Infor

Common Stock - Additional Information (Detail) $ / shares in Units, $ in Thousands	Jun. 22, 2021USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Jan. 31, 2021USD ($)shares	Jun. 30, 2021USD ($)shares	Mar. 31, 2021€ / sharesshares	Dec. 31, 2020shares
Class of Stock [Line Items]
Common stock, shares, issued | shares		13,419,360		154,819,776	13,419,360	114,735,712
Sale of stock issue price per share | (per share)		$ 11.71			€ 9.69
Issuance costs		$ 4,900		$ 10,161
Common stock issuance price, cash		$ 152,200		$ 409,884
IPO [Member]
Class of Stock [Line Items]
Sale of stock issue price per share | $ / shares	$ 15
Stock issued during period, Shares | shares	17,250,000
Proceeds from issuance of IPO	$ 231,600
Underwriting discount	$ 18,100
Common Class A [Member]
Class of Stock [Line Items]
Stock issued during period, Shares | shares	2,250,000
Common Class A [Member] | IPO [Member]
Class of Stock [Line Items]
Sale of stock issue price per share | $ / shares	$ 15
Stock issued during period, Shares | shares	17,250,000
Proceeds from issuance of IPO	$ 231,600
Offering costs	$ 9,000
Apeiron [Member]
Class of Stock [Line Items]
Common stock, shares, issued | shares			2,133,328
Common stock issuance price, cash			$ 12,200

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of share based Payment Arrangement Option Activity (Detail) - Service And Performance Based Options [Member] - Two Thousand And Twenty Incentive Plan [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options,Beginning	11,331,232
Number of Options, Granted	14,051,289
Number of options,Cancelled or forfeited	(1,584,528)
Number of options,End	23,797,993	11,331,232
Number of options,Options exercisable	5,512,278
Weighted- Average Exercise Price,Beginning	$ 1.54
Weighted- Average Exercise Price,Granted	8.69
Weighted- Average Exercise Price,Cancelled or forfeited	2.37
Weighted- Average Exercise Price,Outstanding	5.71	$ 1.54
Weighted- Average Exercise Price,Options exercisable	$ 0.85
Weighted- Average Remaining Contractual Term (Years),Beginning	4 years 5 months 26 days	4 years 7 months 20 days
Weighted- Average Remaining Contractual Term (Years),Options exercisable	4 years 1 month 20 days
Aggregate Intrinsic Value,Beginning	$ 47,735
Aggregate Intrinsic Value,Outstanding	304,470	$ 47,735
Aggregate Intrinsic Value,Options exercisable	$ 97,291

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Detail)	6 Months Ended
	Jun. 30, 2021
HSOP Plan[Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average expected term in years	8 years
Weighted average expected stock price volatility	70.00%
Risk-free interest rate,Minimum	(0.70%)
Risk-free interest rate,Maximum	(0.65%)
Expected dividend yield	0.00%
Service And Performance Based Options [Member] | Two Thousand And Twenty Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average expected term in years	3 years 7 months 20 days
Weighted average expected stock price volatility	81.20%
Risk-free interest rate,Minimum	(0.76%)
Risk-free interest rate,Maximum	(1.27%)
Expected dividend yield	0.00%

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Employee Stock Ownership Plan (ESOP) Disclosures (Detail) - HSOP Shares [Member] - HSOP Plan[Member]	6 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options,Beginning | shares	0
Number of Options, Granted | shares	7,281,376
Number of options,End | shares	7,281,376
Number of Options,Options exercisable | shares	2,736,372
Weighted- Average Exercise Price,Beginning | $ / shares	$ 0
Weighted- Average Exercise Price,Granted | $ / shares	6.64
Weighted- Average Exercise Price,End | $ / shares	6.64
Weighted- Average Exercise Price,Options exercisable | $ / shares	$ 6.63
Weighted- Average Remaining Contractual Term (Years)	14 years 6 months 3 days
Weighted- Average Remaining Contractual Term (Years),Options exercisable	14 years 6 months 3 days
Aggregate Intrinsic Value,Beginning | $	$ 0
Aggregate Intrinsic Value,Granted | $	0
Aggregate Intrinsic Value,End | $	86,346
Aggregate Intrinsic Value,Options exercisable | $	$ 32,483

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Share-based Compensation Arrangements by Share-based Payment Award (Detail) - Share-based Payment Arrangement, Option [Member] - Kures Two Thousand And Nineteen Stock Option And Grant Plan [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options,Beginning	600,000
Number of Options, Granted	0
Number of options,Cancelled or forfeited	0
Number of options,End	600,000	600,000
Number of options,Options exercisable	237,500
Weighted- Average Exercise Price,Beginning	$ 0.10
Weighted- Average Exercise Price,Granted	0
Weighted- Average Exercise Price,End	0.10	$ 0.10
Weighted- Average Exercise Price,Options exercisable	$ 0.10
Weighted- Average Remaining Contractual Term (Years),Beginning	9 years 29 days	9 years 6 months 29 days
Weighted- Average Remaining Contractual Term (Years),Options exercisable	9 years 29 days
Aggregate Intrinsic Value,Beginning	$ 0
Aggregate Intrinsic Value,Exercised	0
Aggregate Intrinsic Value,Outstanding	$ 0	$ 0

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)	Jan. 23, 2021€ / shares	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2021USD ($)€ / shares$ / sharesshares	Jun. 30, 2020USD ($)	Dec. 31, 2021	Dec. 31, 2020shares
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized stock based compensation compensation | $			$ 85,400,000			$ 85,400,000
Unrecognized stock based compensation compensation, Expected period of recognition						2 years 4 months 28 days
Share based compensation expenses | $		$ 20,600,000	0	$ 20,600,000		$ 0
Number of options outstanding		14,573,575		14,573,575	14,573,575
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesExchanged				1,152,192
Weighted average grant-date fair value of options granted  | $ / shares				$ 6.39
Two to fouryear service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding		5,391,184		5,391,184	5,391,184
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				5 years
Four to Five Year Service period [Member] | IPO [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding		400,688		400,688	400,688
Three to Five year service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding		624,000		624,000	624,000
Two to Five year Service Period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding		400,000		400,000	400,000
One to four year service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding		5,241,785		5,241,785	5,241,785
Minimum [Member] | Two to fouryear service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangements, Award vesting rights percentage				25.00%
Maximum [Member] | Two to fouryear service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangements, Award vesting rights percentage				12.50%
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding, including both vested and non-vested options.		14,051,289		14,051,289	14,051,289
Number of share options exercised during the current period				4,566,848
Share-based Payment Arrangement, Option [Member] | Two to fouryear service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding, including both vested and non-vested options.		2,544,784		2,544,784	2,544,784
Share-based Payment Arrangement, Option [Member] | Four year service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				3,027,408
Performancebased vesting [Member] | Four to Five Year Service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding		1,460,784		1,460,784	1,460,784
Liquidity Event [Member] | Four to Five Year Service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding		338,112		338,112	338,112
Liquidity Event [Member] | Five year service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding		94,096		94,096	94,096
specified performancebased vesting [Member] | Four to Five Year Service period [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Number of options outstanding		100,640		100,640	100,640
HSOP Plan[Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangements, Award vesting rights percentage				25.00%			12.50%
Unrecognized stock based compensation compensation | $		$ 14,300,000		$ 14,300,000	$ 14,300,000
Unrecognized stock based compensation compensation, Expected period of recognition				1 year 6 months 10 days
Employee stock ownership plan, Number of shares available for future issuance		718,624		718,624	718,624
Employee stock ownership plan, Weighted average purchase price of shares | € / shares					$ 0.06
Employee stock ownership plan, Employer loan guarantee | $		$ 500,000		$ 500,000	$ 500,000
Percentage of per annum interest rate				2.00%
HSOP Plan[Member] | Non Recourse Loan [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Employee stock ownership plan, Weighted average purchase price of shares | € / shares	€ 0.06
Percentage of compensation received	2.00%
Percentage of per annum interest rate				2.00%
HSOP Plan[Member] | Exchange Options [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangements, Number of employees affected by plan modification		3
Share based payment arrangements, Weighted average grant date fair value of nonvested option | $ / shares		$ 4.20		$ 4.20	$ 4.20
HSOP Plan[Member] | HSOP Shares [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Shares reserved for future issuance		8,000,000		8,000,000	8,000,000
Share based payment arrangements, Equity instruments other than options granted				7,281,376
Two Thousand And Twenty Incentive Plan [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Shares reserved for future issuance		22,658,192		22,658,192	22,658,192
Number of options outstanding		0		0	0
Common stock, for issuance to executive officers				16,000,000
Two Thousand And Twenty Incentive Plan [Member] | Service And Performance Based Options [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangement, Options expected to vest outstanding								3,176,976
Share based payment arrangements, Options cancelled		2,464,720		2,464,720	2,464,720
Share based payment arrangements, Number of employees affected by plan modification		12
Share based payment arrangements, Award vesting rights percentage		25.00%						12.50%
Number of options,Cancelled or forfeited				1,152,192
Employee stock ownership plan, Weighted average purchase price of shares | $ / shares				$ 4.97
Two Thousand And Twenty Incentive Plan [Member] | Service And Performance Based Options [Member] | Cancellation Of Shares [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangements, Equity instruments other than options granted				4,543,936
Kures Two Thousand And Nineteen Stock Option And Grant Plan [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Shares reserved for future issuance		954,315		954,315	954,315
Kures Two Thousand And Nineteen Stock Option And Grant Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangements, Options cancelled		600,000		600,000	600,000			600,000
Number of options,Cancelled or forfeited				0
Unrecognized stock based compensation compensation | $		$ 100,000		$ 100,000	$ 100,000
Unrecognized stock based compensation compensation, Expected period of recognition				2 years 1 month 28 days
Share based payment arrangement, Shares issued in period				600,000
Share based compensation expenses | $		$ 2,618,000,000	0	$ 5,207,000,000		0
Number of options outstanding		354,315		354,315	354,315
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				0
Kures Restricted Common Stock Award [Member] | Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expenses | $			41,033
Kures Restricted Common Stock Award [Member] | Restricted Stock [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized stock based compensation compensation | $		$ 200,000		$ 200,000	$ 200,000
Unrecognized stock based compensation compensation, Expected period of recognition				1 year 1 month 28 days
Share based compensation expenses | $		42,761	41,033
Share based payment arrangement, Equity instrument other than option vested, Fair value | $		100,000
Kures Restricted Common Stock Award [Member] | Restricted Stock [Member] | Unvested Restricted Stock [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangement, Shares issued in period				4,937,530
Recognify Restricted Common Stock Award [Member] | Restricted Stock [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Unrecognized stock based compensation compensation | $		1,300,000		$ 1,300,000	$ 1,300,000
Unrecognized stock based compensation compensation, Expected period of recognition				2 years 2 months 4 days
Share based payment arrangement, Equity instrument other than option vested, Fair value | $		300,000
Recognify Restricted Common Stock Award [Member] | Restricted Stock [Member] | Unvested Restricted Stock [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based payment arrangement, Shares issued in period				1,017,917
Atai Life Sciences Hurdle Share Option Plan [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expenses | $		16,700,000	$ 0	$ 16,700,000		0
Weighted average grant-date fair value of options granted  | $ / shares				$ 4.37
Two thousand twenty Kures Plan [Member] | Restricted Stock [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expenses | $				$ 83,343,000,000		$ 82,067,000,000
Two thousand Twenty Recognify Plan [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share based compensation expenses | $		$ 200,000		$ 300,000

Stock-Based Compensation - Su_4

Stock-Based Compensation - Summary of Kures' restricted common stock awards activity (Detail) - Kures Restricted Common Stock Awards [Member]	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share Based Arrangements To Obtain Goods And Services [Line Items]
Number of options,Beginning | shares	2,743,066
Number of options,Vested | shares	(822,924)
Number of options,End | shares	1,920,142
Weighted Average Grant Date Fair Value, Begining of period | $ / shares	$ 0.10
Weighted Average Grant Date Fair Value, Vested | $ / shares	0.10
Weighted Average Grant Date Fair Value, Ending of period | $ / shares	$ 0.10

Stock-Based Compensation - Su_5

Stock-Based Compensation - Summary of restricted stock awards (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ 20,600	$ 0	$ 20,600	$ 0
Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	37,512		37,723
Atai ESOP [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	20,638		20,638
Atai HSOP [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	16,650		16,650
KuresStock Option [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	3		5
Kures RSA [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	43		83
recognify RSA [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	178		347
Research and Development Expense [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	8,859		9,008
Research and Development Expense [Member] | Atai ESOP [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	8,698		8,698
Research and Development Expense [Member] | Atai HSOP [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0		0
Research and Development Expense [Member] | KuresStock Option [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	3		5
Research and Development Expense [Member] | Kures RSA [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	43		83
Research and Development Expense [Member] | recognify RSA [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	115		222
General and Administrative Expense [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	28,653		28,715
General and Administrative Expense [Member] | Atai ESOP [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	11,940		11,940
General and Administrative Expense [Member] | Atai HSOP [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	16,650		16,650
General and Administrative Expense [Member] | KuresStock Option [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0		0
General and Administrative Expense [Member] | Kures RSA [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	0		0
General and Administrative Expense [Member] | recognify RSA [Member] | Options and Restricted Stock Awards [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total share based compensation expense	$ 63		$ 125

Stock-Based Compensation - Su_6

Stock-Based Compensation - Summary of Recognify' restricted common stock awards activity (Detail) - Recognify Restricted Common Stock Awards [Member]	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Share Based Arrangements To Obtain Goods And Services [Line Items]
Number of options,Beginning | shares	952,387
Number of options,Vested | shares	(198,684)
Number of options,End | shares	753,703
Weighted Average Grant Date Fair Value, Begining of period | $ / shares	$ 1.71
Weighted Average Grant Date Fair Value, Vested | $ / shares	1.71
Weighted Average Grant Date Fair Value, Ending of period | $ / shares	$ 1.71

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net income	$ (53,373)	$ (16,957)	$ (49,329)	$ (1,076)
Net income (loss) attributable to redeemable noncontrolling interests and noncontrolling interests	(4,912)	(600)	(1,556)	(1,022)
Net income attributable to ATAI Life Sciences N.V. shareholders - basic and diluted	$ (48,461)	$ (16,357)	$ (47,773)	$ (54)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. stockholders - basic and diluted	132,265,075	90,709,312	125,797,732	90,709,312
Net income per share attributable to ATAI Life Sciences N.V. shareholders - basic and diluted	$ (0.37)	$ (0.18)	$ (0.38)	$ 0

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Diluted net Income (Loss) Per Share Attributable to Common Shareholders (Detail) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	47,079,369	6,239,485
Options to purchase Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	23,797,993	0
HSOP options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,281,376	0
2020 Convertible Promissory Notes (Note 11)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	16,000,000	2,560,000
2018 Convertible Promissory Notes - Related Parties (Note 11)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	3,679,485

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) - shares	1 Months Ended	3 Months Ended
	Nov. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Two Thousand And Eighteen Convertible Promissory Notes [Member] | Common Stock [Member]
Net Income (Loss) Per Share [Line Items]
Stock issued during period share, Conversion of covertible securities	8,773,056	1,000,000	160,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax Expense (Benefit)	$ 58,000	$ 0	$ 64,000	$ 0

License Agreements - Additional

License Agreements - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
License Agreements [Line Items]
Research and development expenses	$ 8,934,000	$ 120,000
ATAI Kures Inc. [Member] | License Agreement Terms [Member]
License Agreements [Line Items]
Percentage of the common stock shares outstanding		5.00%
Period of notice for termination of agremeent		90 days
ATAI Kures Inc. [Member] | License Agreement Terms [Member] | Regulatory And Sales Based Milestone [Member] | Initial Indication [Member]
License Agreements [Line Items]
Milestone payment payable		$ 15,500,000
ATAI Kures Inc. [Member] | License Agreement Terms [Member] | Regulatory And Sales Based Milestone [Member] | Second And Subsequent Indication [Member]
License Agreements [Line Items]
Milestone payment payable		7,300,000
ATAI Kures Inc. [Member] | License Agreement Terms [Member] | Minimum [Member]
License Agreements [Line Items]
Annual license fee payable		10,000
ATAI Kures Inc. [Member] | License Agreement Terms [Member] | Maximum [Member]
License Agreements [Line Items]
Annual license fee payable		100,000
ATAI Kures Inc. [Member] | License Agreement Terms [Member] | Stock Purchase Agreement [Member]
License Agreements [Line Items]
Research and development expenses		100,000
Stock shares issued during the period for services value		$ 100,000
Otsuka Agreement [Member]
License Agreements [Line Items]
Contract with customer liability, current	100,000
Otsuka Agreement [Member] | Research And Development Services [Member]
License Agreements [Line Items]
Revenue recognized upon performance obligation satisfied	19,700,000
Contract with customer liability, revenue recognized	200,000
Accelerate License Agreement [Member]
License Agreements [Line Items]
Performance obligation	100,000
Otsuka [Member] | Otsuka Agreement [Member]
License Agreements [Line Items]
Performance obligation	20,000,000
Otsuka [Member] | Otsuka Agreement [Member] | Outset Of The Otsuka Agreement [Member]
License Agreements [Line Items]
Performance obligation	20,000,000
Otsuka [Member] | Commercial Milestones [Member] | Otsuka Agreement [Member]
License Agreements [Line Items]
Milestone payments, receivable	66,000,000
Otsuka [Member] | Development And Regulatory Milestones [Member] | Otsuka Agreement [Member]
License Agreements [Line Items]
Milestone payments, receivable	35,000,000
Psyber [Member] | Clinical And Sale Milestones [Member] | Accelerate License Agreement [Member]
License Agreements [Line Items]
Milestone payments, receivable	$ 300,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) $ / shares in Units, $ in Thousands

Jun. 10, 2021USD ($)shares

Mar. 31, 2021USD ($)$ / sharesshares

Jan. 31, 2021USD ($)shares

Dec. 31, 2020USD ($)

Sep. 30, 2020USD ($)shares

Mar. 31, 2020USD ($)

Jun. 30, 2021USD ($)shares

Mar. 31, 2021USD ($)$ / sharesshares

Jun. 30, 2021USD ($)

Mar. 31, 2021€ / shares

Feb. 28, 2021USD ($)

Dec. 01, 2020USD ($)

Related Party Transaction [Line Items]

Proceeds from issuance of common stock

$ 152,200

$ 409,884

Shares issued, price per share | (per share)

$ 11.71

$ 11.71

€ 9.69

Stock issued during period, Value

$ 231,581

$ 23,510

Perception December Two Thousand Twenty Convertible Note Agreement [Member]

Related Party Transaction [Line Items]

Debt instrument, face amount

$ 12,000

Proceeds from licensing and collaboration arrangement

$ 20,000

Series A Preferred Stock [Member] | Perception December Two Thousand Twenty Convertible Note Agreement [Member]

Related Party Transaction [Line Items]

Convertible notes conversion, shares issued | shares

6,456,595

General and Administrative Expense [Member]

Related Party Transaction [Line Items]

stock-based compensation

$ 300

$ 300

Common Stock [Member]

Related Party Transaction [Line Items]

Stock issued during period, Shares | shares

13,419,360

27

17,250,000

15,552,688

Shares issued, price per share | (per share)

$ 11.71

$ 11.71

€ 9.69

Stock issued during period, Value

$ 2,046

$ 1,881

Founder [Member]

Related Party Transaction [Line Items]

Equity method investment, ownership percentage

21.00%

21.70%

21.70%

Galaxy NYC Based Multi Strategy Investment Firm [Member]

Related Party Transaction [Line Items]

Equity method investment, ownership percentage

7.00%

8.00%

8.00%

HCS German Venture Capital Firm [Member]

Related Party Transaction [Line Items]

Equity method investment, ownership percentage

4.00%

6.00%

6.00%

Perception [Member] | Issuance Of Convertible Notes [Member] | First Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

$ 7,000

Perception [Member] | Issuance Of Convertible Notes [Member] | Second Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

$ 5,000

Perception [Member] | Company And Other Investors [Member] | Issuance Of Convertible Notes [Member]

Related Party Transaction [Line Items]

Debt instrument, face amount

12,000

Perception [Member] | Company And Other Investors [Member] | Issuance Of Convertible Notes [Member] | Perception Note Purchase Agreement [Member]

Related Party Transaction [Line Items]

Debt instrument, face amount

$ 3,900

Perception [Member] | Company [Member] | Issuance Of Convertible Notes [Member] | First Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

5,800

Perception [Member] | Company [Member] | Issuance Of Convertible Notes [Member] | Second Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

4,200

Perception [Member] | Company [Member] | Issuance Of Convertible Notes [Member] | Perception Note Purchase Agreement [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

3,300

Perception [Member] | Sonia Weiss Pick And Family [Member] | Issuance Of Convertible Notes [Member] | First Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

$ 500

Perception [Member] | Sonia Weiss Pick And Family [Member] | Issuance Of Convertible Notes [Member] | Second Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

300

Perception [Member] | Sonia Weiss Pick And Family [Member] | Issuance Of Convertible Notes [Member] | Perception Note Purchase Agreement [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

300

Perception [Member] | Other Investors [Member] | Issuance Of Convertible Notes [Member] | First Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

100

Perception [Member] | Other Investors [Member] | Issuance Of Convertible Notes [Member] | Second Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

400

Perception [Member] | Other Investors [Member] | Issuance Of Convertible Notes [Member] | Perception Note Purchase Agreement [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

$ 300

Perception [Member] | Apeiron Related Party [Member] | Issuance Of Convertible Notes [Member] | First Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

200

Perception [Member] | Apeiron Related Party [Member] | Issuance Of Convertible Notes [Member] | Second Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

$ 200

Perception [Member] | Other Investors Related To Company [Member] | Issuance Of Convertible Notes [Member] | First Tranche [Member]

Related Party Transaction [Line Items]

Proceeds from related party debt

$ 400

Presight Roman Two LP [Member] | Issuance Of Common Shares [Member] | Common Stock [Member]

Related Party Transaction [Line Items]

Stock issued during period, Value

$ 13,900

Apeiron [Member]

Related Party Transaction [Line Items]

Proceeds from issuance of common stock

$ 12,200

Apeiron [Member] | Series A Preferred Stock [Member] | Perception December Two Thousand Twenty Convertible Note Agreement [Member]

Related Party Transaction [Line Items]

Convertible notes conversion, shares issued | shares

27,809

Apeiron [Member] | Common Stock [Member]

Related Party Transaction [Line Items]

Stock issued during period, Shares | shares

2,133,328

Stock issued during period, Value

$ 10,500

Apeiron [Member] | Issuance Of Common Shares [Member] | Common Stock [Member]

Related Party Transaction [Line Items]

Stock issued during period, Value

$ 14,500

Mr Angermayer [Member] | Consulting Agreement [Member] | Two Thousand And Twenty Incentive Plan [Member]

Related Party Transaction [Line Items]

Stock issued during period, share based payments | shares

624,000

Member Of The Management Team [Member]

Related Party Transaction [Line Items]

Due from related party, Current

$ 800

Sonia Weiss Pick And Family [Member] | Series A Preferred Stock [Member] | Perception December Two Thousand Twenty Convertible Note Agreement [Member]

Related Party Transaction [Line Items]

Convertible notes conversion, shares issued | shares

440,415

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	1 Months Ended
	Jul. 31, 2021USD ($)
Psyber Purchase Agreement [Member] | Series A Preferred Stock [Member] | Subsequent Event [Member]
Stock Issued During Period, Value, Issued for Services	$ 0.7